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3Abstract
Background
Cardiovascular disease is increased in HIV-infected adults but the underlying
aetiology is incompletely understood. Pre-clinical changes in cardiovascular
structure and arterial stiffness in HIV-infected children are described in mainly
middle to high-income countries with minimal longitudinal data available. Limited
cross-sectional data is available from Africa in settings where 90% of HIV-infected
children live.
Methods
ART-naïve and ART-experienced (on d4T+3TC+NNRTI for >2years, virologically
suppressed at enrolment) HIV-infected children underwent serial assessment within
the CHAPAS-3 trial (evaluating d4T vs ZDV vs ABC-based first line ART in
Zambia/Uganda): extensive cardiovascular assessment of structure (carotid intimal
medial thickness [cIMT] and arterial stiffness (pulse wave velocity [PWV]).
Additionally markers of inflammation, disordered thrombogenesis, vascular damage
and immune activation were measured. Age-matched HIV-uninfected controls had a
single assessment. Baseline differences between ART-naïve/experienced children
vs controls, and longitudinal changes in HIV-infected children were assessed.
Results
In 208 ART-naïve children with median age 2.9y (IQR 1.7–4.4), median CD4% 18%
(11-23) and 209 HIV-uninfected controls median age 3.0y (2.1–4.1), mean(sd) cIMT
was 0.46(0.04) v 0.44(0.04) mm respectively (p<0.001); PWV was 5.85(0.8) vs
5.67(0.74)m/sec respectively (p=0.05). Among 74 ART-experienced children on
ART for a mean of 3.7y with a median age of 6.9y (5.9–8.50), median CD4% 33%
(27-39) and 75 uninfected controls with median age 6.7y (5.6-8.6), the mean(sd)
cIMT was 0.46(0.05) vs 0.45(0.04)mm respectively (p=0.09); PWV was 5.63(0.61)
vs 5.69(0.68)m/s respectively (p=0.57). In ART naïve children IMT and PWV
significantly decreased from baseline (ART initiation) to week 96 mean(sd) cIMT
-0.02(0.04)mm (p<0.001), PWV -0.37(0.82)m/s (p<0.001). In contrast whereas cIMT
had significantly reduced by mean -0.2(0.06)mm (p=0.01) at week 96 in the ART
experienced group PWV increased by 0.34(0.62)m/s (p<0.001). There was no
4evidence that the changes in IMT or PWV over 96 weeks differed by randomisation
ART in either ART naïve or ART experienced children (p≥0.27). Significant 
differences in a panel of 19 biomarkers and immunophenotyping (markers of
activation and proliferation) were demonstrated between HIV infected ART naïve
children and healthy age matched HIV uninfected children. No significant
relationship between any of the biomarkers, immunophenotyping markers and IMT
or PWV was demonstrated.
Conclusion
In this large study of arterial structural and stiffness in HIV-infected children in Africa,
ART-naïve HIV-infected children had significantly poorer IMT and PWV than age-
matched controls, with significant improvement seen after 96 weeks of ART. After a
mean 3.7 years on ART, HIV-infected children had cIMT and PWV comparable to
uninfected age-matched controls. IMT continued to improve after a further 96 weeks
on ART. These findings illustrate that ART can reverse some of the
structural/stiffness changes caused by HIV, strengthening the argument for early
diagnosis and treatment of HIV-infected infants.
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Glossary of terms and abbreviations
3TC Lamivudine
ABC Abacavir
AIDS Acquired Immune Deficiency Syndrome
APC Allophycocyanin
ART Antiretroviral Therapy
BD Becton Dickinson
BD Twice daily
BMI Body mass index
CCA Common carotid artery
CD Cluster of Differentiation
CDC Centre for Disease Control
CHAPAS The Children with HIV in Africa Pharmacokinetics andAdherence/Acceptability of Simple Antiretroviral Regimens trial
CHER The Children with HIV Early AntiRetroviral trial
CI Confidence Interval
CIMT Carotid Intima Media Thickness
CMV Cytomegalovirus
CRF Case Report Form
CVD Cardiovascular disease
d4T Stavudine
DAD The Data Collection on Adverse Events of Anti-HIV Drugs
ddI Didanosine
DICOM Digital Images and Communication in Medicine
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EBV Epstein Barr Virus
EDTA Ethylenediaminetetraacetic acid,
EFV Efavirenz
EID Early infant diagnosis
ELISA Enzyme-Linked Immunosorbent Assay
EMTCT Elimination of mother to child transmission
FACS Fluorescence-activated cell sorting
FBC Full blood count
FDA USA Food and Drug Administration
FDC Fixed dose combination
FITC Fluorescein isothiocyanate
FSC Forward scatter
Hb Haemoglobin
HEU HIV exposed, uninfected
HDL High density lipoprotein
HIC High Income Countries
HIV Human Immunodeficiency Virus
hsCRP High sensitivity C-reactive protein
ICA Internal carotid artery
ICAM InterCellular Adhesion Molecule
IL InterLeukin
IL-1Ra InterLeukin-1 Receptor Antagonist
IQR Interquartile range
JCRC Joint Clinical Research Centre, Kampala, Uganda
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LMIC Low to middle income countries
LPV/r Lopinavir/ritonavir
MCP-1 Monocyte Chemotactic Protein-1
MFI Median fluorescence intensity
MI Myocardial Infarction
MRC-CTU Medical Research Council Clinical Trials Unit at UCL
MTCT Mother-To-Child Transmission
NNRTI Non-Nucleoside Reverse Transcriptase Inhibitor
NRTI Nucleoside Reverse Transcriptase Inhibitor
NVP Nevirapine
OD Once daily
PBS Phosphate-buffered saline
PE Phyoerythrin
PENTA Paediatric European Network for Treatment of AIDS
PerCP Peridinin chlorophyll protein,
PI Protease Inhibitor
PMTCT Prevention of Mother to Child Transmission
PWV Pulse Wave Velocity
RNA Ribonucleic acid
SIV Simian immunodeficiency virus
SMART The “Strategies for Management of Anti-Retroviral Therapy” trial
SSC Side scatter
START The “Strategic Timing of AntiRetroviral Treatment” trial
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TDF Tenofovir
TNFα Tumour Necrosis Factor alpha
TRECS T-cell receptor excision circles
UNAIDS The Joint United Nations Programme on HIV/AIDS
UTH University Teaching Hospital, Lusaka
VCAM Vascular cell adhesion molecule
VEGF Vascular Endothelial Growth Factor
VL Viral load
WHO World Health Organisation
ZDV Zidovudine
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Chapter 1 Introduction and overview of thesis
The availability of antiretroviral therapy (ART) has created a new population of
perinatally HIV-infected adolescents who are entering adulthood with an uncertain
future ahead. Co-morbidities, including cardiovascular disease, are well described in
horizontally HIV-infected adults and detrimental functional and structural arterial
changes have been described in older children. No studies have looked at the
extent of pre-clinical cardiovascular damage in very young HIV-infected children and
minimal research has focused on children living in Africa, where over 90% of HIV-
infected children live.
This research project was devised at a time when abacavir (ABC), a nucleoside
reverse transcriptase inhibitor (NRTI), was associated in adults with cardiovascular
damage, manifesting as an increased incidence of myocardial infarctions. The
implications of these observations for children are uncertain. Optimising ART in
childhood is a careful balance between efficacy, toxicity, cost and availability.
This thesis describes the cardiovascular health of a large cohort of young (aged 1
month – 13 years) children living in Zambia and Uganda. A total of 208 ART-naïve
and 74 ART-experienced HIV-infected children were recruited to the cardiovascular
sub study of a larger ART toxicity trial (CHAPAS 3; http://www.chapas3trial.org/)
along with an equal number of age matched HIV-uninfected controls. A detailed
cardiovascular assessment, including carotid intimal medial thickness (IMT) and
pulse wave velocity (PWV), was performed at baseline and after 48 and 96 weeks of
follow up.
The results show the influence of HIV-infection on vascular phenotype by comparing
ART naïve HIV-infected children with controls. Longitudinal changes over 96 weeks
are discussed along with the impact of three different ART regimens. Analysis of the
cellular and circulating markers of inflammation, immune activation, and vascular
damage measured have provided insight into potential mechanisms operating in
HIV-infected young children living in Africa.
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Chapter 2 Background
2.1 The changing nature of paediatric HIV-infection
In 1981 reports of an unexplained severe immunodeficiency in homosexual men
living in San Francisco were published [1], shortly followed by reports of an acquired
severe immunodeficiency in infants and children [2, 3]. Subsequently HIV was
identified as the cause [4-6]. Without an effective treatment available it became clear
that perinatally HIV-infected children had a very high mortality rate; twenty per cent
died by 3 months of age, half died by 2 years of age and a majority had died by the
age of 10 years [7, 8].
The discovery of the first antiretroviral drug, zidovudine (ZDV), brought hope that
treating HIV was possible; however it soon became apparent that the virus could
mutate and resistance quickly developed. New classes of antiretroviral drugs were
developed and combined into dual and subsequently triple therapies for adults. The
development of paediatric formulations lagged behind; the pharmacokinetic studies
were expensive and intensive to run, limited liquid formulations were available for
younger children and those available were unpalatable or required refrigeration.
However more recently paediatric options have been expanded and where
comprehensive paediatric HIV care is available, antiretroviral therapy (ART) has
transformed the lives of perinatally HIV-infected children who are now surviving into
adulthood [9, 10] and having (mostly uninfected) children of their own [11].
In 2016, in high income countries (HIC) mothers gaining access to comprehensive
HIV care has resulted in mother to child transmission (MTCT) rates declining from
40% to under 1% [12]. In low to middle income countries (LMIC) and with the roll out
of ART in the last decade, MTCT rates are higher but impressive reductions have
been achieved; for example in a clinical trial setting in Botswana, perinatal
transmission was 1.1% [13]. A shift to a programmatic, public health based
approaches where all HIV-infected pregnant women commence and remain on ART
for life is a major step towards making elimination of MTCT (EMTCT) an achievable
goal.
For children for whom HIV preventive strategies were not available or were
unsuccessful and who acquire HIV perinatally a healthy life is possible if ART can be
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accessed. HIV as a chronic disease brings new challenges and the co-morbidities
currently affecting HIV-infected adolescents living in HICs, whom have had access
to ART for longer, need considering as the burden of co-morbidities become
increasingly relevant globally [14]. Priorities in both HIC and LMIC include optimising
ART provision, selecting effective yet affordable ART combinations whilst minimizing
adverse effects and monitoring for co-morbidities which may not manifest clinically
during childhood. Predictions are that the number of new paediatric infections will
decline, but even with optimal scale up of ART in 2020, 1,940,000 children
worldwide are expected to be living with HIV-infection [15]. Ensuring that this
population of perinatally HIV-infected children reaches adulthood with future
treatment options preserved and free from overt or silent co-morbidities is a
challenge.
2.2 Epidemiology of HIV
2.2.1 Incidence and prevalence
The global HIV epidemic is thought to have peaked in 1996 when it was estimated
that 3.5 million new infections occurred. Between 2001 and 2013 there has been a
58% decline in the number of new perinatally acquired HIV-infections; a success of
a scale up of prevention of mother to child transmission (PMTCT) programmes.
Despite these successes, 240,000 new paediatric infections still occurred in 2013.
Globally an estimated 67% of pregnant women had access to HIV care and
treatment. However disparities exist; in 10 out of the 21 of the UNAIDS/ World
Health Organisation (WHO) Global Plan priority countries, MTCT rates remain over
15% [16]. By the end of 2013, 3.2 million children were HIV-infected, of whom 90%
were living in Sub-Saharan Africa, Figure 2-1.
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Figure 2-1. Estimated numbers of HIV-infected children by region in 2013.
Taken from UNAIDS Global Report 2014 [16]
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2.2.2 Life expectancy without antiretroviral therapy
Untreated approximately 25% of HIV-infected children living in Europe exhibit rapid
disease progression, dying by a year of age. After this age, approximately 5% of
surviving children progress to AIDS each year, with 50% surviving to 10 years of
age [17], Figure 2-2. A proportion of surviving ART naïve HIV-infected children have
considerable morbidities including stunted growth, cardiomyopathies, bronchiectasis
and neurocognitive impairment. However half of perinatally infected adolescents
living in the UK were diagnosed after the age of 13 years and were asymptomatic at
presentation [18].
Figure 2-2. Estimated time to progression to CDC clinical categories for all
untreated children.
Kaplan-Meier life-table analysis of the outcome of children being cared for in 11
European centres [17].
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HIV-infected, ART naïve children living in Africa have higher mortality rates. A large
meta-analysis of mortality of infants born to mothers in one of 7 randomised African
MTCT intervention trials (mothers received ART, no infant ART given) gave
estimated cumulative mortality rates of 110 per 1000 live births by 12 months and
174 per 1000 live births at 24 months. At one year of age 35/5% of HIV-
infected/uninfected infants had died; by two years this had increased to 53/8%
respectively. Unsurprisingly maternal death, low maternal CD4 count and infant HIV-
infection were all associated with increased infant mortality [7].
2.3 Anti-retroviral therapy
Until the mid-1990s ZDV monotherapy was the only treatment option. It wasn’t very
successful and resistance quickly developed. Dual therapies were introduced in
1996 and based on NRTI and NNRTI, often using drugs such as didanosine (ddI)
and stavudine (d4T) which had undesirable side effects including the development
of stigmatising lipodystrophy. Triple ART became available for children from 1997
and impressive data from the UK and Ireland based CHIPS cohort illustrated the
dramatic reduction in hospital admissions, morbidity and mortality in HIV-infected
children living in the UK after the introduction of triple ART - Figure 2-3, a trend seen
across Europe and Northern America [19]. A study of over 3,500 HIV-infected
children enrolled in the PACTG (now IMPAACT) 219 long-term follow up study in the
USA. The death rate in 1994 was 7.2/100 patient years compared to 0.6/100 patient
years in 2006 once ART was widely available. The age of death increased from 8.9
years in 1994 to 18.2 years in 2006, however mortality remained over 40 fold higher
than HIV-uninfected age matched controls [20].
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Figure 2-3. The dramatic reduction in hospital admissions, AIDS and death
following the introduction of triple ART in children living in the UK and Ireland
Data from the CHIPS cohort covering the majority of HIV-infected children living in the UK
and Ireland [19]
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2.4 The global roll out of ART
Building on the successes of ART seen in HICs an international effort to provide
ART across Africa began. The Global Fund to fight AIDS and the President’s
Emergency Plan for AIDS relief (PEPFAR) were amongst the first programmes to
deliver ART to HIV-infected adults and subsequently children. Initially these were
programmes dealing solely with HIV-infection, in larger urban centres and the
success was impressive with substantial improvements in adult mortality for those
who were able to access care [21, 22]. Fixed dose combinations (FDCs) were
developed for adults that were easier to transport and store which simplified
treatment delivery. The scale up of ART was made more feasible by the availability
of low cost generic antiretroviral drugs produced initially by Cipla (Mumbai, India)
and later by other companies.
Early in the global roll out of paediatric ART, syrup formulations, licensed in HICs,
were used. Compared to tablets, syrups, were bulky to transport and store (often
requiring refrigeration), complex to administer and expensive. Thus clinicians in
some countries attempted to treat children by giving part of an adult FDC tablet.
However unscored tablets were tricky to break, leading to unequal dosing and the
ratio of some components, especially nevirapine (NVP) were unsuitable for young
children, who require relative higher doses per kilogramme of body weight [23]. This
lead to the development of the first paediatric FDC tablets, Triomune Baby and
Junior, which combined stavudine (d4T), lamivudine (3TC) and nevirapine (NVP)
with a higher ratio of NVP compared to adult formulations. The Children with HIV in
Africa Pharmacokinetics and Adherence/Acceptability of Simple Antiretroviral
regimens trial (CHAPAS-1) demonstrated good efficacy and tolerability of these
formulations [24] and contributed to FDA approval in 2007. For many thousands of
children in LMIC countries Triomune was lifesaving.
Unfortunately with time it became clear that d4T caused long-term changes in fat
distribution (lipodystrophy and lipoatrophy) especially in peri/post-pubertal females,
adults with higher CD4 counts and patients with a BMI of over 25 [25]; reassuringly
pre-pubertal children appeared to be at less risk [26, 27]. Lipodystrophy was
especially stigmatising and led to lower adherence to ART. Thus WHO 2010
guidelines recommended phasing out d4T restricting use only where alternative
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nucleoside reverse transcriptase inhibitors (NRTIs) such as ZDV or abacavir (ABC)
were not available or not tolerated.
Whilst the number of children on ART has tripled between 2008 and 2013, access to
ART is not universal; in 2013 only 34% of children who were eligible, using current
WHO treatment guidelines, received ART [16, 28]. Now there are over 25
antiretroviral drugs suitable for adult patients; but for children there are fewer
formulations and dosing schedules are often based upon limited data. Not all
antiretroviral drugs can be formulated into FDCs, and of the first line WHO
recommended ART combinations for children under 12 years only one,
ZDV/3TC/NVP is available as a FDC. Several gaps remain in available products for
children before the 2013 WHO guidelines can be implemented in most LMIC.
Optimising new paediatric friendly FDCs, which are harmonised to adult ART
regimens, is a priority to ensure all HIV-infected children who need ART can access
it. Simplifying treatment will help to decentralise HIV care and treatment to lower
level health facilities integrating HIV care into broader primary health care.
Building upon adult experience, more paediatric appropriate FDCs are being
developed; scored tablets allow doses to be easily tailored to the child’s weight
using the WHO weight band tables, dispersible tablets can be dissolved and given
to infants and smaller children in suspension. New formulations of established
antiretrovirals such as lopinavir/ritonavir (LPV/r) minitabs [29], efavirenz sprinkles,
atazanavir powder and chewable raltegravir have or are being developed. There are
expanded options for first, second and third line therapies including integrase
inhibitors, CCR5 receptor antagonists and next generation non-nucleoside reverse
transcriptase inhibitors, although these are expensive, prohibiting access for the
majority of children in need of them.
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2.5 The new generation of perinatally infected adults
With comprehensive HIV-care perinatally HIV-infected children survive childhood
and enter adulthood [19]. In the UK/Ireland over 60% of children followed as part of
the Collaborative HIV Paediatric Study (CHIPS) cohort are now aged 15 years and
older, a reflection of very low numbers of newly infected children and improved
survival of older children - Figure 2-4.
Figure 2-4. Change in the age distribution of UK/Irish paediatric HIV-infected
cohort between 1996 and 2013.
An increasing proportion of HIV-infected children followed up in the Collaborative
HIV Paediatric Study (CHIPS) in the UK and Ireland are now aged over 15 years
and transiting to adult care. Reproduced with permission.
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2.6 Causes of mortality in HIV-infected children and adolescents
In LMIC paediatric mortality rates remain high; in 2013 190,000 HIV-infected
children were estimated to have died including 530 children a day from AIDS-related
illnesses [16]. Causes of death include severe bacterial infections, cardiomyopathies
and malignancies [30, 31]. In HIC mortality rates are falling and the causes of
paediatric mortality are changing from end stage AIDS and AIDS related
opportunistic infections to a notable increase in the proportion of non-communicable
causes -Table 2-1, [20, 32]. Mortality in perinatally infected adolescents living in the
UK/Ireland and Northern America who have transitioned into adult care settings is
significantly higher than the general population, deaths mostly due to HIV-related
conditions associated with virological failure and immune suppression [33, 34].
Within the UK this is mainly due to inadequate engagement with available care and
ART adherence issues, as untreatable HIV in this population is thankfully very rare
[33].
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Grouped Cause of Death Total n=298 1994–1996 1997–2000 2001–2006
n = 152 n = 66 n = 80
AIDS-Defining Infection 92 55 (36.2%) 18 (27.2%) 19 (23.8%)
 Mycobacterium avium complex 43 29 (19.0%) 9 (13.6%) 5 (6.3%)
 Pneumocystis jirovecii pneumonia 27 14 (9.2%) 5 (7.6%) 8 (10.0%)
 Cytomegalovirus 10 5 (3.3%) 2 (3.0%) 3 (3.8%)
 Cryptosporidium 5 4 (2.6%) 1 (1.5%) 0
 Cryptococcus/Toxoplasmosis 4 2 (1.3%) 0 2 (2.5%)
 Invasive Candidiasis 3 1 (0.7%) 1 (1.5%) 1 (1.3%)
End-Stage AIDS 48 18 (11.8%) 11 (16.7%) 19 (23.8%)
Pneumonia 41 23 (15.1%) 13 (19.7%) 5 (6.3%)
Sepsis - bacterial or fungal 34 16 (10.5%) 6 (9.1%) 12 (15.0%)
Cardiomyopathy 20 11 (7.2%) 3 (4.5%) 6 (7.5%)
Central Nervous System Disease 19 12 (7.9%) 4 (6.1%) 3 (3.8%)
Malignancy 9 3 (2.0%) 3 (4.5%) 3 (3.8%)
Renal failure 7 1 (0.7%) 2 (3.0%) 4 (5.0%)
Stroke/cerebral Hemorrhage 5 1 (0.7%) 2 (3.0%) 2 (2.5%)
Hepatitis 4 2 (1.3%) 0 2 (2.5%)
Accidental 2 0 0 2 (2.5%)
Other/Unknown 17 9 (5.9%) 4 (6.1%) 4 (5.0%)
Calendar Period
* = Test of trend in proportion of deaths due to each cause over calendar periods using Mantel-
Haenszel Chi-Square test. For trends in Opportunistic Infection (OI)-related vs non-OI related
deaths, the Mantel-Haenszel test p-value is 0.03.
Table 2-1. Primary Cause of Death for HIV-infected Children living in the USA.
The children were part of the Paediatric AIDS Clinical Trials Group 219/219c long term
follow up [20]
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2.7 Paediatric HIV care in 2016
Without doubt in 2016, the availability of ART continues to be lifesaving. However
HIV-infected children require ongoing access to comprehensive HIV care and
considerable therapeutic, practical and psychosocial issues persist for HIV infected
and affected children. These will be discussed in the following sections.
2.7.1 Making a diagnosis of HIV in infants
Without knowing the HIV-status of a child, appropriate care cannot be accessed but
determining the HIV status of an infant in LMIC can be challenging. Due to the trans-
placental passage of maternal antibody babies born to HIV-infected mothers are
HIV-antibody positive regardless of HIV status. A definitive HIV diagnosis in infants
under 18 months of age requires PCR confirmation. Ideally a mother is tested in the
1st trimester of pregnancy (with a repeat 3rd trimester test if she is at risk of
seroconverting in pregnancy) and the baby tested after birth (by 2 months of age at
the latest) and repeatedly until at least 6 weeks after the cessation of breastfeeding.
Worryingly a recent study found that in babies who were being breastfed by mothers
on ART, routine PCR assays to detect infant HIV DNA were insensitive. 22 weeks
after cessation of breastfeeding were needed before a positive test result was
obtained using standard PCR testing. Ultrasensitive testing confirmed the presence
of HIV DNA before the routine PCR tests became positive. This suggests that
maternal antiretrovirals can suppress HIV replication within an infant sufficiently to
cause a false negative PCR result [35]. A single test at 6 weeks after cessation of
breast feeding may be too early. Whilst early infant diagnosis (EID) is feasible in
resource limited setting globally in 2013 only 42% of children exposed to HIV were
tested by 2 months of age. Large geographical differences exist; for example whilst
by 2 months of age 94% of infants in South Africa are tested, just 4% of infants in
Chad and Nigeria have had a PCR performed [16, 36, 37]. Decentralisation of EID
to rural health centres is integral to the success of an EID programme.
PCR testing requires technology that is usually only available at centralised large
laboratories. PCR can be performed on dried blood spots which are simple to collect
at a primary care level and can be easily transported for centralised testing.
However long turnaround times getting the results back to the families, especially in
remote areas, can be tricky. Innovative solutions such as using Global Package
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Radio Service (GPRS) printers are promising in reducing turnaround times of
returning results to the family [38, 39]. Point of care tests can provide decentralised
EID providing same day results. Several technologies are under development
although hurdles that need to be overcome include a limited number of samples
tested per day, the sensitivity/specificity of each test and prohibitive costs [40, 41].
Targeting resources to the higher risk groups for testing is important, for example
using precious resources to test children born to mothers who are in PMTCT
programmes has a very low pick up rate of HIV-infection given the success of
PMTCT interventions. Conversely testing all children admitted to a malnutrition unit
or an acute medical word is likely to result in a far higher proportion of positive HIV
results [42].
2.7.2 When to start antiretroviral therapy
The Children with HIV Early Anti-Retroviral (CHER) trial provided unequivocal
evidence that all children under the age of 2 years should be commenced on ART
as soon as possible once a diagnosis of HIV is made, to reduce HIV related
morbidity and mortality [43]. CHER data are supported by similar findings from a
large European infant cohort meta-analysis [44]. The WHO expanded this finding to
recommend that all children under the age of 5 years commence treatment and
some African countries, such as Uganda, opted for all children to start ART without
measuring CD4 counts, a pragmatic way of reducing the barriers to accessing ART.
In May 2015 The Strategic Timing of ART (START) trial interim findings were
announced early at a press release [45] and published shortly after [46]. This global
trial took asymptomatic HIV-infected adults with a CD4 count greater than 500
cells/mm3 and randomised them to either immediate ART regardless of
immunological or clinical status, or withholding ART until their CD4 count fell below
350 cells/mm3. The trial was terminated early as interim results provided compelling
evidence of the benefit of early ART. These results have major global implications;
the updated WHO 2015 guidelines recommended immediate treatment for all,
including children. Early treatment aims to optimise immune status,
neurodevelopment, minimising development of viral reservoirs, resistance and
limiting toxicities.
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Young children respond well to ART, and this is related to the ability of the immature
immune system to reconstitute [47]. There is mounting evidence that delaying ART
until the CD4 count drops impairs the potential for immune recovery [48, 49] and
earlier treatment may be associated with lowered viral reservoirs [50-53], with time it
may be that those with smaller reservoirs are candidates for future curative
strategies. The European (PENTA 2015, [54]), American (DHHD 2014, [55]) and
2013 WHO guidelines [28] for commencing treatment prior to the release of the
updated WHO 2015 guidelines are compared in Table 2-2.
< 1 year
1 - 3 years
1-2 years
WHO stage 3/4
CD4 count ≤ 750 cells/ul
CD4 percentage ≤ 25% All All*
3 - 5 years
WHO stage 3/4
CD4 count ≤ 750 cells/ul
CD4 percentage ≤ 25% Consider
All
> 5 years
WHO stage 3/4
CD4 count ≤ 350 cells/ul Consider Consider
All CD4 count ≤ 500 copies / ml
HIV VL > 100,000 copies / ml
CD4 count ≤ 350 cells/ul
CDC category B/C
WHO stage 3/4
"All", all children irrespective of immunological status; CDC, Centres for Disease Control and Prevention; VL, viral
load. * In children aged 1 - 3 years consider ART in all especially if VL > 100,000 copies / ml
HIV VL > 100,000 copies / ml
Consider
CD4 count ≤ 1000 cells/ul
CD4 percentage ≤ 25%
WHO stage 3/4
CD4 count < 500 cells/ul
CDC category B/C
HIV VL > 100,000 copies / ml
CD4 ≤ 500 cells/ul
Prioritize
CD4 count < 750 cells/ul
CD4 percentage < 25%Prioritize
Consider Consider
PENTA 2015
All
CDC category B/C
HIV VL > 100,000 copies / ml
CDC category B/C
CD4 count ≤ 750 cells/ul
CD4 percentage ≤ 25%
CDC category B/C
WHO stage 3/4
DHHS 2014
All
CD4 count < 1000 cells/ul
CD4 percentage < 25%
CDC category B/C
HIV VL > 100,000 copies / ml
WHO 2013
All
All
Prioritize
All
Table 2-2. Comparison of previous guidelines for the initiation of antiretroviral
therapy prior to the updated 2015 WHO recommendation of immediate ART for
everyone.
Where resources are limited guidance on whom to prioritise is provided based upon World
Health Organisation (WHO), US Department of Health and Human Services (DHHS) and
Paediatric European Network for the Treatment of AIDS (PENTA) guidelines for
antiretroviral therapy (ART) initiation. Table adapted from [54]
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2.7.3 First line antiretroviral options
WHO, European and USA guidelines provide recommendations on which ART
combinations should be commenced [28, 54, 55]. Standard first line therapy in all
guidelines consists of a three drug regimen made up of two nucleoside/nucleotide
reverse transcriptase inhibitors with either a boosted protease inhibitor or a non-
nucleoside reverse transcriptase inhibitor. The current WHO guidelines are listed in
Table 2-3.
Some evidence from Africa suggests that LPV/r has virological advantages over
NVP in neonates exposed to NVP perinatally although concerns exist about the
interpretation of the trial findings. Where possible infected infants exposed to NVP
during failed PMTCT should be started on a boosted PI containing regimen as
transmitted resistance can lead to failure of NVP containing regimen [56, 57].
However LPV/r syrup is unpalatable, interacts with tuberculosis treatment and until
recently was only available in a liquid formulation that required refrigeration. In May
2015 the USA FDA tentatively approved LPV/r pellets (Cipla) for infants and children
aged less than 3 years. Whilst this is progress results from CHAPAS 2 showed that
whilst pharmacokinetic data were similar between syrups and pellets caregivers
initially preferred pellets at 12 weeks however by 48 weeks, mainly due to the
adverse taste of the pellets, syrups were preferred [29, 58].
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Age Group Preferred first-line regimens Alternative first-line regimens
Children < 3 years ABC or ZDV + 3TC + LPV/r
ABC + 3TC + NVP
ZDV + 3TC + NVP
Children 3 years to less
than 10 years and
adolescents <35kg
ABC + 3TC + EFV
ABC + 3TC + NVP
ZDV + 3TC + EFV
ZDV + 3TC + NVP
TDF + 3TC (or FTC) + EFV
TDF + 3TC (or FTC) + NVP
Adolescents (10-19 years)
≥ 35 kg
TDF + 3TC (or FTC) + EFV
ZDV + 3TC + EFV
ZDV + 3TC + NVP
TDF + 3TC (or FTC) + NVP
ABC + 3TC + EFV (or NVP)
3TC, lamivudine; ABC, abacavir; EFV, efavirenz; FTC, emtricitabine; LPV/r, lopinavir/ritonavir;
NVP, nevirapine; TDF, tenofovir; ZDV, zidovudine;
Table 2-3. Preferred and alternative first-line regimens for children.
Adapted from the 2013 WHO Consolidated ARV Guidelines [28]
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In young children ABC remains a preferred first line treatment. As will be described
further in section 2.10.8 concerns have been raised about the potential adverse
cardiovascular effects of ABC and cardiovascular disease in adults. Alternatives
such as ZDV, which has been associated with anaemia, have previously been used
with caution in countries with high prevalence of malaria and anaemia. Tenofovir
(TDF) has recently been given FDA approval from 2 years of age however concerns
over renal and bone toxicity remain [59, 60].
The CHAPAS 3 study was the first study to compare first line treatment using d4T
with ZDV or ABC in an African setting. The trial will be described in more details in
section 3.1 but briefly 478 children, three-quarters of whom were ART naïve, were
randomised to either d4T, ZDV or ABC with 3TC and either NVP or EFV. Children in
all three arms did equally well; only 6% had to change any of their initial regimens
due to side effects and 1% had to switch to second line treatment for virological
failure. No difference was demonstrated between groups in terms of adverse effects
(including anaemia), hospitalisations or disease progression. The majority of
patients maintained virological suppression at 48 and 96 weeks with no difference
between arms [27] however a relationship between long term use of d4T in older
children was associated with adverse changes in markers of clinical lipodystrophy
[61].
2.7.4 How to simplify antiretroviral therapy
With children facing a lifetime on ART once started on ART, it is critical to simplify
treatment, optimise adherence, minimise toxicities and limit the development of
resistance. Simplifying treatment is the first step to improve adherence. Once daily
ART is far more convenient and leads to improved adherence [62]. The once daily
administration of ABC/3TC from aged 3 months has been shown in several trials to
be safe and efficacious [27, 63, 64].
2.7.5 Once started can antiretroviral therapy ever be stopped?
The Paediatric European Network for the Treatment of AIDS (PENTA) 11 study
investigated the effect of planned treatment interruption in 109 children and found, in
a small group of carefully monitored children, this strategy was safe [65, 66]. This
was in stark contrast to the findings from The Strategies for Management of
AntiRetroviral Therapy (SMART) study. This was a large treatment interruption trial
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that recruited 5472 adults, with a CD4 count of greater than 350cells/mm3 (the then
threshold for commencing ART) and randomised patients to either continuous or
CD4 count guided (treatment interruption) ART. The trial was terminated early when
it was demonstrated that the treatment interruption arm had significantly increased
incidence of opportunistic disease or death from any cause [67].
Within the paediatric population controversy remains as to whether ART can be
safely interrupted once started. The long term follow up of the children recruited in to
the CHER study showed that the infants whom received immediate ART for 96
weeks tolerated later treatment interruptions well, with 32% remaining off ART by
the end of the 6 year trial. The CHER investigators concluded that treatment
interruption after intensive time limited primary treatment was well tolerated and
different to interrupting treatment in chronic HIV-infection, possibly reflecting a
decreased HIV reservoir or reflecting young infants ability to reconstitute their CD4
cells, related to their increased thymic output [68].
The BREATHER trial has shown that in a highly selected group of children and
adolescents short cycle therapy is non inferior to continuous ART. This trial took 199
8 – 24 year olds from across the world who were stable on first line efavirenz based
ART and randomised half to take two consecutive days off ART each week. Young
people in the trial randomised to the SCT arm enjoyed the freedom of not having to
take ART at the weekends and reported that after a period of adjustment their
quality of life improved [69].
2.8 Anti-retroviral therapy in 2016 and beyond
The evidence to start ART early is strong and it is without doubt that ART is
lifesaving. There are concerns that periods of viraemia will replenish HIV reservoirs,
increase immune activation and in the adolescent and adult population, increase the
risk of transmission. However there are also concerns about the cumulative life time
ART exposure in HIV-infected individuals. The choice of paediatric ART needs
careful consideration to ensure that the delicate balance between cost, formulation
and side effects is addressed to ensure success in mortality is not at the cost of
increased long term toxicities and co-morbidities. Ongoing pharmacovigilance is
important and often difficult to coordinate in resource limited countries [70].
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2.9 Emerging complications
Before the availability of effective ART, opportunistic infections, end stage AIDS and
HIV-related malignancies were the main causes of mortality in HIV-infected adults;
the majority of adults progressed to end stage AIDS within 2-15 years of primary
infection [71]. In 2016 if ART is commenced with a CD4+ count greater than 350
cells/mm³, non-smoking horizontally HIV-infected adults whom subsequently
achieve immune reconstitution (CD4+ counts above 500 cells/mm³) and maintain
virological suppression, are thought to have a mortality approaching that of the
general population. Conversely a CD4 count less than 350 cells/mm3 when ART is
commenced may reduce life expectancy by 20 years [72-74]. However these figures
may be overestimates as they exclude “out of care patients” and a survivorship bias
for older patients who survived in the pre-ART era exists. Non-HIV related mortality
by age remains higher than in the general population; the reasons for this are multi-
factorial and yet to be fully determined. The leading causes of morbidity and
mortality among HIV-infected adults on ART now include cardiovascular, pulmonary
and renal disease [75].
2.10 Mechanisms implicated in cardiovascular dysfunction and
disease in HIV-infected adults
Based upon mainly adult studies multiple mechanisms have been proposed to
explain the increased risk of CVD in HIV-infected patients. Whilst the strongest
evidence exists for inflammation (more pronounced in patients with detectable
viraemia) and excessive immune activation (more pronounced in patients with
virological suppression) contributing to accelerated atherosclerosis, no one clear
mechanism has emerged. Among men with low coronary artery calcium scores HIV
infection was associated with an increased prevalence of non-calcified coronary
plaque independent of traditional cardiovascular risk factors. This finding adds
weight to the argument that non-traditional pathways and more than one mechanism
are implicated in the increased risk of CVD in HIV infected adults [76].
Potential mechanisms unique to HIV
a) Inflammation; related to the consequences of viraemia
b) Immune activation despite viral suppression or low level viral replication
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c) Accelerated atherosclerosis
d) Endothelial dysfunction
e) Altered haemostasis
Risk factors
a) Viraemia
b) Advanced immune suppression
c) Co-infections
d) Exposure to certain antiretroviral medication especially older protease
inhibitors and a controversial role of ABC
2.10.1 Inflammation; related to the consequences of viraemia
Current thinking places inflammation as a key component of the increased CVD risk
in HIV-infected individuals.
Much of the initial data on the role of inflammation in HIV came from the SMART
(Strategies for Management of Antiretroviral Therapy) trial. The SMART study
demonstrated that uncontrolled viraemia itself can raise the risk of cardiac disease
and cardiovascular risk is decreased in patients with sustained virological
suppression. In the treatment interruption arm uncontrolled viraemia accompanied
by elevated inflammatory indices was thought to be driving the increased CVD risk
[77]. This prompted vigorous studies of inflammation as a possible mediator of CVD
in treated and untreated HIV-infection [78].
HIV has pro-inflammatory actions as shown by increased expression of several
inflammatory markers, such as, high-sensitivity CRP (hsCRP) [79-81] and IL-6 [78,
80] and the expression of endothelial adhesion molecules such as VCAM-1 [82].
Higher levels of such markers are associated with both AIDS related and non-AIDS
related morbidity and mortality [83]. Increased progression of carotid IMT was
associated with higher levels of hsCRP [84]. Viral suppression though ART usually
improves these pro-inflammatory parameters [85, 86] and suggests an inflammatory
set point. An impressive finding, that a single IL-6 and d-dimer can predict 10 year
morbidity and mortality [87] unfortunately was not repeated in other studies
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suggesting that risk can be modified through external factors [88]. However despite
early ART persistent abnormalities in inflammatory markers remain suggesting there
are other mechanisms at play [89].
The role of inflammation and risk of CVD is not unique to HIV-infected adults. In the
JUPITER study, HIV uninfected adults with high levels of CRP but LDL-C levels
below the threshold for lipid lowering agents were commenced on a statin with anti-
inflammatory actions. Results showed that the patients in the arm randomised to
statin therapy had a lower incidence of primary cardiovascular disease [90]. When a
similar study, SATURN-HIV was carried out in a high risk HIV-infected population no
reduction in cardiovascular events were seen in the patients randomised to statins
[91]. Additionally the benefits in lowering of LDL-C levels were also not seen.
Although the dose of rosuvastatin used in SATURN-HIV was half that used in
JUPITER due to the interactions with PI use, even patients on PIs did not have the
lipid changes expected. 48 weeks of rosuvastatin treatment reduced significantly
several markers of inflammation including CD38+HLA-DR+ and lymphocyte and
monocyte activation in ART-treated subjects[92]. These results taken together
suggest that unique mechanisms are operating in HIV-infected individuals.
2.10.2 Immune activation despite viral suppression or low level viral
replication
Early animal models suggested that immune activation had a role in the
pathogenesis of AIDS. Silvestri et al demonstrated that in Sooty Mangabeys simian
immunodeficiency virus (SIV) infection leads to high levels of viral replication without
the development of AIDS and with a normal lifespan. In contrast Rhesus macaques
develop AIDS. The difference being that the Sooty Mangabeys have minimal
immune activation whilst widespread immune activation in the rhesus macaques is
implicated in the development of AIDS [93].
The finding that adults who fail to reconstitute their CD4+ T cells whilst taking ART
have a higher risk of cardiovascular disease may be explained by T cell activation
causing persistent pro-atherogenic inflammation despite viral load suppression [94].
Early ART reduces the risk of CVD, delaying ART leads to persistently abnormal
immune activation and a greater HIV reservoir [95].
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2.10.3 Accelerated atherosclerosis
Atherosclerosis plays an important role in the pathophysiology of cardiovascular
disease. Development of atherosclerosis is a result of complex interactions between
intrinsic and extrinsic risk factors, both modifiable (such as type 2 diabetes mellitus,
hypertension, and dyslipidaemia) and non-modifiable (such as genetic
susceptibility). Coronary angiography studies show that asymptomatic HIV-infected
adults have a doubling of risk for non-calcified, vulnerable plaques which are at
increased risk for rupture compared to controls matched by Framlington risk scores
[96, 97]. Mounting evidence supports HIV associated inflammation and immune
activation driving atherosclerosis [98, 99] with contributions from both cellular and
humoral immunity [100-102].
To understand how HIV affects the development and progression of atherosclerosis
it is important to understand the underlying pathophysiology.
2.10.4 Endothelial dysfunction
The endothelium is a single layer of cells that provides the interface between the
intra and extra vascular components. The layer is metabolically active and regulates
haemostasis, cellular adhesion, vascular growth and coagulation partially through
the production, expression and modulation of adhesion molecules and pro-
inflammatory cytokines including TNFa, IL-6, sVCAM-1 and MCP-1. Endothelial
dysfunction can be thought of simply as an imbalance between vasodilation and
vasoconstriction substances produced by (or acting on) the endothelium [103].
Endothelial dysfunction is seen early in the atherosclerotic process and leads to
reduced vasodilation, increased inflammation, impaired coagulation and fibrinolysis
contributing to plaque initiation and progression. In HIV-infected patients endothelial
dysfunction is well recognised and has been associated with both HIV-infection and
antiretroviral therapy [104-107]. HIV-infection itself is associated with a more
pronounced adhesion of leukocytes to endothelial cells [104] and high levels of the
endothelial markers (ICAM-1, VCAM-1 and E-selectin) have been described in HIV-
infected patients [105].
Fatty streaks / atheromata development
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Within areas of endothelial dysfunction the first changes are the development of
arterial fatty streaks, an accumulation of lipid-laden macrophages and T-cells
beneath the endothelium [108]. Fatty streaks may regress or progress to
atheromata. Atheromata are asymmetrical focal thickenings of the intima, the inner
layer of the artery. Atheromata comprise a core of foam cells and extra cellular lipid
droplets surrounded by a cap of smooth muscle cells and a collagen rich matrix
[109].
Infiltration of atheromata and vessel walls
As illustrated in Figure 2-5 low density lipoprotein (LDL) infiltrates the arterial wall
and is modified by oxidative and enzymatic reactions. The modified LDL particles
induce expression of the leukocyte adhesion molecules VCAM-1 and ICAM-1 which
attract the accumulation of activated inflammatory cells; these produce inflammatory
cytokines [110-114]. Leukocytes then roll along the wall of inflamed vessels before
adhering, infiltrating the atheromata and transmigrating. Monocytes are attracted to
the endothelium via MCP-1, attach via ICAM-1 and VCAM-1 and become activated
macrophages. Higher levels of sCD163 suggestive of monocyte activation are seen
without an increase in more traditional measures of inflammation such as CRP
[115]. Activated macrophages transform into foam cells after taking up large
quantities of oxidized LDL. Further T cell activation amplifies the inflammatory
response via production of mediators such as IFN-γ contributing to a pro-thrombotic 
local environment, more amenable to a build-up of plaques with lipid laden foam
cells and a thin necrotic surface.
Plaque rupture or endothelial erosion
As illustrated in Figure 2-6 antigen presenting cells within the atherosclerotic plaque
trigger a predominantly Th1 T cell response characterised by secretion of IFN-γ and 
further macrophage activation. T cell factors and mediators from the activated
macrophages reduce plaque stability and release proteases that degrade the
extracellular matrix. Activated macrophages may also produce pro-thrombotic and
pro-coagulant factors that directly precipitate the formation of thrombus at the site of
plaque rupture. Regulatory T cells modulate the atherogenic process by secreting
anti-inflammatory cytokines whilst foam cells set up a cycle of chronic inflammation
and plaque rupture. The activation of the atherosclerotic plaque precipitates
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ischaemia and infarction either as a cause of plaque rupture or endothelial erosion,
if this affects coronary blood flow myocardial infarction ensues.
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Figure 2-5. The initial stages in the atherosclerotic process.
1. Infiltration of the arterial wall by LDL
2. LDL is modified by oxidative and enzymatic reactions.
3. Modified LDL particles induce expression of VCAM-1 and ICAM-1
4. Monocytes migrate into the vessel wall and differentiate into macrophages
5. Macrophages take up oxidized LDL and transform into foam cells
6. Activated T-cells produce pro-inflammatory cytokines that further amplify the
inflammatory response
Adapted from [158]
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Figure 2-6. The role of T-cells in the pathogenesis of arterial plaque development.
1. Within the atheromata antigen presenting cells trigger an inflammatory response
casusing furhter activation of macrophages
2. Pro-inflammatory cytokines reduce the stability of plaque and release proteases
that degrade the extracellular matrix.
3. Activated macrophages also produce prothrombotic and procoagulant factors that
directly precipitate the formation of thrombus at the site of plaque rupture.
4. Regulatory T cells modulate the atherogenic process by secreting anti-
inflammatory cytokines.
Adapted from [158]
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2.10.5 Altered haemostasis
Evidence for the role of altered coagulation in the development of end-organ
disease, including myocardial infarction during HIV-infection, is accumulating [78].
Abnormalities predisposing to a hypercoagulable state have been reported in both
ART naïve and experienced HIV-infected adults including presence of the lupus
anticoagulant [116], deficiencies of protein C and protein S [117, 118], heparin
cofactor II [119], anti-thrombin [120] and increased levels of von Willebrand factor
[121, 122] although many of these abnormalities correlate with the severity of HIV-
associated immunosuppression and with the presence of co-infections [123].
2.10.6 Co-infections
Infections other than HIV can act as a trigger or mediators of the inflammatory
response in atherosclerosis and both HIV-infected children and adults are at
increased risk of co-infections [124]. In a study of Ugandan HIV-infected children
attending an outpatient clinic 92/140 (66%) and 57/73 (78%) ART experienced and
ART naive children had detectable Epstein Barr virus (EBV) DNA levels. Mean EBV
DNA levels were lower in ART experienced children and tended to be inversely
associated with ART duration [125].
Co-infections such as CMV or hepatitis C have also been shown to have adverse
effects on circulating levels of pro-inflammatory cytokines [126]. For example Italian
adults with CMV/HIV coinfection had increased severe non–AIDS-defining
events/non–AIDS-related death, especially with cardiovascular and cerebrovascular
events, independently of other prognostic factors [127]. A cohort of HIV/CMV co-
infected adults living in the USA, despite effective ART had elevated CD4 and CD8
T cell activation [128] and detectable CMV is associated with higher HIV DNA levels
after early commencement of ART which may affect the stability of the HIV DNA
reservoir [129].
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2.10.7 ART related toxicities
Without doubt uncontrolled viraemia is a risk factor for CVD and the benefits of ART
are clear. Optimising ART regimens to reduce toxicities that have been implicated in
the pathophysiology of CVD is important. As summarised in Table 2-4 some
antiretroviral drugs have direct effects on cardiovascular disease or indirectly though
metabolic derangements such as insulin resistance and dyslipidaemia may
contribute towards increased CVD [130].
2.10.7.1 Dyslipidaemia
Historically the protease inhibitor (PI) class has been considered to have a major
impact on pro-atherogenic serum lipid elevations [131, 132], The D:A:D team
demonstrated that cumulative exposure to PIs contributed to an increased rate of MI
thought to be partially (but not fully) explained by PI associated dyslipidaemia [133]
a finding seen in several other cohorts [134, 135].
However HIV-infected ART naïve children and adults also have abnormal lipid
profiles so HIV infection itself appears to also cause a dyslipidaemia. A particular
dyslipidaemia has been described in HIV-infected ART naive adults; lower levels of
high-density lipoprotein (HDL) cholesterol that inversely correlates with HIV RNA
levels. This is thought to be due to HIV mediated interruption of the reverse
cholesterol transport pathway through which cholesterol is cleared from the
peripheral tissues [136].
ART naïve and experienced HIV-infected children have been shown to have
adverse lipid profiles [137] (including high non-HDL-C, LDL-C triglycerides and low
HDL-C) with less favourable profiles seen with current PI use [138-140].
The role of different subclasses of lipids in the pathophysiology of atherosclerosis is
becoming increasingly understood. A key initiating set in the process of
atherosclerosis is thought to be the sub endothelial retention of apolipoprotein B
containing lipoproteins. These retained lipoproteins then initiate local responses
including a chronic T-cell and macrophage driven inflammatory response. This is
then thought to drive the development of atherosclerotic lesions. Ongoing work
looking at therapeutic manipulation of this pathway aims to further reduce the risk of
58
atherosclerosis [141]. Recently post prandial hypertriglyceridemia has become
established as a risk factor for the development of atherosclerotic lesions.
Overproduction and/or decreased catabolism of triglyceride rich lipoproteins
predispose to hypertriglyceridemia especially in those with a genetic predisposition
or who are obese. Post prandial accumulation of triglyceride rich lipoproteins
promotes the retention of remnant particles in the arterial wall. Remnant particles
contain up to 40 times the amount of cholesterol compared with LDL. The larger size
of remnant particles cannot cross the endothelium as efficiently as smaller LDL
particles and predispose to accelerated atherosclerosis and increased risk of
cardiovascular disease [142]. To date no work has examined these pathways in
HIV-infected patients.
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Table 2-4. Antiretroviral therapy and impact of individual drugs on lipid and glucose
metabolism and coronary artery disease.
Class of ART Antiretroviral Effects on lipids* Effects on glucose • Impact on coronary artery disease
Abacavir TC↑ LDL↑ No effect
Potential increase in MI following recent
exposure (see section 2.x)
Emtricitabine Neutral effect No effect No known association
Lamivudine Neutral effect No effect No known association
Stavudine Dyslipidaemia + Insulin resistance + No known association
Tenofovir TC↓ LDL↓ No effect No known association
Zidovudine TC↑ LDL↑ Insulin resistance + No known association
Efavirenz TC↑ LDL↑ No effect No known association
Etravirine Neutral effect No known effect Insufficient patients exposed
Nevirapine HDL↑ No known effect No known association
Rilpivirine Neutral effect No known effect Insufficient patients exposed
Amprenavir +
Ritonavir
Dyslipidaemia ++ Insulin resistance +
Cumulative exposure independently
increased risk for MI
Atazanavir +
Ritonavir
Dyslipidaemia + Insulin resistance + No known association
Darunavir +
Ritonavir
Dyslipidaemia + Insulin resistance + Insufficient patients exposed
Indinavir Dyslipidaemia + Insulin resistance +++ Controversial results
Lopinavir +
Ritonavir
Dyslipidaemia +++ Insulin resistance +++
Cumulative exposure independently
increased risk for MI
Nelfinavir Dyslipidaemia + Insulin resistance + No known association
Saquinavir Dyslipidaemia + Insulin resistance + No known association
Tipranavir +
Ritonavir
Dyslipidaemia + Insulin resistance + Insufficient patients exposed
Elvitegravir /
cobicistat
Neutral effect No effect Insufficient patients exposed
Raltegravir Neutral effect No effect Insufficient patients exposed
Entry
inhibitors
Maraviroc Neutral effect No effect Insufficient patients exposed
* Dyslipidaemia defined as increased total cholesterol (TC), low density lipoprotein cholesterol (LDL), triglycerides and
decreased high-density lipoprotein cholesterol (HDL);   • + weak eﬀect; ++ moderate eﬀect ; +++ important eﬀect; ↑ 
ŝŶĐƌĞĂƐĞ͖љ ĚĞĐƌĞĂƐĞ͕D /ŵǇŽĐĂƌĚŝĂůŝŶĨĂƌĐƟŽŶ͘
Nucleos(t)ide
reverse
transcriptase
inhibitors
Non-
nucleoside
reverse
transcriptase
inhibitors
Protease
inhibitors
Integrase
inhibitors
Adapted from [174]
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2.10.7.2 Lipodystrophy
The use of ddI, d4T and EFV are associated with lipodystrophy, especially in
adolescents and adults. Lipodystrophy in younger children does occur but less
frequently [143-146]. In the entire CHAPAS 3 cohort (478 children) only two
children, both of whom were older and had been on d4T for a mean of 3.9 years at
enrolment, developed lipodystrophy.
Expanding or altering the distribution of visceral fat may promote the development of
atherosclerosis; the visceral fat deposits are metabolically active and may promote
an inflammatory reaction. Epicardial fat, given its close proximity to the coronary
vessels may influence atherosclerosis due to the pro-inflammatory cytokines
released. Recent work has shown that epicardial fat is higher in HIV-infected adult
males and positively associated with duration of ART, especially ZDV and correlated
with increased coronary calcium and subclinical coronary atherosclerosis [147].
2.10.8 Abacavir and cardiovascular disease – an ongoing debate
In 2008 the unexpected results of the D:A:D cohort created a storm of controversy
[129]. The D:A:D cohort was a prospective observational cohort study of 33,347
patients followed in total for 367,559 person-years during which 517 patients had a
myocardial infarction (MI) however, a lack of HIV-negative controls meant this could
not be compared to the expected age-related incidence. Investigators found a 16%
increased relative risk of acute MI with every year of exposure to ART. Initially this
was linked to the use of PIs but after adjusting for use of NRTI class and lipids an
attenuated risk of 10% risk per year of ART exposure was found. The initial
hypothesis, that ZDV and d4T were implicated, was rejected after further analysis
suggested that exposure to ABC within the last 6 months was associated with a 1.90
relative risk of acute MI and to a lesser extent cumulative use of ABC also was
associated with an increased MI risk [84, 130, 131]
Following this multiple retrospective analyses have been carried out looking for an
ABC signal. An independent analysis of the patients in the continuous arm of the
SMART dataset also gave a signal that ABC, was associated with an increased risk
of cardiovascular disease [132] and combined with the D:A:D results led to the USA
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Department of Health and Human Services ART guidelines reclassifying ABC from a
preferred first-line agent to an alternate agent in November 2008.
Conflicting reports over the relationship of cardiovascular disease with ABC continue
to be published. These are summarised in Table 2-5 and no clear answer has
emerged, with opposing opinions being obtained when even the same data set is
analysed [133, 134]. It is important to highlight that most conclusions have been
drawn from cohorts or trials that were not specifically designed to assess ABC
cardiotoxicity and given the low cardiovascular event rates most cohorts are
underpowered. Furthermore, differences in study designs, populations, and scope of
data collection have meant no studies have been able to specifically address the
risk of MI following recent ABC exposure.
A major confounder in the cohort studies is channelling bias; individuals at higher
risk of metabolic disease, lipodystrophy or cardiovascular disease may have been
preferentially treated with ABC after previous studies had shown a favourable
change in lipid profile when PIs were changed to ABC [135-138]. Similarly impaired
renal function is a cardiovascular risk factor in HIV-infected individuals [139, 140];
individuals with known renal dysfunction may have been preferentially prescribed
ABC as the commonest prescribed NRTI alternative, tenofovir, poses a risk of renal
toxicity [141].
The studies showing an association between ABC and cardiovascular events
tended to include patients who were virologically suppressed, and those that did not
report an association (generally the meta-analyses of RCTs) generally included
ART-naive subjects. It may be argued that in ART-naive patients, the overall
benefits of achieving virological suppression and limiting ongoing inflammation with
ART may outweigh any potential negative effects of ABC, or alternatively the trials
did not have sufficient follow up time for any risk to manifest.
To overcome the large numbers and long term follow up needed to specifically
address the risk of CVD with ABC, smaller studies have looked at indirect
biomarkers of cardiovascular risk and pre-clinical markers of vascular dysfunction.
No adverse changes in patients on ABC have been seen in a large number of
studies [142-153]. A small trial of 40 adult patients randomised to either ABC or TDF
containing regimens revealed a small transient increase in E-selectin and sVCAM-1
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at week 4 but long term there were no significant differences in a panel of
biomarkers that also included hsCRP and d-dimer [154]. A small study of 35 adults
switching to an ABC containing regimen showed increased levels of various
inflammatory markers including hsCRP compared to adults switching to a non-ABC
regimen [156]. Finally a study of high risk male adults revealed moderate
improvements in cardiac biomarkers and arterial stiffness when switched from an
ABC containing regimen to a TDF containing regimen [157].
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Table 2-5. Summary of cohort analyses investigating associations between the use
of abacavir and cardiovascular disease.
Total patients
RR CV event
with ABC use
(95% CI)
Comments
Increased risk of cardiovascular disease with abacavir use
Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) [148-150]
33,347 HIV+ (178,835
patient yrs)
Update 367,559 patient
yrs
1.9 (1.47 : 2.45)
1.98 (1.70 : 2.29)
Potential for confounders and remember benefit
of ART. Update - a strong association between
current ABC use and MI risk remains,
channelling bias unlikely
Independent analysis of SMART data [151]
2752 HIV+ 4.3 (1.4 : 13.0) ABC may cause vascular inflammation which
may precipitate a CVD event
Nested case control – Quebec (QPHID) [152]
7053 HIV+
27681 HIV-
1.79 (1.16 : 2.76) An association with EFV and LPV/r use also
noted. No data on smoking / HIV disease status.
**Cohort study - USA Veterans Study [153]
10931 HIV+ 1.48 (1.08:2.04) Recent ABC exposure associated with
increased CVD.
Danish prospective nationwide cohort study [154]
2952 HIV+ 2.0 (1.1 : 3.64) Association confirmed but confounders not fully
accounted for.
North Carolina Medicaid (comparator cohort study) [155]
3481 HIV + 2.05 (0.72 : 5.86) Need either large prospective RCT or larger
observational study
RCT – treatment simplification – STEAL study group[156]
357 HIV+ 2.79 (1.76 : 4.43) A larger study with more CV events needed for
a more definitive result
Australian retrospective case–control study [157]
68 HIV+ with CVD
136 HIV+ no CVD
OR:2.10, p=0.03 PI therapy, HIV viral load and duration of known
HIV-infection were not predictive:
A systematic review and meta-analysis of studies [158]
23 studies*** 1.09 (1.02:1.16) Inconsistent findings, duration of ABC treatment
important.
NA-ACCORD [159]
14,785 HIV+ no ABC
1,948 HIV+ on ABC
1.71 (1.11 : 2.64)
Adjusted 1.34
(0.96 :1.88)
Increased MI risk with recent ABC use but
reduced statistical significance after adjusting for
RF
Swiss HIV Cohort Study [160]
11,856 HIV+ 2.06 (1.43 : 2.98) ABC cumulative increase in risk of a CVD event.
Kaiser Permanente, California [161]
8154 HIV+ 2.2 (1.4 : 3.5) Increased risk with ABC not explained by
confounders.
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No relationship between cardiovascular disease and abacavir use
GSK analysis: A pooled analysis of 52 manufacturer trials including 12 RCTs [162]
9502 HIV+ on ABC
4672 HIV+ not on ABC
0.81(0.38:1.75) Need further data, very few MI overall
A pooled analysis from 5 clinical trials (ALLRT / ALTG) [163]
5056 HIV+ starting
ART, 17,404 patient
years
0.6 (0.3 : 1.4) More important to assess classic CV risk
factors
Meta-analysis of RCTs [164]
28 RCTs
9233 HIV+
0.95(0.62:1.44) No evidence ABC increases risk of major CV
event
**a retrospective observational cohort study using Veterans dataset (VACCR) [165]
19424 HIV+ 1.18 (0.92 : 1.5) Increased use ABC with chronic kidney
disease.
Nested case control – analysis plan specifically looking at ABC and risk of MI within the
French Hospital Database) [135]
74,958 HIV+ 2.01 (1.11 : 3.64) Increased risk of ABC confined to those who
used cocaine / iv drugs.
The HEAT study a RCT comparing ABC v TDF [166]
688 HIV+ Not given No increase in CVD in ABC group and all
explained by other RF.
The US Food and Drug Administration (FDA) meta-analysis of RCTs [167]
26 RCTs
9868 HIV+
Risk difference -
0.008% (20.3%:
0.3%).
No association between ABC use and MI risk.
10 year post marketing surveillance in Japan [168, 169]
1087 HIV+ (2453
patient years)
Not given Japanese population – lower incidence of
CVD, possible incomplete reporting or not
assigning risk to ABC (industry sponsored)
ABC Abacavir; BMI body mass index; CAD coronary artery disease; CVD cardiovascular
disease; ART antiretroviral therapy; HDL high density lipoprotein; HEAT study, the HIV
Study with Epzicom And Truvada; MI myocardial infarction; PI protease inhibitor; pyrs
patient years follow up, RCT randomized controlled trial.
SMART definition Major CVD – MI, stroke, surgery for CAD, cardiovascular mortality.
Expanded CVD – major CHD + heart failure, peripheral vascular disease, CAD needing
treatment, unwitnessed death.
Reporting CVD, defined as myocardial infarction (MI), ischaemic heart disease,
cardiovascular and cerebrovascular events or coronary heart disease
** These 2 have conflicting results yet same data set
*** Of the 23 studies included in the meta-analysis 3 cross sectional, 2 case controlled,
16 cohort studies and 2 RCTs.
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2.10.9 Postulated mechanisms linking ABC and cardiovascular disease
Since the first reports of an interaction between ABC and CVD, extensive research
to determine underlying the mechanisms through which ABC may be exerting an
effect on cardiovascular disease has been undertaken.
Endothelial dysfunction
In virologically suppressed patients an independent association between ABC use
and endothelial dysfunction was observed [170]. ABC has been shown to cause
down regulation of endothelial nitric oxide synthetase and superoxide anion
production which leads to leucocyte accumulation and endothelial dysfunction [171-
173].
Pro-inflammatory actions
Proposed pro-inflammatory actions of ABC could contribute to the atherosclerotic
process by increasing plaque instability and risk of rupture. Analysis of the SMART
study found higher levels of hsCRP and IL-6 in patients on ABC [151], a small study
of 10 patients commencing ABC showing significant increases in pro-atherogenic
inflammatory biomarkers [174] and in pregnant women in Botswana significantly
higher levels of 4 pro-inflammatory cytokines were seen in the arm randomized to
ABC [175]. However other population-based studies or post hoc trial analyses which
have measured pro-inflammatory biomarkers have failed to provide convincing
evidence [176].
Dysregulation of gene expression
Recent work investigated changes in gene expression in subcutaneous adipose
tissue biopsies using microarray in HIV-infected patients commencing ZDV, TDF or
ABC containing ART and followed for up to 24 months. Results at all time points
showed that patients receiving ABC displayed a markedly different pattern of gene
expression within subcutaneous adipose tissue. The differences were particularly
marked at month 6 but still evident at month 24. The ABC group showed enrichment
of a number of pathways involved with cell processes and cell communication
(adherence junction, focal adhesions, tight junctions) and environmental information
processing (WNT signaling, Extra-cellular membrane (ECM) receptor interaction,
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leukocyte trans endothelial migration, neuro-active ligand interactions, MAP-kinase
signaling) highlighting some novel mechanisms by which ABC may interfere with the
endothelial adhesion process and endothelial function in subcutaneous adipose
tissue, particularly early in the treatment. In particular abnormalities in tight junction
and adherence junction brought about by ABC use, if observed in other tissues, may
be a contributing factor to cardiovascular events in persons already with some
underlying risk for atherosclerosis and may require further study [177].
2.10.10 Cardiovascular disease in HIV-infected adults
Much research has investigated cardiovascular disease (CVD) in HIV-infected
adults; reported rates of cardiovascular disease have, until recently, remained
stubbornly high and the incomplete understanding of the pathophysiology has
limited intervention strategies. Absolute risk of HIV-associated CVD varies
depending on the population studied (differences between LMIC and HIC), access
to ART and prevalence of other risk factors. Different patterns of cardiovascular
disease have emerged and appear to be influenced by ART exposure.
ART naïve patients
Without ART advanced immunosuppression and opportunistic infections dominate
leading to pericardial disease (often secondary to tuberculosis), dilated
cardiomyopathies and pulmonary hypertension [178-181].
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Recently commenced or stopped ART or intermittent ART
The SMART study demonstrated that intermittent CD4 cell count guided ART
treatment was associated with an unacceptably high risk of cardiovascular events in
patients in the treatment interruption arm [67].
ART experienced with virological suppression
With ART an increase in CVD, manifesting clinically as higher rates of myocardial
infarction (MI), ischaemic heart disease (IHD), peripheral vascular disease,
pulmonary hypertension and cerebrovascular disease (mainly stroke), has been
reported [158, 182-185].
Table 2-6 summarises the main results of the larger cohort analyses of HIV-infected
adult patients. A summary of the findings of the 10 largest analyses from North
American and Europe are illustrated in Figure 2-7. Whilst a significant increased risk
is seen in 9, the study designs were not ideal. These estimates are based upon
retrospective cohort data and adjusting fully for risk factors, such as obesity,
smoking and drug use, is not always possible. An assumption that HIV-infected and
uninfected populations are broadly similar in terms of co-morbidities, socioeconomic
and lifestyle factors is incorrect; HIV-infected adults aged over 45 years have a
greater burden of co-morbidities compared to age matched controls [186, 187].
Additionally it is suggested that HIV-infected individuals have increased
susceptibility to some risk factors; for example in a cohort of 17,996 HIV-infected,
ART experienced, adults living in Europe and North America a two fold increase in
mortality was seen in HIV-infected smokers compared to non-smokers (all-cause
mortality rate 7.9 / 4.2 per 1000 person years for smokers / non-smokers) [188].
Freiberg et al [189] used the large Veterans Aging Cohort Study Virtual Cohort to
carefully match HIV-infected to uninfected controls and found HIV-infection was
associated with a 50% increased risk of acute MI beyond that explained by
recognised risk factors. An excess risk (hazard ratio 1.39; 95% CI, 1.17 – 1.66)
remained even in adults who had achieved virological suppression. Similarly using
traditional cardiovascular risk prediction scores, developed on a population level,
appears to underestimate the cardiovascular risk in HIV-infected adults [190].
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At least two different underlying pathophysiological mechanisms are implicated in
the development of a MI; primary (type 1) due to atherosclerotic plaque rupture and
secondary (type 2) due to supply demand mismatch. Recent evidence suggests that
type 2 may be more common in HIV [191]. Many of the studies presented within this
chapter have not been able to differentiate MIs by type which confuses the
interpretation into potential mechanisms by which HIV is influencing cardiovascular
risk.
The final bar of Figure 2-7 presents study findings showing no increase in the
incidence of MI above that of the general population [192]. Patients were
Californians with medical insurance and with aggressive attention to and treatment
of cardiovascular risk factors the investigators have shown it has been possible to
reduce that rate from previously published higher rates from the same cohort [193,
194].
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[152, 189, 192-199]
Figure 2-7. Relative risk of cardiovascular disease in HIV-infected adults
compared to the general population.
Based on 10 analyses of 8 cohorts. The 3 studies marked with a “ * “ are all based upon
the same cohort – the Kaiser Permanente cohort in Northern California. The Silverberg
results show the risk in patients with a CD4 > 500. The 2015 Klein results show that with
intensive HIV care and aggressive management of cardiovascular risk factors it is
possible to return the cardiac risk to background levels. Red horizontal line demonstrates
background risk.
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Table 2-6. Summary of cohort studies reporting incidence of cardiovascular disease
in HIV-infected adults
Population
Number / age
of cohort /
controls
Primary result Ref.
Increased cardiovascular disease reported in HIV+ adults
D:A:D 23,437 HIV+,
no controls,
median 39 yrs
Increased CVD with PI exposure and recent (but not
cumulative) use of ABC and ddI. Limited evidence of
accelerated CVD with increasing age.
[133,
149,
200,
201]
French
Hospital
Database
34,976 HIV+,
no controls,
mean 38yrs
Increased cardiovascular events seen with PI
exposure.
[202]
Californian
Medicaid
28,513 HIV+
3.053,696 HIV-,
age 18–75 yrs
CHD increased in HIV+ males <34 yrs and women
<44yrs, RR 2.06 (p<0.001) of CVD if on ART and
aged 18-33yrs. Effect not seen in older age bands
[195]
* Kaiser
Permanente
22,081 HIV+,
230,069 HIV-,
age 18 – 65 yrs
CVD increased in HIV+, no effect of PI or ART. CD4
>500cells/mm3 protective, lower CD4 count increased
risk of MI in HIV+
[193,
194]
American
Partners
Health care
3851 HIV+,
1,044,589 HIV–,
Age 18-84 yrs
MI increased (RR 1.75, p<0.0001) in HIV+, especially
in women. Increased co-morbidities seen in HIV+,
unknown smoking status.
[196]
HIV
Outpatient
Study
6945 HIV+,
no controls,
median 42 yrs
Decreased CVD with increasing use of ART,
relationship between PI use and MI (adjusted HR 6.5
95%CI (0.9 : 4.78)
[134,
203]
Veterans
Aging Cohort
Study Virtual
Cohort
27,376 HIV+,
55,083 HIV-,
median 49 yrs.
Increased MI in HIV+, HR 1.48 95%CI (1.27 : 1.72),
even if virologically suppressed HR 1.39 95% CI (1.17
: 1.66)
[189,
204]
Danish
National
Hospital
Registry
3953 HIV+,
373,856 HIV-,
median 37yrs
HIV+ on ART have increased CVD: ARR 2.12
95%CI(1.62 : 2.76), no increase in the 8 years after
ART initiation
[197]
New York City
HIV
Surveillance
Registry
24,768 HIV+,
257,600 HIV-,
mean 41 yrs
Both viraemic and virologically suppressed HIV+ have
increased CVD until age 65 yrs RR1.54 (1.47 : 1.62).
[199]
Quebec
dataset
7053 HIV+
27681 HIV-,
mean 40yrs
Increased MI in HIV+, RR 2.11 (95%CI 1.69 : 2.63),
increased risk with ABC, EFV, LPV/r, no data on
smoking status nor HIV clinical status.
[152]
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No difference in overall cardiovascular risk between HIV+ and control population
American
Veterans
Affairs
Healthcare
system
1st analysis: 36,766
2nd analysis: 41, 213
no controls
age 35-55yrs
1st analysis: No increase in CVD with ART
2nd analysis a small increase in CVD; HR 1.05,
95%CI(1.05 : 1.06) if on ART, older and pre-existing
vascular disease. Lower risk for African Americans
HR 0.8 95% CI(0.69 : 0.98). Ongoing benefit of ART
after 6 years.
[205,
206]
* Kaiser
Permanente
in Northern
California
24,768 HIV+,
257,600 HIV-
mean 41/40 yrs
With intensive HIV care decline in CVD. RR 1.0 (95%
confidence interval, .7–1.4) in 2010–2011.Comment
that may be underlying immune activation and
subclinical changes not yet detected. In HIV+
evidence of similar/superior CVD risk profiles (these
patients had ben intensively managed)
[192]
ABC, abacavir; ART, anti-retroviral therapy; ARR, adjusted relative risk; CHD, coronary
heart disease; CI, confidence interval; CVD, cardiovascular disease; DAD, data collection
on adverse events of Anti-HIV drugs; ddI, didanosine; EFV, efavirenz; HR, hazard ratio;
LPV/r, Lopinavir/ritonavir; MI, myocardial infarction; PI, protease inhibitor; RR, relative
risk; *Kaiser Permanente cohort.
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2.10.11 Assessment of pre-clinical cardiovascular changes
The use of clinical end points to assess the risk of CVD is not ideal as the low
incidence per year necessitates large patient numbers followed for long periods for
sufficient power to detect statistically significant differences. An alternative strategy
is to look at pre-clinical cardiovascular changes. Techniques that have been
employed to examine pre-clinical changes include:
Intimal medial thickness (IMT)
IMT is measured by external ultrasound (also possible to measure invasively) and is
the combined thickness of the tunica intima and tunica media, the innermost two
layers of the wall of an artery. IMT will be described in greater detail in sections 3.2
and 3.3 but briefly carotid artery IMT can be used as a surrogate endpoint for
evaluating the regression and/or progression of atherosclerotic cardiovascular
disease. An IMT greater than 0.9-1mm is indicative of atherosclerosis and increased
risk of cardiovascular disease.
Pulse wave velocity (PWV)
PWV, will be described in greater detail in sections 3.2 and 3.4 but briefly is a non-
invasive method of measuring arterial stiffness. It has a strong correlation with
cardiovascular events and all-cause mortality.
Computed Tomography (CT) angiography
CT angiography can be used to visualize atherosclerotic disease. It is more precise
than ultrasound but requires the injection of contrast material, thus exposing the
patient to a not insignificant dose of ionizing radiation, making its use in a paediatric
research setting inappropriate.
Ankle brachial pressure index (ABPI)
ABPI is the ratio of the blood pressure in the lower legs to the blood pressure in the
arms measured using a Doppler ultrasound probe. Abnormal results can be
indicative of peripheral arterial disease.
Studies in HIV-infected adults using these techniques are summarised in Table 2-7.
The majority of these studies show subtle but detrimental changes in HIV-infected
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individuals compared to age matched controls. Some signals suggesting subtle
differences between ART classes are seen although the implications are not always
fully understood.
In summary, earlier epidemiological and cohort studies, albeit not perfect, suggest
unique patterns of CVD in HIV-infected patients, with an increase in CVD at a
younger age, in both men and women when compared to the general population.
This excess risk cannot be explained by correction for traditional risk factors and it is
clear that the established algorithms for identifying adults at high risk of CVD are not
accurate in HIV infected adults. The lack of effect after the age of 65 years in some
cohorts may be a reflection of a survival bias. Recent findings that CVD risk can be
returned to the background population rate with intensive management of
cardiovascular risk such as strict treatment of dyslipidaemia, hypertension and
glycaemic control [83] are promising. However ongoing research needs to focus
upon the complex pathophysiology of the increased cardiovascular risk in adults;
hypotheses will be explored in the next section.
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Table 2-7. Pre-clinical cardiovascular changes in HIV-infected adults
Study
population
Number and
age of cohort Primary result Ref.
Evidence of accelerated pre-clinical changes in HIV-infected adults
Cross sectional
study of FRAM
and MESA
study groups
433 HIV+,
5749 HIV-
mean 49/61
yrs
HIV+ significantly greater IMT after adjusting for
confounders. The risk conferred by HIV was
similar to that of smoking.
[207]
San Francisco
Study of the
Consequences
of PI Era
(SCOPE) cohort
148 HIV+,
63 HIV-, mean
45 yrs
Increased and accelerated progression of IMT in
HIV+, IMT changes proportional to classic risk
factors and CD4<200 cells/mm3 associated with
an increased IMT. CMV specific T-cell responses
independently associated with IMT.
[208]
[209]
SMART –
randomised
CD4 guided
treatment
interruption
4831 HIV+
with no prior
IHD
Over 11% asymptomatic HIV-infected adults had
ECG changes of myocardial ischaemia.
Traditional RF factors were the predominant
determinants of risk. No clear association between
class/duration of ART and asymptomatic IHD was
noted.
[210]
Males recruited
from Boston
Clinics
78 HIV+
32 HIV-
Mean 47/45yrs
CT angiography used to assess coronary plaque –
higher proportion of HIV+ had plaque (59% v 34%,
p = 0.02), affecting more coronary segments (2.2
v 1.2 p = 0.03) and increased plaque volume (173
uL v 85uL, p = 0.02)
[96]
Beijing, China 82 HIV+
43 HIV-
HIV is a RF for peripheral arterial disease, no
adverse effects of NRTI / NNRTI
[211]
Ugandan cross
sectional
outpatient study
245 HIV+
median age 37
year (IQR 31-
43)
18% had thickened IMT diagnostic of subclinical
atherosclerosis (14% of ART nave, 24% of ART
experienced)
[212]
START arterial
elasticity sub-
study – baseline
results
337 of the
START
patients
Impaired small arterial elasticity with older age and
among those with prior CVD, women and those of
black race, also observed differences by global
region
[213]
Multicenter
AIDS cohort
study
618 HIV+
383 HIV-
40-70 yrs
Coronary artery plaque, especially non calcified
plaque is more prevalent and extensive in HIV
infected males independent of traditional RF for
CVD,
[97]
Boston Medical
Centre ID clinic
75 HIV+
223 HIV-
Impaired FMD in HIV+, associated with current IV
drug use and low α-high density lipoprotein 
triglyceride levels.
[214]
No evidence of pre-clinical changes in HIV-infected
American multi-
site study
44 HIV+ on PI
44HIV+ not on
PI
44 HIV-
No statistically significant difference over 3 years
in IMT progression between HIV-infected and un-
infected adults. Higher homocysteine and LDL
cholesterol predicted IMT progression
[215]
Washington
University
General Clinical
Research
Centre
50 HIV+
50 HIV-
No difference in IMT progression between HIV+
stable on ART and HIV- adults. Insulin resistance
a strong predictor of IMT.
[216]
CT ECG; FRAM, Fat redistribution and metabolic change in HIV-infection; IMT;
MESA, multi-ethnic study of atherosclerosis;
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2.11 Cardiovascular morbidity and mortality in HIV-infected children
Similar to the patterns seen within the adult HIV-infected population specific patterns
of CVD are emerging in children with no/suboptimal ART exposure and with
prolonged ART exposure. Of concern cardiac manifestations may remain
undetected in childhood/adolescence and not manifest until early adulthood.
Antenatal factors
Antenatal factors can impact on later CVD risk. In some, but not all, cohorts it is
reported that children born to HIV-infected mothers have a higher incidence of low
birth weight and prematurity, especially if on a PI containing regimen or commencing
ART late in pregnancy [217-219]. Prematurity and low birth weight are both known
risk factors for the later development of cardio-metabolic disease [220, 221]
microvasculature changes, elevated blood pressure and increased cIMT [222]. HIV-
exposed uninfected (HEU) children exposed to antenatal ART have left ventricular
structural changes and diastolic dysfunction, the long term significance of which is
as yet undetermined [223, 224]. A need for longitudinal cardiac studies in HEU
children assessing long-term cardiac risk is recommended to determine the
implications of these findings.
ART naïve HIV-infected children
Similar to the findings in HIV-infected adults in the pre-ART era or when ART was
commenced only in the late stages of immunosuppression left ventricular
hypertrophy, dilated cardiomyopathy, congestive heart failure, severe dysrhythmias,
cardiac tamponade, pulmonary hypertension and pericardial effusions in children
and adolescents were common. Specific risk factors for the development of
structural cardiac disease identified include no or short duration of ART, ZDV
monotherapy and advanced AIDS [225-230].
ART experienced HIV-infected children
Since the introduction of effective ART the incidence of clinically overt CVD has
fallen; for example the prevalence of cardiomyopathy fell from 44% to 3.7% with the
introduction of ART [231], however an increased risk of cardiomyopathy remains
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and ongoing ZDV exposure is implicated [232]. There is evidence that cardiac
abnormalities where ART is available are mostly mild and asymptomatic in
childhood [231, 233]. In HICs a worrying increase in the prevalence of cardiac risk
factors are described in HIV-infected children; for example in one study 20% of a
HIV-infected cohort of children were hypertensive, a finding of concern. The life-long
cardiovascular risks associated with HIV-infection and its management mandate the
need for closer monitoring and possibly treatment of elevated blood pressure in this
population [234]. A significant proportion of HIV-infected adolescents living in the
USA have been shown to have high coronary and aortic atherosclerotic risk scores,
worse in adolescents on protease inhibitors and not taking tenofovir (although this
may be a challenging bias associated with not putting adolescents with renal
disease on tenofovir) [235].
As the complications of atherosclerosis (myocardial infarction, stroke and peripheral
artery disease) occur later in life surrogate endpoints have been used for the
detection of early signs and disease changes. Anatomical studies have shown that
the atherosclerotic process starts in childhood, even in healthy HIV-uninfected
children [236] and evidence is accumulating that this is accelerated in HIV-infected
children and adolescents [237]. Non-invasive methods such as PWV, IMT and Flow
Mediated Dilation (FMD) are well validated methods of assessing impaired vascular
function and structure have been shown, in some studies, to be abnormal in HIV-
infected young people, Table 2-8. However to date studies have been small, cross
sectional and mostly conducted in middle to high income countries with a
heterogeneous mix of ART exposure and regimens. The additional confounders of
sedentary lifestyle, obesity and dyslipidaemia have been difficult to control for. To
date only a single cross sectional study and no longitudinal studies have been
conducted in an African setting [238].
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Table 2-8. Summary of pre-clinical cardiovascular changes in HIV infected children
and adolescents.
Population Country Mean age inyears (range) Parameters measured Ref.
Differences between HIV+ and controls
49 HIV + (34
on ART for
median 96
months, 15
ART naïve,
27 PI based)
24 HIV– age
/sex matched
France
13.5 (3.5:19)
12 (5:17)
IMT: No difference in IMT seen
between groups (0.47 v 0.49mm)
however reduced variation in
CCA diameter between systole
and diastole and reduced
distensibility in HIV+, no
difference between ART naïve
and experienced.
FMD: Reduced FMD in HIV+
[239]
100 HIV + (all
on ART, for
median 129
months, 48 PI
based, 82
undetectable
VL)
50 HIV -
Thailand
15.5 (12:20)
16.1 (12:19)
IMT: proximal and distal CCA and
ICA, no difference between HIV+
and controls. In HIV+ higher IMT
if on PI regimen (0.38 v 0.36mm)
Echo:4 HIV+ had abnormal
myocardial function – all 4 on PI
based regimen.
[240]
83 HIV + (56
ART
experienced,
48 on ART for
median 5
years, 31 PI
experienced,
23 on PI, 27
ART naive)
59 HIV–
unmatched
UK
11.0 (5: 18)
12.2
IMT: Significantly increased IMT
(0.6 v 0.47) seen in HIV + - age
and PI exposure significant.
FMD: Reduced FMD in controls
compared to HIV+, also reduced
with PI use
PWV: Increased PWV (7.5 v 7
m/s) in HIV+ with an age effect
seen, no difference between ART
naïve and controls, no effect of PI
[241,
242]
83 HIV + (73
on ART for
median 84
months, 37 on
PI, 6 ART
naïve)
83 HIV - age,
sex and
economic
class
matched
Brazil
10.8 (sd 2.6)
10.7 (sd (2.9)
IMT: Increased IMT (0.48 v 0.426)
in HIV+, increased IMT
associated with stavudine use (no
PI effect), high CD8 and low CD4,
lower IMT seen with higher TC
and CD8 zenith.
[243]
150 HIV +
(145 on ART,
115 VL
undetectable)
150 HIV -
age, sex and
BMI matched
Spain 14.9 (3: 24)14.7 (3:23)
IMT: thicker in HIV + v HIV –
(0.434 v 0.424mm). HIV
independently associated with
increased IMT. Low CD4
associated with higher IMT. No
relationship between IMT
inflammation, immune activation
or senescence.
[244,
245]
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No difference between HIV+ and controls
59 HIV + (all
commenced
PI based ART
under 3
months of
age, 91% VL
undetectable)
43 HIV -
South
Africa
7.7 (7.6 – 7.8)
8.5 (7.8 – 8.7)
PWV: after adjustment for age,
gender and sBP no difference in
PWV between HIV + and
controls
[246]
101 HIV + (all
stable on ART
with VL
<1000copies/
ml, median
(IQR) ART 3
(1 : 10 )
years)
86 HIV -
USA
20 (17 : 23)
19 (14 : 23)
PWV: no difference between
HIV+ and HIV -. In HIV + group
PWV was positively associated
with systolic and diastolic BP,
IMT, male sex, current alcohol
use, detectable VL and current
TDF use. PWV negatively
correlated with CD4 count and
ART duration
[247]
No controls; impact of ART
230 HIV + (45
ART naïve,
90 EFV, 76
NVP, 19
LPV/r)
No controls
Ethiopia
6 – 18 years
(no mean
given)
IMT: no difference between
groups
PWV: elevated in LPV/r-treated
subjects v EFV / NVP / ART-
naïve - 5.2m/sec vs. 4.7 / 4.6 /
4.6 m/sec
FMD: no difference between
groups
[238]
Longitudinal Study
Pilot
31 HIV + (all
on ART for
median 64
months, 13 on
PI)
31 HIV –
Baseline
39 HIV + (34
on ART, 30
VL
undetectable,
4 horizontally
infected)
39 HIV –
Week 48
35 HIV +
37 HIV -
USA
9 (2 -20)
9 (2 -21)
Baseline IMT significant
differences between HIV+ and
HIV- ( ICA 0.9 v 0.78 mm, CCA
1.0 v 0.95mm), duration on ART
associated with thicker IMT
In HIV + significant
improvements in ICA
0.73v0.65mm and CCA 0.85 v
0.9mm over 48 weeks, no
significant difference between
HIV+ and HIV-. Improvement in
HIV – not fully explained.
Duration of ART and CD4%
affect change in IMT. Female
sex, age LDL, ART and PI use
all affect change in IM
[248,
249]
CCA, common carotid artery; EFV, efavirenz; FMD, flow mediated dilation; ICA, internal
carotid artery; IMT, intimal medial thickness; LVIMP, left ventricular index of myocardial
performance; LPV/r, lopinavir/ritonavir; NVP, nevirapine; PI, protease inhibitor; PWV,
pulse wave velocity; TC, total cholesterol.
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2.11.1 Use of abacavir in the paediatric population
Abacavir is a key antiretroviral drug in the treatment of paediatric HIV. The PENTA 5
study proved its superiority over other first line antiretrovirals available at that time
[202]. Non-inferiority, compared to d4T and ZDV, has been shown in the CHAPAS-3
study [27], suitable formulations exist and once daily dosing is an option for older
children [64]. ABC remains a preferred first line NRTIs for the treatment of paediatric
HIV in children under 10 years of age / 35 kg [7] as it avoids the toxicities seen with
zidovudine (anaemia), stavudine (lipodystrophy) and tenofovir (renal glomerular /
tubular toxicities and decreased bone mineral density). As discussed in section
2.10.8 the long term impact that ABC has on cardiovascular function in adults
remains undetermined and if there is a true relationship between ABC use and
increased risk of CVD then using it during the paediatric years may be the optimal
time before other risk factors start to increase.
2.12 Conclusions
Paediatric HIV has been transformed since the first case studies of the 1980s to a
chronic but manageable illness, where ART is available. Whilst considerable
progress has been made towards the eventual goal of EMTCT by the end of the
current decade, there are 2 million HIV-infected children and many more perinatally
infected adolescents and adults estimated to be living with HIV.
Commencing children on ART remains the top priority, with ART optimization to
minimise toxicities. The increased risk of CVD in HIV-infected adults and the
potential implications of this for children living with HIV cannot be ignored.
Assessment of cardiovascular health in HIV-infected young children is not easy,
especially at primary or secondary care level and as yet no simple screening test
has been developed for use outside of a research setting
The mechanisms underlying CVD are multifactorial and may vary by setting e.g.
high versus low to middle income countries. Traditional and non-traditional risk
factors contribute to increased cardiovascular risk in HIV-infected populations. The
roles of inflammation and immune activation are likely to be key factors and novel
ways of modulating these pathways such as the use of CCR5 antagonists,
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interleukin antagonists, methotrexate and renin-angiotensin blockade are being
considered.
2.13 Aims of the Thesis
The key aims of this thesis were:
1. To determine the influence of HIV infection on vascular phenotype by comparing
HIV infected ART naïve children with HIV uninfected African controls
2. To determine the effects of ART on vascular phenotype by comparing children
stable on ART to drug naïve about to start treatment and monitor changes in arterial
stiffness over time.
3. To gain insight into the potential mechanisms operating to mediate vascular
dysfunction.
2.13.1 Primary hypothesis
1. HIV infected, ART naïve children have impaired arterial structure and
distensibility compared to HIV uninfected, age matched controls.
2.13.2 Secondary hypotheses
1. 96 weeks of antiretroviral therapy can improve arterial structure and
distensibility in HIV infected children who were previously ART naïve.
2. Significant baseline differences in markers of inflammation, vascular injury
and disordered thrombogenesis exist between HIV infected, ART naïve and
HIV uninfected children.
3. 96 weeks of antiretroviral therapy can improve markers of inflammation,
vascular injury and disordered thrombogenesis exist in HIV infected children
who were previously ART naïve.
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Chapter 3 Methods
This chapter describes the rationale behind the methods selected and the
techniques used to address the specific aims of the project.
3.1 Population and study design - The CHAPAS 3 trial
HIV infected children were recruited in Zambia and Uganda as part of “The Children
with HIV in Africa Pharmacokinetics and Acceptability /Adherence of Simple
Antiretroviral Regimens (CHAPAS) 3 trial”. This was an open label randomised
phase II/III trial (ISRCTN69078957) evaluating new formulations of solid, dispersible
scored antiretroviral fixed dose combinations (FDC). CHAPAS 3 tested the
hypothesis that the newly formulated FDC tablets containing abacavir (ABC) or
zidovudine (ZDV) rather than stavudine (d4T) would provide superior toxicity and/or
adherence/acceptability profiles in both ART naïve (group 1) and ART experienced
(group 2) children, whilst maintaining adequate pharmacokinetics and similar cost-
effectiveness and viral load suppression. Children were aged 13 years or younger;
those recruited to group 2 had to have been on d4T containing first line ART for a
minimum of two years and have an undetectable viral load (VL) at recruitment.
Specific inclusion and exclusion criteria are listed in Table 3-1.
The local team verbally explained the study and recruited the children; all families
were given a patient information leaflet written in English, Nyanjan (Lusaka) or
Lugandan (Uganda) as appropriate. Children from each group were randomised to
one of 3 treatment arms; ABC v ZDV v d4T with 3TC and either nevirapine (NVP) or
efavirenz (EFV) and followed for 96 weeks. The choice of NVP or EFV was made by
the clinical team; generally children aged under 3 years received NVP.
Randomisation was stratified by age/ART experience, NNRTI and centre.
A total of 480 children were recruited at 4 sites (three in Uganda, one in Zambia)
between the 8th November 2010 and 28th December 2011. The last child recruited
reached 96 weeks follow up on the 30th October 2013. At the end of the trial children
remained on ART (the ART regimen dictated by local availability/national guidelines)
and continued to receive ongoing healthcare in a local clinic (where possible) or at
the trial centre.
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Inclusion Criteria
1. Aged 1 month to 13 years
a) ART naïve children in Uganda randomised to a d4T based regimen must be
0-4 years old in accordance with local guidelines
b) ART experienced children randomised to continue therapy on a d4T based
regimen must be ≥5 years without symptoms of lipodystrophy.  
2. Weight >3kg and <25kg
3. Participants must have a confirmed documented diagnosis of HIV-1 infection
a) <18 months: two separate peripheral blood specimens taken on different
days, both must test positive with HIV-DNA PCR.
b) ≥18 months: antibody positive serology by ELISA test (confirmed by licensed 
second ELISA or Western Blot) or WHO approved rapid test (performed in
series) both on the same sample.
4. Parents or guardians, and children where appropriate, must be willing and able to give
informed consent for randomisation to first-line ART strategy
5. a) ART naïve (except perinatal ART for PMPCT), meeting WHO or national (WHO
modified) criteria for initiating therapy and ready to start an initial 2NRTI+NNRTI based
regimen according to local guidelines.
 WHO paediatric clinical stage IV disease: treat regardless of CD4 absolute/%
 WHO paediatric clinical stage III disease:
o < 12 months: treat all
o > 12 months: treat all children irrespective of CD4 absolute/% except
tuberculosis, lymphocytic interstitial pneumonia (LIP), oral hairy
leukoplakia (OHP) or thrombocytopenia guided by CD4 assays
 WHO paediatric clinical stage II or I disease: treat guided by CD4 absolute/%
percent or count ( as per WHO guidelines in 2010)
Criteria to start ART
Age <12 months 12 - 35 months 36 - 59 months ≥5 years  
%CD4
All
<20 <20 <15
Absolute CD4 <750mm3 <350mm3 <200
b) ART experienced, currently taking first line d4T based regimen ≥ 2 years with: 
 screening HIV RNA viral load <50 copies/ml
 no history of receiving other ART
 CD4 count and/or CD4 percent stable over the previous 6 months.
Exclusion Criteria
1. Cannot, or unlikely to attend regularly (e.g. lives too far from study centre)
2. Likelihood of poor adherence
3. Presence of acute infection (e.g. malaria, helminthiasis, acute hepatitis, acute
pneumonia, septicaemia, meningitis). Children may be admitted after recovery of an
acute infection. Children with chronic lung disease, including recurrent respiratory
infections, are eligible. Children with tuberculosis (TB) not be enrolled during the
intensive phase of TB treatment.
4. In receipt of medication contraindicated by ART
- Children <3 years on TB treatment should not be enrolled (as they will have
to receive nevirapine).
- on chemotherapy for malignancy
5. Laboratory abnormalities which are a contra-indication for the child to start
ART/change to any of the 3 possible regimens (haemoglobin <8.5g/dL; neutrophils
<0.50x109/L; AST or ALT >5 x the upper limit of normal (ULN); grade 3 renal
dysfunction - creatinine >1.9 x ULN).
6. Being pregnant or breast-feeding an infant
7. Perinatal exposure to NVP (either through PMTCT or breastfeeding) for children aged
3 - 6 months only
Table 3-1. Inclusion and exclusion criteria for children recruited to CHAPAS 3
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3.1.1 Ethical approval and consent
The CHAPAS 3 trial including cardiovascular sub-study has full ethical approval
from University College London (1665/002), Baylor College of Medicine, Uganda (H-
27028), Joint Clinical Research Centre, Uganda, National Drug Authority, Uganda
(293/ESR/NDA/DID-12/2010), Uganda National Council for Science and Technology
(HS 774), University of Cape Town (143/2010), Pharmaceutical Regulatory
Authority, Zambia (DMS/105/1/112) and The University of Zambia (012-01-09).
Parents / guardians of all children included in the study provided written informed
consent for study entry. Older children deemed competent provided informed
consent / assent as appropriate. Example consent forms are given in appendix 1.
Families / guardians received reimbursement for their travel expenses and children
received a meal at clinic visits which required them to be fasted but no financial
incentives were given for participation in the study.
3.1.2 Funding
The CHAPAS 3 trial was funded from a European & Developing Countries Clinical
Trials Partnership (EDCTP) award. The cardiovascular sub-study was fully funded
by a Wellcome Trust Research Training Fellowship competitively awarded to myself.
3.1.3 Clinical data management
All CRFs were double entered locally by the data entry team to a central database
held at the MRC Clinical Trial Unit. All patients and controls were anonymized and
the database was password protected.
3.2 Selection of methods to assess the structure and arterial
stiffness of the vascular system
Several methods of assessing early pre-clinical changes in the cardiovascular
system have been described including coronary artery calcification, flow mediated
dilation (FMD), intimal medial thickness (IMT) and pulse wave velocity (PWV). Given
the age, size and number of the children that were to be assessed annually,
investigations had to be quick, harmless (not involving any radiation) and painless.
The techniques had to be simple allowing a number of local doctors and nurses at
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each site to be trained to a high standard with acceptably low inter and intra
operator variability. Any required equipment had to be affordable, transportable and
sufficiently robust to cope with hot, humid and dusty environments.
Coronary artery calcium scores and coronary computed tomographic angiography
been described in adult populations and provide tools to assign cardiac risk in
adults. However the equipment required (a computerised tomography (CT)
scanner), the radiation exposure and lack of evidence of any detectable changes in
young children meant these techniques were not appropriate for this study [250].
FMD, whilst useful in assessing endothelial dysfunction [251, 252], requires patients
to lie very still for a minimum of 10 minutes and is very sensitive to environmental
and lifestyle factors such as ambient temperature [253], recent food consumption
[254], mental stress [255] and intercurrent illnesses [256]. For these reasons using
FMD was deemed unfeasible for this very young population.
IMT is a measurement of the thickness of tunica intima and tunica media, the
innermost two layers of the artery wall (Figure 3-1), IMT provides a method of
detecting pre-clinical thickening which is described in the early stages of the
atherosclerotic process [257]. It is measured by non-invasive high resolution B mode
ultrasonography. In B-mode (brightness mode) ultrasound, two-dimensional images
are produced from a linear array of transducers simultaneously scanning across a
plane. In adults, IMT has been extensively measured in different populations and
disease states; it can be related to cardiovascular risk and used as a surrogate
endpoint for evaluating the regression and/or progression of atherosclerotic
cardiovascular disease [258-262]. A relationship between measured IMT and
histological findings has been described [263] and improvements in IMT following
therapeutic interventions with anti-hypertensive medication, lipid lowering agents
and strict diabetic control reported [264-266]. IMT is influenced by age, ethnicity,
diabetes mellitus [267, 268], dyslipidaemia [269, 270], hypertension [271, 272]
cholesterol, BMI and smoking [273].
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In paediatric/adolescent studies an increased aortic IMT has been demonstrated in
children at high risk of developing atherosclerosis [274] and known cardiovascular
risk factors are associated with increased carotid IMT [275-279]. As described in
section 2.11 and detailed in table 2.8 a number of studies looking at IMT in older
HIV infected children have been carried out with conflicting results.
An increase in arterial stiffness has been demonstrated early in the process of
atherosclerosis. PWV is a well-established non-invasive reproducible technique for
measuring arterial stiffness [280-282]. PWV can be affected by ambient
temperature, movement and recent food consumption, however is relatively simple
to perform and if performed carefully, confounding factors can be minimised. An
increase in PWV is strongly correlated with cardiovascular risk factors and events
[283] and all-cause mortality [284-286]. HIV infection has been demonstrated to
have a detrimental impact on PWV in HIV-infected adults [86, 287] and as detailed
in section 2.11 and table 2.8 in children [238, 241].
IMT and PWV were therefore felt to be the most practical and robust techniques to
use for this study. Whilst no published data existed in children less than 5 years of
age at the time the study was being designed, it was considered feasible to attempt
Adventitia
Media
Intima
Figure 3-1. Cross section through an artery.
A) a normal artery showing the 3 layers of the arterial wall and B) early changes in the
atherosclerosis process are thickening of the intimal and medial layers with narrowing of
the lumen.
A B
86
the these techniques in children of all ages. The sample size was sufficient to
absorb loss of data from a predicted significant proportion of the younger children
whom may be un-cooperative with the scanning techniques.
3.3 Technique to measure Intimal Medial Thickness
Whilst theoretically any artery can be used to measure IMT, the carotid artery is
most frequently used. Peripheral arteries such as the femoral, brachial and radial
arteries are more muscular and changes in IMT are more difficult to interpret [288].
The common carotid artery (CCA), 1 -2 cm proximal to the carotid bulb runs close
and parallel to the skin surface, so it is easier to obtain clear images and accurate
measurements. The internal carotid artery (ICA) and carotid bulb are not studied as
frequently as obtaining measurements is more technically demanding especially in
young children with shorter necks [289, 290]. Atherosclerotic lesions appear later in
the CCA compared to within the ICA or bifurcation although thickening at all sites is
equally associated with risk of subsequent cardiovascular events [261, 266]. IMT
measurements can be taken from either the near or the far wall of the artery; far wall
measurements are generally preferred as obtaining reliable and reproducible
images of the near wall are dependent upon gain settings and are more difficult to
standardise. Reproducibility of IMT measurement is improved if the mean, rather
than the maximum IMT is measured and if automated software for analysis is used
[291].
The protocol followed was the standard protocol used by the Vascular Physiology
Department, University College London [241]. A robust and portable ultrasound
machine, the Sonosite MicroMaxx® (FUJIFILM SonoSite, Washington) was used at
both sites - Figure 3-2.
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Following an explanation of the investigations, patients lay semi prone / supine
either on an examination couch or in their carers’ arms. Ambient temperature was
recorded and children were distracted using hand puppets. Using a 13-6 MHz
Transducer the carotid bulb was identified and the segment of the common carotid
artery 1cm proximal to the bulb located. The transducer was then placed parallel to
the carotid artery with the lumen maximised in the longitudinal plane. The probe was
gently repositioned until an image was obtained that was sufficiently centred and
clear – as demonstrated in Figure 3-3. The image had to allow quantitative
measurements of:-
a) The vessel interfaces; the near and far wall adventitia-periadventitia, media-
adventitia, lumuna-intima of both common carotid arteries, and carotid bulbs.
b) The wall thickness; including mean and maximum intimal-medial thickness of
near and far walls of both common carotid arteries.
c) The vessel width; including mean and maximum width of the common carotid
arteries.
Once an optimal image was obtained, a minimum of 3 separate 10 second
recordings were saved in Digital Images and Communication in Medicine (DICOM)
format. These were downloaded for transfer to the UK for subsequent offline
analysis using an automated computerized edge tracking package (Carotid Analyzer
Figure 3-2. The Sonosite Micromaxx portable ultrasound machine.
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for Research (Medical Imaging Applications, Iowa, USA)). Carotid IMT was
calculated as the distance between the first bright line (luminal-intimal interface) and
the leading edge of the second bright line (medial-adventitial interface) as
demonstrated in Figure 3-4. Since the IMT of the carotid artery changes throughout
the cardiac cycle (maximal during diastole), the three measurements of the right and
left CCA at the end of diastole from three different frames were averaged [241]. For
a cIMT scan to be accepted, all readings (end diastolic diameter, systolic diameter
and end-diastolic IMT) from both sides had to be with 0.1mm of each other. If a
medical practitioner was only able to obtain an analysable scan on one side, the
mean of 3 readings from that side was calculated.
Figure 3-4. Calculation of cIMT using Carotid Analyzer for Research
automated software.
Figure 3-3. Ultrasound image of the left common carotid.
A, intima; B, media; C, adventitia
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3.4 Technique to measure Pulse Wave Velocity
PWV was measured after the IMT. The majority of babies and children had been
fasted for at least an hour prior to the PWV being performed. Where this was not
possible the time of last milk / meal was documented. Recordings were performing
with the children lying in the semi-prone position (at approximately 30°) to prevent
venous contamination of the arterial signal. The PWV was measured using a
Vicorder (Skidmore Medical, Bristol, UK) - Figure 3-5.
Figure 3-5. Picture of the Vicorder used to measure the Pulse Wave Velocity
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The carotid artery was palpated and a 30mm neck cuff placed where the carotid
artery pulse could be palpated. An appropriately sized femoral cuff was placed
proximally on the thigh, as high as possible. Three distances were recorded using a
paper tape measure to the nearest mm:
a) Distance between the base of the carotid cuff and suprasternal notch
b) Distance from the top of the suprasternal notch to the middle of the thigh cuff
c) The direct measurement between the base of the carotid cuff to the middle of the
thigh cuff.
Once the cuffs were adequately positioned they were simultaneously inflated to
60mmHg. Ten seconds of waveform data were recorded once a reproducible signal
was obtained, Figure 3-6, and the integral software calculated the difference in
speed from the upstrokes of the waveforms. A PWV was calculated on this
difference, and the arterial path length between the two sites [242]. PWV was
calculated as the distance: transit time ratio and expressed as meters per second
(m/sec). For each subject at least 3 PWV readings within 0.5m/second were
recorded and the mean calculated.
To date no consensus has been reached as to how best to standardize
measurement of the arterial path [292]. For this study direct measurements from the
suprasternal notch to the middle of the femoral cuff were used. This excludes the
proximal segment of the aorta and includes a variable length of iliac and femoral
arteries [284, 286]. Two other methods of measurement have been described.
Firstly, direct measurements from the base of the carotid cuff to the top of the
femoral cuff and then subtracting the distance from the base of the carotid cuff to the
suprasternal notch [293]. Alternatively measuring the distance between the carotid
and femoral sites directly, and applying a correction factor of 0.8 has been
suggested which appears to fit better with actual path length distance, measured
from MRI [294]. The different methods used may give different values. PWV results
obtained using a direct measurement between carotid and femoral cuffs will be
higher than those using the other methods used. This may limit comparison with
other cohorts or its utility for clinical use to stratify vascular risk. For this study all
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measurements were recorded so that adjustments could be made retrospectively if
needed.
Figure 3-6. Example of a PWV trace obtained.
The carotid waveform is displayed in the top half of the screen, the femoral waveform
is displayed in the bottom half of the screen. The waveforms are consistent beat to
beat with the amplitude optimised
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3.5 Blood pressure measurement
Accurate measurement of blood pressure (BP) can be difficult in childhood. Options
include a manual sphygmomanometer or automated oscillometric devices such as
the Omron M2 (Omron Healthcare, Milton Keynes, UK), which have been validated
in children. The automated machines have the advantage that they are smaller,
portable and are without observer bias. The Omron M2 was chosen after ensuring
paediatric validation with the Association for the Advancement of Medical
Instrumentation (AAMI), The British Hypertension Society working party on BP
measurement and the European Society for Hypertension [295].
3.6 Biomarkers
3.6.1 Rationale behind biomarkers selected.
As will be discussed further in Chapter 6.1 and summarised in table 6.1 a large body
of literature exists describing the changes in biomarkers with HIV infection and the
use of these markers in HIV disease progression and cardiovascular risk
assessment. I set up a panel of 19 biomarkers to be studied in several trials within
Professor Klein’s HIV laboratory. Together they form a comprehensive panel
covering markers of inflammation (IL-1Ra, CRP, TNFa, IL-10, IL-6, IL-8, serum
amyloid A (SAA) and ICAM-3), cardiovascular injury (MCP-1, Angiopoeitin-1 and 2,
E-selectin, P-selectin, sICAM-1, VCAM, VEGF) and disordered thrombogenesis (d-
dimer, thrombomodulin (TM) and tissue factor (TF)).
3.6.2 Rationale behind methods selected.
The blood volume that can be collected in children is limited, which influenced the
techniques selected for this study. The assay selection was also influenced by the
robustness to freezing at -70oC for variable periods of time. Multiple assays had to
be able to be run on one day to avoid repeat freeze-thaw cycles.
3.6.3 Laboratory methodology
Blood was collected in Ethylenediaminetetraacetic acid (EDTA) and spun within 4
hours of collection at 1500g (≥2500 rpm) for 15 minutes to separate cells from 
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plasma. The supernatant was removed and placed in aliquots with a minimum of
500µL of plasma in each cryovial. Samples were immediately frozen at -70oC.
All samples were transported on dry ice to the Institute of Child Health, UCL and the
assays ran in batches. All standards were run in duplicate. Initial work within our lab
showed that the co-efficient of variance (CV) between duplicate samples was ≤10%. 
Given the small volumes of blood available and the cost of the reagents and
consumables, 95% samples were run singularly, with 5% duplicated to ensure
consistent intra and inter assay precision. The lower limit of detection, determined
by the mean +2 standard deviations of the output signal of 10 blank samples, was
calculated for each biomarker.
3.6.4 Meso scale discovery (MSD) technique
A total of 17 biomarkers were analysed using Meso Scale Discovery (MSD) assays
(MesoScale Discovery, Gaithersburg, MD, USA). MSD assays use an
electrochemiluminescence detection method similar to a sandwich ELISA technique.
Electrochemiluminescent (SULFO-TAG) labels are conjugated to detection
antibodies. The microplates have high binding carbon electrodes in the base. Within
the analyser, electricity applied to the plate electrodes causes light emission by the
SULFO-TAG labels. Light intensity is then measured to quantify analytes in the
sample. Multiple excitation cycles of each label amplify the signal to enhance light
levels and improve sensitivity allowing ultrasensitive assays to be run [296].
Five MSD plates were used, 3 of which were custom built for this study, Table
3-2Error! Reference source not found. summarises the details of the plates used.
Assays were conducted according to standard manufacturer’s protocols. Samples
were read using the QuickPlex SQ analyser (Meso Scale Discovery®, Gaithersburg,
MD, USA).
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Method Plate Biomarker Units Lower limit of detection
TM ng/ml 0.064
ICAM-3 ng/ml 0.064
E-SEL ng/ml 0.064
P-SEL ng/ml 0.064
SAA ng/ml 10.9
CRP ng/ml 1.33
VCAM-1 ng/ml 6
ICAM-1 ng/ml 1.03
IL-6 pg/ml 0.192
IL-8 pg/ml 0.132
IL-10 pg/ml 0.0806
MCP-1 pg/ml 0.116
TNFa pg/ml 0.0798
VEGF pg/ml 0.229
IL-1Ra IL-1Ra pg/ml 2.44
Ang-1 pg/ml 24.4
Ang-2 pg/ml 2.44
TF TF pg/ml 0.69
D-dimer D-dimer ng/ml 0
ELISA
IL-1Ra, interleukin-1 receptor antagonist; CRP, C reactive protein; TNFa, tumour necrosis factor A; IL-10, interleukin-10; IL-6,
interleukin-6; IL-8, interleukin-8; ICAM-3, intracellular adhesion molecule-3; SAA, soluble amyloid A; MCP, Monocyte
chemoattractant protein-1; Angio 1, angiopoietin-1; Angio 2, angiopoietin-2, Ang 2: Ang 1, ratio of angiopoietin 2:1; sICAM, soluble
intracellular adhesion molecule; VCAM, soluble vascular cell adhesion molecule-1; VEGF, vascular endothelial growth factor; TF,
tissue factor; TM, thrombomodulin.
MSD
Vascular injury-1
Vascular injury-2
Custom cytokine
Ang 1+2
Table 3-2. Summary of Biomarkers measured.
Method used for detection and lower limit of detection per assay
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3.7 Tissue factor
Tissue Factor (TF) levels were measured using a commercial quantitative sandwich
Enzyme-Linked Immunosorbent Assay (ELISA) kit (Quantikine® ELISA Human
Coagulation Factor III/Tissue Factor, R&D Systems, Minneapolis). 100 µL of assay
diluent (R&D) was added to 96-well microplates pre-coated with a monoclonal
antibody against human tissue factor. Subject plasma was diluted two-fold in
Calibrator diluent RD5-20 (R&D). 100uL standards (R&D) and diluted subject
plasma were added and incubated for 2 hours at room temperature on a horizontal
orbital microplate shaker set at 600 rpm. The plate was manually washed 4 times
using Wash Buffer (R&D), and excess fluid removed by tapping the plate on a paper
towel before 200 µL of Tissue factor enzyme linked polyclonal antibody conjugate
was added. After further 2 hours incubation the wash cycle was repeated and 200
µL of substrate solution (stabilized hydrogen peroxide / chromogen
(tetramethylbenzidine) R&D) added. The plate was then protected from light during
the final 30 minutes incubation after which 50µL of stop solution (2N Sulfuric Acid,
R&D) was added and optical density was measured within 30 min using a
microplate reader (Thermo Multiskan EX) set to 450nm. A four parameter logistic
curve fit was calculated using Ascent software 2.6 (Thermo Labsystems Oy) and the
concentration read from the standard curve and multiplied by the dilution factor of 2.
3.8 D-dimer
The commercial TECHNOZYM® D-dimer ELISA assay (Technoclone, Austria) was
chosen following a comparison of 2 ELISA methods with 2 automated methods used
in the NHS coagulation laboratory at Great Ormond Street Hospital. The
TECHNOZYM assay provided consistent results and required smaller volumes of
blood than the automated methods.
Undiluted samples were used after pilot runs showed most patients had levels below
the limit of detection when a 2 fold dilution was used. 100ul of calibrator and sample
were added to wells pre-coated with anti D-dimer monoclonal antibody then
incubated at 37oC for 60 minute. Following manual plate washing 3 times using
wash buffer (Technoclone – PBS; pH 7.3) 100ul conjugate (monoclonal Anti D-
dimer-POX) working solution was added before further 60 minute incubation at
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37oC. Following a second plate wash 100ul substrate solution (Chromogen
tetramethylbenzidine) was added. After a 10 minute incubation at room temperature
100ul stop solution (sulphuric acid) was added and the plate read immediately using
a microplate reader (Thermo Multiskan EX) set to 450nm. A linear regression curve
fit was calculated using Ascent software 2.6 (Thermo Labsystems, Helsinki, Finland)
and the concentration read from the standard curve.
3.9 Immunophenotyping
3.9.1 Immunophenotyping background
The concept of the role of immune activation in the pathogenesis of AIDS is not new
[297-299]. Strong indirect evidence comes from studies of Simian Immunodeficiency
Virus (SIV) infections in Rhesus macaque and Sooty mangabey monkeys. SIV
infected Sooty mangabey monkeys whom, despite high levels of viral replication,
have low levels of immune activation and do not progress to AIDS. Conversely SIV
infected Rhesus macaque monkeys have increased levels of immune activation and
progress to AIDS [93, 300-303]. Assessment of immune activation and proliferation
can be made through measuring HLA-DR, CD38, CD45RA/RO and Ki-67, on T cell
subsets [304-306]. Human studies have described that excessive or uncontrolled
immune activation, evidenced by high levels of activated CD8 T-cells expressing
CD38 and HLA-DR, correlate with CD4 death [307] and disease progression more
closely than viral load [308-311].
To characterise the extent of immune dysfunction in individual patients 2 panels
were used looking specifically at activation and proliferation markers - Table 3-3.
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Table 3-3. T cell markers studied
Marker Function Effect of HIV Ref.
Activation panel
HLA-DR
A MHC class II cell surface
receptor that is up-regulated
on activated T cells
Related to viral load
A sensitive marker of disease
progression
[312]
CD38
A transmembrane glycoprotein
expressed by T, B and
dendritic cells, associated with
intracellular signalling
A T-cell activation marker but
is very person and disease
specific, changes can be seen
with intercurrent infections and
with disease progression.
CD8+CD38+ strongly related to
disease progression in ART naïve
patients. On ART levels abnormally
high despite VL suppression, which
are of unknown significance but may
represent a CD38+ compartment
enriched in naïve recent thymic
emigrants (CD45RA+)
CD8+CD38-HLA-DR+ identified in
elite controllers and have a protective
function
[94,
309,
310,
313-
317]
Proliferation panel
CD45
Leukocyte common antigen.
2 isoforms RA/RO. CD45RA+
are naïve cells, CD45RO+ are
memory cells having been
exposed to antigen.
At birth >90% are naïve cells
the proportion of which
progressively decreases until
18 years of age by which 50%
naïve : 40% memory cells.
With HIV infection memory cells lost
more than naïve in adults.
After commencing ART in adults
initially redistribution of memory cells
then an increase in naïve cells
Post ART initiation in children
increase mainly in naïve component
With treatment interruption CD4
expression of RA and RO remains
constant in children
[47,
48,
318,
319]
CD31
Also known as platelet
endothelial cell adhesion
molecule-1
CD31+ recent thymic
emigrants, fall with age.
CD31- have proliferated in the
circulation
With ART CD31+CD45RA+ see
similar levels to controls, CD31-
CD45RA+ remain lower than controls.
[320]
Ki67
A nuclear cell cycle antigen
Expressed preferentially during
all active phases of the cell
cycle but absent in resting cells
(G0), making it a useful marker
of proliferation
In ART naive individuals up to 50% of
the circulating cells may be
proliferating then dying
ART reduces proportion of
proliferating cells
[321]
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3.9.2 Whole blood flow cytometry staining protocol
To assess activation an activation panel was set up to subdivide CD4+ / CD8+ cells
into 4 populations based upon expression or lack of HLA-DR and CD38 and to
quantitatively detect the percentage of cells within each of these populations that
expressed HLA-DR. Within 4 hours of collection whole blood was incubated for 30
minutes at room temperature with 4 antibodies; anti-HLA-DR, anti-CD3, anti-CD8
and anti-CD38 - Table 3-4. Appropriate isotypic controls (mouse IgG1-PE and
IgG2b-APC) were used to evaluate non-specific staining. Cells were then washed
with Automacs Buffer (Milteny Biotec Inc. Auburn, CA, USA) to remove unbound
antibody and lysed red blood cells and re-suspended in Phosphate buffered saline
((PBS), Invitrogen Ltd, UK) supplemented with 1% paraformaldehyde.
Table 3-4. Antibodies used in flow cytometric analysis.
Human target
molecule Mouse isotype Conjugate Source
Activation panel
HLA-DR IgG2b APC BD Biosciences UK
CD3 IgG PerCP BD Biosciences UK
CD8 IgG1 FITC BD Biosciences UK
CD38 IgG1 PE BD Biosciences UK
Proliferation panel
CD4 IgG1 PerCP BD Biosciences UK
CD45RA IgG2b APC BD Biosciences UK
CD31 IgG1 PE BD Biosciences UK
Ki67 IgG FITC BD Biosciences UK
The source, mouse isotype and flurochrome conjugation used are detailed. FITC -
fluorescein isothiocyanate, PerCP - peridinin chlorophyll protein, PE - phyoerythrin, APC –
allophycocyanin.
To assess proliferation, a flow cytometric assay was used to subdivide CD4+ T cells
into four populations based on expression of CD45RA and CD31 and to
quantitatively detect the percentage of cells within each of these populations that
expressed Ki67. Within 4 hours of collection whole blood was incubated with 3
antibodies: antiCD4, anti-CD45RA and anti-CD31 with appropriate isotypic controls
(mouse IgG1-PE and IgG2b-APC) - Table 3-4. The red blood cells were lysed and
washed with Automacs Buffer. The remaining cells were fixed then permeabilised
with Perm Buffer containing Saponin (Sigma-Aldrich, UK). Saponin was chosen as it
does not destroy the cell or affect membrane expression of surface antigens. Cells
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were then incubated with anti-Ki67 antibody for 30 minutes. The excess antibody
was removed by washing with Perm buffer followed by FACS buffer the cells were
re-suspended and fixed in Phosphate buffered saline ((PBS), Invitrogen Ltd, UK)
supplemented with 1% paraformaldehyde.
All samples were analyzed by four-color flow cytometry using a FACS Calibur
(Becton-Dickinson) with a 488 nm argon-ion laser and a 635 nm red diode laser.
50,000 events were collected in the lymphocyte gate using morphological
parameters (Forward and Side scatter). Data were processed using CellQuest Pro
Software (Becton-Dickinson).
Data was stored and transferred to the UK. Consistency was ensured by a single
observer re-analysing all the data. Flow Jo software version 7.6.4 (Treestar Inc,
California, USA) was used and the methods used for analysis were in agreement
with techniques used in the clinical laboratories at Great Ormond Street Hospital.
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3.9.3 Identification of activated lymphocytes
Forward and side scatter were used to identify the lymphocytes, monocytes and
neutrophils to which tight gates were applied Figure 3-7 i). A gate was applied to the
monocyte population, and the proportion expressing DR used to set the gates for
subsequent analysis. If a clear boundary could be identified on a dot plot this was
used; for indistinct plots, a contour plot helped place the gate at the point where the
contours start to space out.
The percentage of monocytes positive for HLA-DR (quadrant 2 (Q2) was recorded
along with the mean fluorescence intensity (MFI) of HLA-DR - Figure 3-9. The
lymphocyte populations were then selected and the CD3+ cells divided into
populations of CD4+ and CD8+ cells - Figure 3-8. The CD4 and CD8 populations
were divided into 4 sub populations based on the expression of HLA-DR and CD38 -
Figure 3-10 using the same gate set after gating on DR expression by monocytes.
Figure 3-7. Identification of activated lymphocytes.
A. Plot of forward against side scatter height, tight gates applied to each cell
population (lymphocytes, monocytes and neutrophils). Monocyte population were
then selected B. plot of monocyte population; gated to identify the HLA-DR+
population, this gating was used for subsequent analysis.
A B
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Figure 3-8. Using the lymphocyte population to separate into CD4+ and CD8+
lymphocytes.
A) Gating on the lymphocytes the CD3+ population were selected
B) and C) CD3+ cells were divided into CD8- (CD4+) and CD8+
A B C
Figure 3-9. Using the monocyte population to set the DR gate
The percentage of DR+ monocytes (Q2) and MFI of the HLA-DR were then able
to be calculated.
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Figure 3-10. Using the expression of HLA-DR and CD38 to sub divide into 4
populations
Dividing A) CD4 and B) CD8 cells into 4 sub populations based upon the expression of
HLA-DR and CD38
A B
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3.9.4 Analysis of proliferation data
Forward and side scatter were potted to identify the lymphocyte population. The
lymphocytes were gated Figure 3-11 A) and the CD4+ population Figure 3-11 B)
then subdivided into 4 populations based upon the expression of CD31 and
CD45RA, Figure 3-12.
Figure 3-11. Identification of the CD4+ lymphocyte subpopulation.
A) Using forward and side scatter to identify the population of lymphocytes B) CD4+
lymphocytes selected.
A
B
104
Figure 3-12. Diving CD4+ lymphocytes into 4 subpopulations based upon the
expression of CD31 and CD45 RA.
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The proportion of proliferating cells, as evidenced by expression of Ki67, was then
quantified in the total CD4+ lymphocyte population as well as in each sub-
population. The gates were applied using the dot plot and contour plots adding the
gate where the contour lines become less dense, Figure 3-13.
Figure 3-13. Quantifying the proportion of Ki67 + cells
A) CD4+ lymphocytes, B) CD31+ CD45RA- lymphocytes, C) CD31+ CD45RA+
lymphocytes, D) CD31- CD45RA+ lymphocytes, E) CD31- CD45RA- lymphocytes.
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3.10 Missing data
For the cardiovascular scans (IMT/ PWV) incomplete baseline data was mainly due
to the young age of children. The age range of HIV-infected / controls with
cardiovascular scan data remained balanced and further analyses took account of
missing data. Less than 5% of patients had missing biomarker results at any time
point whilst technical difficulties with the IPT data meant that <24% samples at each
time point were missing but subsequent analyses were adjusted for this.
3.11 Statistics
Comparison of categorical variables was performed using Chi squared test or
Fishers exact test (depending upon sample size). Normally distributed data is
expressed as mean +/- SD, where normality cannot be assumed, the median with
the range or interquartile range (as appropriate) will be stated. Parametric tests were
used whenever possible (i.e. when the data is normally distributed, or can easily be
transformed to normality). Normality of the data was assessed by plotting
histograms and applying the Kolmogorov-Smirnov test of normality. When the data
could not be transformed, non-parametric tests were performed. The differences in
the distribution of non parameteric parameters were tested using the Mann-Whitney
test (2 groups) or Kruskal-Wallis (3 or more groups). Associations between 2
continuous variables were tested for statistical significance using the Spearman’s
rank correlation test. Comparisons of related variables in the same subject were
performed using the Wilcoxon signed rank test. All tests for statistical significance
were two-tailed and p valves <0.05 were considered significant. Repeated
measurements collected from the study population linear mixed effects models were
used to assess the association of IMT and PWV with clinical and sociodemographic
characteristics of the HIV infected study population. Multiple regression analysis,
backward elimination selection was used to determine variables independently
associated with cardiovascular parameters. P values and coefficients they were
rounded to 2 decimal places / 1 significant figure. Stata 13 analysis package
(Statacorp. College Station, TX) was used for data analysis.
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Chapter 4 Establishing the cardiovascular sub study
4.1 CHAPAS 3: The Cardiovascular Sub study
The CHAPAS 3 cardiovascular sub study was established at 2 of the 4 CHAPAS 3
sites; University Teaching Hospital (UTH), Lusaka, Zambia and the Joint Clinical
Research Centre (JCRC), Kampala, Uganda (see Chapter 3 for details of the CHAPAS
3 study). The funding available only permitted recruitment to the cardiovascular sub-
study at 2 of the 4 sites so the larger sites that had capacity to employ additional staff
were selected. All 282 children recruited at these 2 sites were consented and enrolled
into the cardiovascular study at the same time as enrolment to the main CHAPAS 3
study; no children were excluded. In addition 284 age-matched HIV uninfected control
children were recruited from community well child clinics, surgical outpatient clinics and
healthy siblings of CHAPAS 3 patients. Eligible controls (for inclusion / exclusion criteria
see Table 4-1) were approached by the local study team, the study explained verbally
and a patient information leaflet was provided in English, Nyanjan (Lusaka) or
Lugandan (Kampala) as appropriate. To confirm HIV status all children had an HIV 4th
generation antibody test performed. If this was positive and the child was aged less
than 18 months of age a HIV DNA PCR was performed. If either the 4th generation
antibody test (>18 months) or the HIV DNA PCR (<18 months) was positive a repeat
confirmatory test was performed on a second sample. If a child was found to be HIV-
infected the child was referred for routine HIV care. The control children were assessed
once and not followed up.
CHAPAS 3 recruits were seen at screening, baseline (week 0), 2 weeks, 6 weeks then
at a minimum of 12 weekly intervals until the end of the trial (defined as the last patient
recruited reaching week 96 – 30th October 2013). The cardiovascular assessment is
detailed in Table 4-2. Medical and family histories were obtained, specifically
documenting personal and family history of cardiovascular disease, birth
weight/gestation and parental tribe. Anthropometric measurements, skin fold thickness
and body circumferences were measured every 24 weeks. HIV disease activity was
assessed by general health, clinical examination and monitoring of CD4 count as part of
the CHAPAS 3 protocol. A full blood count, renal and liver function tests were
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performed 24 weekly. An additional 5ml of blood was taken at 0, 48 and 96 weeks for
extended cardiovascular assessment. Blood was processed immediately for 2
immunophenotyping (IPT) panels looking at markers of immune activation and
proliferation (see section 3.9). The remainder of the blood was collected into EDTA and
citrate tubes, spun within 4 hours of collection and frozen at -70oC for later batch
analysis of biomarkers of systemic inflammation, disordered thrombogenesis and
cardiovascular damage. Vascular assessment using non-invasive techniques to
measure cIMT and PWV were performed at 0, 48 and 96 weeks. Examples of the
consent and clinical report forms (CRFs) used are in appendix 1.
Inclusion Criteria
1. Aged 1 month to 13 years
2. Weight >3kg and <25kg
3. Parent / guardian and children (where appropriate according to age and
knowledge of HIV), must be willing and able to give informed consent for
HIV testing and cardiovascular assessment
4. Confirmed HIV-1 uninfected
a. All children aged ≥18 months: antibody negative serology by 
ELISA test or WHO approved rapid test
b. For children aged <18 months: either antibody negative serology
by ELISA test / WHO approved rapid test or a negative HIV-DNA
PCR.
Exclusion Criteria
1. Presence of acute infection (e.g. malaria, helminthiasis, acute hepatitis,
acute pneumonia, septicaemia, meningitis).
2. Children with tuberculosis (TB) during the intensive phase of anti-
tuberculosis therapy
3. Being pregnant or breast-feeding an infant
Table 4-1. Inclusion and exclusion criteria for HIV uninfected children recruited to
the control arm of the cardiovascular sub-study.
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Table 4-2. Overview of the CHAPAS-3 cardiovascular sub-study.
Frequency Rationale for inclusion indata collection
Low birth weight a RF for
CVD
Genetic RF for CVD
Rapid re-feeding a potential
RF for later development of
Assessment of severity of
HIV disease
Baseline and end of
trial
Genetic RF for CVD
Every visit
6 monthly (more if
indicated)
Hypertension a RF for CVD
Lipodystrophy associated
with CVD
FBC Cardiac effects of anaemia
Lipids (HDL, LDL,
Cholesterol)
Dyslipidaemia a RF for CVD
Biochemistry Renal disease a RF for CVD
Absolute CD4 count
and percentage
Marker of HIV disease
activity
Immunophenotyping Week 0, 48, 96 Evidence of immune
activation and ongoing
Viral Load Baseline and week 96 Marker of HIV disease
activity
Inflammatory panel Markers of ongoing
inflammation
Disordered
thrombogenesis
Evidence of disordered
haemostasis
Vascular injury panel Evidence of vascular injury
Structural arterial damage
Arterial stiffness
Baseline
Previous and current WHO
staging
Baseline and every visit
Im
ag
in
g Carotid intima media
thickness
Pulse Wave Velocity
Full examination
Ex
am
in
at
io
n
Assessment of
lipodystrophy
Week 0, 48, 96
Assessment of general
health, obesity a risk factor
for CVD
Bl
oo
d
S
TO
R
E
D
sa
m
pl
es
RF, risk factor; CVD, cardiovascular disease; HDL, high density lipoprotein; LDL, low density
lipoprotein. Inflammatory panel: (IL-1Ra, CRP, TNFa, IL-10, IL-6, IL-8), Disordered
thrombogenesis: (DD, TM, TF), Vascular injury panel: (MCP-1, angiopoietin 1+2, E-selectin, P-
selectin, ICAM-3, SAA, ICAM-1 VCAM-1, VEGF)
R
E
A
L
TI
M
E Baseline, week 6, 12,
24 then every 24 weeks
Week 0, 48, 96
Week 0, 48, 96
Weight and height
Blood pressure
Parameter
Hi
st
or
y
Gestation and birth weight
Malnutrition
Family history of
cardiovascular disease
Tribal descent
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4.2 Cardiovascular skills training
A physician-sonographer were selected from both sites as well as a nurse from JCRC,
Kampala participated in 2 weeks intense training with the Vascular Physiology
laboratory team at University College London (UCL), Figure 4-1. Following an overview
of the principles of IMT and PWV each medical practitioner practiced daily on different
subjects until they were deemed competent to perform the recordings unaided. I
performed further in country training during which an additional doctor and 4 nurses
were trained using the same training methods - Figure 4-2. Overall 8 medical
practitioners (3 doctors and 5 nurses) completed the basic training, 4 at JCRC and 4 at
UTH.
Figure 4-1. Cardiovascular training taking place in the Vascular Physiology
Laboratory, UCL.
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Once training had been completed, each medical practitioner took part in a validation
study to assess the outcome of the training. This ensured quality in the reproducibility
and accuracy of the measurements performed by each individual. Healthy adult
volunteers were recruited at each site from colleagues, friends and family. The
volunteers were counselled and verbal consent obtained. All volunteers were scanned
in the morning to minimise fluctuations in environmental temperature which can affect
PWV (See Section 3.2) and where possible had fasted for a minimum of 3 hours prior to
the recording being performed. Volunteers were examined by all 4 medical practitioners
at either UTH or JCRC and the examinations repeated at least 24 hours after the first
examination to allow comparison of intra and inter operator variability. The validation
study continued until all medical practitioners had performed reproducible cIMT and
PWV recordings on at least 8 of the volunteers twice. All recording were transferred
electronically to the UK and were read by myself with support from an established
sonographer where needed.
Figure 4-2. Cardiovascular training taking place at UTH, Lusaka.
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4.2.1 Validation of cIMT and PWV
Previous studies have considered intra-observer variability of IMT between 2.4% to
10.6% and inter-observer variability of between 3.1% to 18.3% to be acceptable [322].
For an IMT scan to be accepted all criteria listed in section 3.3 had to be met and all
readings (end diastolic diameter, systolic diameter and end-diastolic IMT) from both
sides had to be within 0.1mm of each other for the scan to be included in the study. An
example of a rejected scan is given in Figure 4-3.
For PWV readings all measurements had to be within 0.5m/second of each other. The
lengths measured (carotid-notch, notch-femoral, carotid-femoral) were also checked to
ensure accuracy and reproducibility between medical practitioners.
Figure 4-3. An example of a poor quality IMT scan
The artery is not positioned in the middle of the screen, the carotid bulb is not visible,
the artery is not horizontal and the cut throught the artery is not at 90 o so the near wall
IMT is not clearly defined.
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In Zambia 4 medical practitioners (A, B, C and D) performed 117 IMT scans and 98
PWV recordings on 15 subjects during the period 15th June 2010 – 28th October 2010.
In Uganda 3 medical practitioners (E, F, and G) performed 81 IMT scans and 75 PWV
recordings on 14 subjects during the period 31st May 2010 – 11th November 2010. A
4th Ugandan medical practitioner, H, was unable to complete a sufficient of number
scans; results were excluded from the statistical analysis.
Only the scans that fulfilled the criteria for a satisfactory scan were used in the following
calculations.
Total number of
scans performed
Number (%) of
acceptable scans
Total number of
scans performed
Number (%) of
acceptable scans
A 22 17 (77) 15 15 (100)
B 29 21 (71) 26 25 (96)
C 31 16 (50) 27 22 (82)
D 35 17 (49) 30 28 (93)
E 29 27 (93) 28 26 (93)
F 31 21 (68) 29 27 (93)
G 21 13 (62) 18 18 (100)
IMT PWV
ZA
M
B
IA
U
G
A
N
D
A
Table 4-3. Summary of total IMT and PWV recordings performed during the
validation study.
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4.2.2 Intra-operator variability
To compare medical practitioners’ personal variation when examining the same
volunteer on subsequent days, the co-efficient of variation and a paired t-test to
compare the mean of IMT and PWV were calculated. The results from volunteers who
were only scanned successfully once were excluded from this analysis.
Table 4-4. Analysis of intra-operator variability.
Difference between scans performed on the same volunteers by the same medical practitioners
(A – G) at least 24 hours apart.
The coefficient of variation (CV) should be as small as possible and for this study a cut
off of <10% was set as acceptable. Medical practitioners A, B, E, F and G had
satisfactory intra-operator variability. Medical practitioner C failed to reach a satisfactory
level of reproducibility for cIMT (CV = 11.1%). The proportion of acceptable scans for
medical practitioners C and D were under 50%, which was deemed unacceptable. All
medical practitioners had satisfactory intra-operator variability when performing PWV
measurements (CV 4.1 – 8.1%)
Number of
volunteers* CV p-value
Number of
volunteers* CV p-value CV p-value
A 8 3.8% 0.80 7 4.1% 0.31 4.0% 0.49
B 10 6.8% 0.64 12 7.1% 0.53 5.1% 0.88
C 7 11.1% 0.11 10 7.5% 0.11 4.4% 0.69
D 7 9.6% 0.31 13 8.1% 0.31 4.0% 0.72
E 12 4.6% 0.48 12 5.6% 0.97 2.6% 0.31
F 9 6.1% 0.57 12 7.5% 0.43 4.0% 0.54
G 6 3.6% 0.02 9 7.1% 0.59 4.7% 0.86
PWV LENGTH
ZA
M
BI
A
N
M
E
D
IC
AL
P
R
A
C
TI
C
TI
O
N
ER
S
U
G
AN
D
A
N
M
E
D
IC
A
L
PR
AC
TI
C
TI
O
N
ER
S
IMT
CV = co-efficient of variation; * to be included in this analysis a volunteer had to be
successfully scanned twice by the same medical practitioner
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Looking at the intra-operator variability in IMT the p-values for the co-efficient of
variance for all medical practitioners were non-significant (p>0.1), with the exception of
medical practitioner G (p=0.02). The null hypothesis was that the average difference
between first and second measurements was zero; when the raw data for medical
practitioner G was analysed in five out of the six cases the second IMT measurement
was marginally higher than the first, so the significant p value was reflecting this trend.
All the other parameters measured were satisfactory for medical practitioner G and as
such this p value was interpreted with caution as it was not believed that there was a
statistical significance between IMT readings taken on subsequent days.
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4.2.3 Inter-operator variability for cIMT
Table 4-5 lists the co-efficient of variance and p values for the differences in the mean
value obtained at the first IMT examination of the same volunteers by each medical
practitioner.
Medical practitioners “A” in Zambia and “E” in Uganda were used as a baseline to which
the other medical practitioners results were compared using a mixed-effects restricted
maximum likelihood (REML) model. The REML approach is a form of maximum
likelihood estimation that does not base estimates on a maximum likelihood fit of all the
information, but instead uses a likelihood function calculated from a transformed set of
data, so that nuisance parameters have no effect.
The regression coefficients indicated that medical practitioner A slightly under
measured cIMT compared to B, C and D and that medical practitioner E slightly
under/over measured cIMT compared to F/G. However with an overall p value of 0.30
and with all the confidence intervals containing 0, no overall significant difference
Table 4-5. Results of the analysis of inter-operator variability
A B C A B C
B 13.0 0.29
C 8.6 10.5 0.68 0.90
D 6.1 9.3 6.7 0.33 0.22 0.64
E F E F
F 6.8 0.50
G 3.8 5.4 0.90 0.52
IMT
CV (%) p-value
ZA
M
B
IA
U
G
AN
D
A
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between the IMT results was seen between different medical practitioners. An intra-
class correlation (ICC) calculation to assess overall reproducibility between all the
medical practitioners was calculated whereby a result >0.80 is deemed very good. The
ICC was 0.94 for the Zambian team and 0.83 for the Ugandan team,
4.2.4 Inter-operator variability for PWV
Table 4-6 details the CV / p values reflecting the difference between PWV results when
the same volunteer was scanned by different medical practitioners. Unacceptable
differences in the results obtained when A and C measured PWV in the same volunteer
were seen (p=0.04). An ANOVA calculation suggested that for the Zambian medical
practitioners there was a trend towards a difference in the PWV measured between
medical practitioners (p=0.05) with statistically significant larger PWV values obtained
by C (p=0.01) and D (p=0.03) compared to A. For the Ugandan medical practitioners
there was no statistical difference in the PWV measurements (p>0.50). For the length
measurements again as expected a difference was seen between volunteers (p<0.001)
but the variation between medical practitioners was not significant (p=0.40 / 0.84).
The ICC for PWV at both sites (Zambia/Uganda) (0.72/0.68) and length (0.77/0.77)
were all deemed to be highly acceptable.
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In summary, medical practitioners A, B, E, F and G were all deemed competent to
proceed with performing scans on the patients. Medical practitioners C and D were
asked to undertake further practice in the techniques and to repeat the validation study.
Unfortunately this was not possible in the time available before the CHAPAS 3 trial
started recruiting and they were therefore unable to scan any of the patients.
Table 4-6. Results of the analysis of inter-operator variability for PWV measurements.
A B C A B C A B C A B C
B 5.8 0.48 6.2 0.18
C 7.4 8.8 0.04 0.35 4.1 3.6 0.25 0.49
D 7.3 7.1 7.9 0.55 0.97 0.12 3.9 4.8 4.5 0.65 0.61 0.93
E F E F E F E F
F 6.9 0.77 4.5 0.20
G 8.2 8.1 0.86 0.95 3.6 5.6 0.72 0.57
CV, co-efficient of variance.
ZA
M
BI
A
U
GA
N
DA
PWV PWV length
CV (%) p-value CV (%) p-value
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Figure 4-4. The JCRC team.
From left to right Dr Victor Musiime, Mrs Florence Odongo, Dr Grace Mirembe,
Mrs Priscilla Wavamunno.
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4.2.5 Ongoing validation
Ongoing training and validation was arranged during the 3 years of CHAPAS 3 data
collection. Yearly refresher courses and repeat mini-validation studies were carried out
with satisfactory results obtained by all medical practitioners throughout (data not
shown). Fortunately only one medical practitioner left during the trial and the remaining
team had the capacity to continue the scans so no new personnel had to be trained.
4.2.6 Minimising confounders and blinding
To maximise consistency, where possible sequential scans on each patient were
performed by the same practitioner. Given the small number of medical practitioners at
each site this was usually possible. As the scans were being performed by the
children’s own medical team it was impossible to blind the medical practitioners
performing the scan to the patient’s ART randomisation arm, although where possible
the scans were performed before the case notes were reviewed. All scans were
electronically transferred and read by myself; I was blind to HIV status and treatment
arm. Overall 5% of scans were checked by an experienced sonographer to ensure
consistency in interpretation.
4.3 Discussion
The CHAPAS 3 trial provided a structure to intensively study cardiovascular structure
and arterial stiffness in a large group of HIV infected children in an African setting. If
successful this would be the largest study of HIV infected children worldwide and the
only longitudinal study to date in an African setting. Compared to other studies the
population to be studied would be unique with a large ART naïve group (208 children)
and the ART experienced children were all stable on the same first line ART regimen.
Different individual drugs, such as protease inhibitors, have been shown in other
studies to have detrimental effects on IMT/PWV so by controlling for previous and
current ART exposure results are easier to interpret. By studying very young children
the impact of other cardiovascular risk factors such as obesity and smoking were
minimised. By carefully selecting HIV uninfected controls from the same community
differences in confounders such as co-infections, malnutrition and diet were limited.
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I was able to devise a process for training and to demonstrate the reproducibility of
medical practitioners measuring cIMT and PWV following an intensive training course.
Medical practitioners who failed to reach the standard were prevented from scanning
the study participants. Ongoing training and validation ensured that the standards
remained high throughout. Methods were put in place to maintain consistency and
blinding to group and randomisation arm.
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Chapter 5 Results: Structural vascular changes in
children with HIV
As discussed in chapter 2 HIV-infected adults have an increased incidence of
cardiovascular disease whilst older children and adolescents have evidence of pre-
clinical changes in the structure and arterial stiffness of their cardiovascular system.
However, minimal data from children living in Africa is available. Detecting pre-clinical
changes during childhood is important as underlying cardiovascular disease may be
silent until a child reaches adulthood. Two methods of detecting pre-clinical changes,
IMT and PWV have been described in chapter 3. These techniques were used to
assess the cardiovascular structure and arterial stiffness of a large cohort of ART naïve
and experienced HIV-infected children and age matched controls.
5.1 Methods
5.1.1 Recruitment
As described in chapter 3 children were recruited to the CHAPAS 3 trial. 208 HIV-
infected ART naïve children were recruited (group 1) with 209 age matched HIV-
uninfected children recruited as a control group. 74 HIV infected ART experienced
children were also recruited (group 2) with 75 age matched HIV uninfected children as a
second control group. Sites were asked to age match controls to within a year either
side of the age of the CHAPAS 3 recruits at baseline. Controls were seen once;
children in groups 1 and 2 were seen at 12 weekly intervals up until the end of the
CHAPAS 3 trial, defined as when the last patient recruited reached week 96 of follow
up. All children recruited to group 2 reached week 96 of follow up. 13 children in group
1 died and 16 were lost to follow up before week 96 - Figure 5-1.
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Figure 5-1. Flow diagram to show the outcome of children recruited to CHAPAS-3.
Arm A, stavudine; Arm B, zidovudine; Arm C, abacavir; LTFU, lost to follow up.
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5.1.2 Baseline demographics
Clinical and immunological factors
Baseline demographic and clinical characteristics are listed in Table 5-1. All children
were Black-African and had vertically acquired HIV. 208 were ART naïve (group 1) and
these children were significantly younger (median age 2.9 years, range 0.3-13.6 years)
than the 74 ART experienced (group 2) children (median age 6.9 years, range 5.1-12.3
years). The percentage of males was 52% and 54% in group 1 and 2 respectively.
Group 1 and 2 were well matched to their control groups for sex (p=0.35/0.80) and age
(p=0.21/0.60).
Not unsurprisingly between group 1 and the control group there were significant
differences in CD4 count, CD4%, weight-for-age z-score, height-for-age z-score, BMI
for age z score and CD4 z score (all p<0.001) with the HIV infected cases all
significantly impaired. Group 2 and controls were well matched for CD4% (p=0.11) and
BMI for age z score (p=0.90) but impairments were seen in the HIV infected children in
weight for age z score (p=0.03) and height for age z score (p=0.01). Interestingly,
despite CD4% being similar, CD4 z-scores and CD4 counts were significantly higher in
group 2 (who had been on ART for a median of 3.9 years) compared to their age and
sex matched controls (p=0.002 and p=0.004 respectively). Most ART naïve children
had not had a CD4 count measured previously so the screening CD4 count was taken
as their nadir. Of note the healthy control children were significantly lighter and shorter
than UK children of an equivalent age (mean WAZ in control groups -0.8 / -0.9 and
mean HAZ in control groups -1.2 / -1.3), if the control population was perfectly matched
to the reference population the mean should be 0 and the standard deviation 1.
Cardiovascular parameters
Specifically looking at known cardiovascular risk factors no child was overweight /
obese (defined as a BMI >85/95th percentile). Significantly less healthy (i.e. higher)
diastolic blood pressure (p=0.002) and resting heart rate (p<0.001) were seen in ART
naïve children in group 1 compared to their age matched controls.
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Table 5-1. Demographic data and clinical parameters for all children recruited.
Male 0.35 0.80
Age in yrs 0.21 0.60
Weight-for-age Z < 0.001 0.03
Height-for-age Z < 0.001 0.01
BMI-for-age Z < 0.001 0.90
Mean sBP (mmHg) (SD) 0.82 0.21
Mean dBP (mmHg) (SD) 0.002 0.21
Mean HR (mmHg) (SD) < 0.001 0.92
Previous WHO stage III/IV
(%)
Baseline VL (copies/ml)
Duration on ART (yrs)
Age started ART (yrs)
CD4 count < 0.001 0.004*
CD4 % < 0.001 0.11
CD4 z score < 0.001 0.002*
Total cholesterol (mmol/L) <0.001** 0.001
Triglycerides (mmol/L) < 0.001 0.07
LDL (mmol/L) 0.001** 0.09
HDL (mmol/L) < 0.001*** 0.21
Hypercholesterolemia
>5.2mmol/L
0.01** 0.56
Hypertriglyceridemia
>1.7mmol/L
0.02 0.56
HyperLDL >3.4mmol/L 0.33 0.62
HypoHDL <0.9mmol/L < 0.001 0.04
Minutes fasting prior to lipid
sample
< 0.001 0.19
(1) Mann Whitney rank sum used for non parametric variables, two sample t-test used for parametric variables. Values are given as median
and IQR unless otherwise stated. BMI, body mass index; dBP, diastolic blood pressure; HDL, high density lipoprotein; HR, heart rate; LDL,
low-density lipoprotein; sBP, systolic blood pressure; VL, viral load. *CD4 and CD4 z scores higher in HIV infected, ART experienced children
compared to controls ** cholesterol and LDL levels higher in controls compared to HIV infected ART naive children ***HDL levels higher
(healthier) in HIV infected, ART experienced children compared to controls.
108 (52%)
2.9 (1.7 : 4.4)
99 (47%)
3.0 (2.1 : 4.1) 6.9 (5.9 : 8.5)
HIV infected, ART
naïve (Group 1)
n = 208
HIV uninfected
matched to group 1
n = 209
HIV infected, ART
experienced (Group 2)
n = 74
p value
(1)
119 (57)
823 (507 : 1244) 1335 (1012 : 1781) 1192 (893 : 1532)
HIV uninfected
matched to group 2
n = 75
40 (54%) 39 (52%)
147/184 (80%)
810 (286 : 900)
51/182 (28%)
5/180 (3%)
35/190 (18%) 4/65 (6%)
0.7 (0.5 : 0.8)
5/187 (3%)
5/71 (7%)
8/192 (4%)
1.2 (0.9 : 1.8)
1.7 (1.3 : 2.3) 2.0 (1.6 : 2.4) 2.1 (1.7 : 2.5)
3.1 (2.6 : 3.8)
59 (7)
-0.6 (-1.3 : 0.3) 0.1 (-0.7 : 0.8) -0.6 (-1.1 : 0.02)-2.0 (-3.0 : -1.1)
974 (823 : 1175)
18 (11 : 23) 37 (32 : 41) 33 (27 : 39) 35 (31 : 42)
-2.4 (-3.4, -1.1) -0.8 (-1.6, -0.02) -1.3 (-2, -0.5) -0.9 (-1.9, -0.2)
-2.6 (-3. 7 : -1.6) -1.2 (-2.2 : -0.1) -1.7 (-2.6 : -1.2) -1.3 (-2.2 : -0.5)
-0.8 (-1.7 : 0.2)
Current WHO stage (%)
I/II 62 (84)
III 7 (10)
IV 5 (7)
46 (62)
I/II 91 (44)
III 97 (47)
IV 20 (10)
p value
(1)
2/59 (3%) 2/71 (3%)
52/192 (27%) 5/64 (8%) 14/71 (20%)
120 (69 : 310) 845 (796 : 930) 477 (164 : 1058)
1.8 (1.5 : 2.4)
1.0 (0.9 : 1.5) 1.4 (1.1 : 1.6) 1.3 (1.0 : 1.7)
18/192 (9%) 7/66 (11%) 7/71 (7%)
3.6 (3.1 : 4.3) 4.1 (3.6 : 4.5) 3.6 (3.1 : 4.1)
1.0 (0.7 : 1.5) 0.9 (0.7 : 1.0) 0.7 (0.5 : 1.1)
6.7 (5.6 : 8.6)
Clinical variable
HIV related variables
Immunological variables
Lipids
110 (17) 98 (16) 91 (13) 91 (16)
314,565 (134830 :
810820)
<50 copies / ml
3.9 (2.9 : 4.3)
3.2 (1.8 : 5.0)
-0.1 (-0.9 : 0.5) -0.3 (-0.8 : 0.3) -0.1 (-0.9 : 0.5)
95 (9) 95 (12) 100 (8) 101 (8)
59 (8) 56 (10) 60 (7)
126
Lipids
ART naïve children had significantly healthier (lower) total cholesterol and LDL-C both
(p=<0.001) than controls but less healthy (lower) HDL-C and (higher) triglyceride levels
(both p<0.001). In the ART experienced group total cholesterol profiles were
significantly worse (higher) compared to controls (p=0.001), whilst HDL-C, triglyceride
and LDL-C levels were not significantly different between HIV infected and uninfected
children (p≥0.07). Using internationally recognised cut offs [323] the proportion of ART 
naïve/controls and ART experienced/controls with hypercholesterolemia was 3%/9%
and 11%/7%; hypertriglyceridemia, 28%/18% and 6%/7%; hyperLDL-C 3%/4% and
3%/3%; hypoHDL-C 80%/27% and 8%/20%. Some of these results may reflect the fact
that recruitment of the controls was opportunistic at times and hence it was difficult to
ensure that the children had fasted for an adequate period of time; mean period of
fasting in group 1 v controls was 810 v 120 minutes (p<0.001), in group 2 v controls 845
v 477 minutes (p=0.19). Whilst the international guidelines used did not specify an age
range, it is also important to note that in this cohort a large proportion of children were
aged less than two years for which normal ranges are less well defined. The proportion
of children with hypertriglyceridemia and hypoHDL-C differed significantly between
children aged less than two years and children aged over two years of age - Table 5-2.
Past medical history and viral load
Among group 1 and 2 57% / 62% had experienced WHO stage III/IV events. To be
recruited to the study children in group 2 had to have virological suppression (assay
<50 copies / ml) and have been on first line ART for at least 2 years, the median
(range) of prior ART treatment was 3.9 (2 : 7.1) years. In group 1 1% had a baseline VL
<1000 copies/ml; 2% 1000-9,999 copies/ml; 14% 10,000–99,999 copies/ml; 63%
100,000–999,999 copies / ml and 19% ≥1,000,000 copies / ml. 
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Table 5-2. Summary of lipid levels in the ART naive children and their controls looking
at the effect of age under 2 years of age compared to greater than two years of age.
p value p value
Number of samples
available
Total cholesterol
(mmol/L) 2.8 (2.3 : 3.6) 3.6* (3.0 : 4.8) <0.001 3.3 (2.8 : 3.8) 3.6* (3.1 : 4.2) <0.001
Hypercholesterolaemia
>5.2 mmol/L 0.002 0.15 p = 0.43
Triglycerides (mmol/L) 1.6 (1.2 : 2.4) 1.2 (0.9 : 1.8) 0.03 1.1 (0.9 : 1.5) 0.9 (0.6 : 1.3) <0.001
Hypertriglycercidemia
> 1.7mmol/L 0.22 0.39 p < 0.001
LDL (mmol/L) 1.5 (1.0 : 2.0) 1.9 (1.4 : 2.3) 0.01 1.9 (1.4 : 2.4) 2.0 (1.6 : 2.4) 0.13
HyperLDL >3.4
mmol/L 0.33 0.81 p = 0.72
HDL (mmol/L) 0.6 (0.4 : 0.7) 1.0 (0.9 : 1.6) <0.001 0.7 (0.6 : 0.9) 1.1 (0.9 : 1.5) <0.001
HypoHDL <0.9mmol/L <0.001 <0.001 p = 0.001
Minutes fasting prior to
sample 280 (122 : 840) 80 (34 : 150) 0.001 845 (740 : 925) 135 (79 : 361) <0.001
4 (3.4%) 6 (3.9%)
Overall
effect of
age < 2
or > 2
years
Absolute values compared between groups using rank sum and categorical values compared using chi-squared. Values are given as median and IQR
unless otherwise stated. HDL, high density lipoprotein; HR, heart rate; LDL, low-density lipoprotein.
* cholesterol levels higher in controls
40 (26.3)89 (74.2%)12 (30%)
> 2 years< 2 years
HIV uninfected
matched to group 1
29 (46.8%) 13 (34.2%) 22 (18.3%) 22 (14.5%)
58 (90.6%)
1 (1.6%) 2 (5%)
152
1 (1.5%) 7 (18%) 4 (3.3%) 11 (7.2%)
HIV infected, ART
naïve (group 1)
HIV uninfected
matched to group 1
HIV infected, ART
naïve (group 1)
65 40 122
128
5.2 CD4 count / percentages in HIV negative controls
As illustrated in Figure 5-2 the majority of the 284 HIV uninfected children recruited to
the control study had a satisfactory absolute CD4 count / percentage, however 25 (9%)
of the “healthy” HIV negative controls fulfilled absolute or percentage CD4 count
immunological criteria for commencing ART according to WHO 2013 guidelines1
although only five (2%) met criteria on both absolute CD4 count and CD4 percentage -
Table 5-3. These children may have been suffering from infections such as Epstein Barr
Virus (EBV) or cytomegalovirus (CMV) that provoke a lymphocytosis with a relative
increase in CD8 and overall lowering of the relative CD4%. Normal ranges are based
on values derived from the European Collaborative Study (ECS) [324]; whilst a
substantial proportion of these children were of African origin no normal data exists for
HIV-infected African children living in Africa. A provisional study looking at normal
ranges in African HIV-infected infants has not found a difference from the values
obtained from the ECS (Helen Payne, personal communication). In other cohorts of HIV
uninfected African children ≥ 99% aged over three months of age have a CD4 count 
above the threshold for treatment initiation [325]. Maternal HIV status for the controls
was not collected so some of these children may be HIV exposed but uninfected [326,
327]. All children recruited to the control study aged less than 18 months had a HIV
DNA PCR performed and children over 18 months an HIV fourth generation antibody
test. It is possible that these gave a false negative HIV result and in fact the child was
HIV infected; increasingly early false negatives are being recognized especially if
children were breastfed whilst their mothers were taking ART [328]. Finally the CD4
measurement was only performed once so may be falsely low if there was a sample
processing error.
1 WHO 2013 immunological guidelines for commencing ART: < 3years CD4 < 1000 / CD4% < 25%, 3 –
5 years CD4 < 750 / CD4 < 25%, >5 years CD4 <500
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Figure 5-2. Distribution of CD4 count and absolute percentage in HIV uninfected
controls by age band.
A) CD4 count and B) CD4 percentage
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Shading indicates values that are below the recommended WHO threshold for
commencing ART.
Table 5-3. HIV uninfected controls with low absolute CD4 count or percentage
ID AGE (years) Absolute CD4 CD4% Total CD3
Lymphocytes
(%)
CD3+ CD8-
%
CD3+ CD8+
% CD4:CD8 CD4 z score
K20007 0.7 1100 19 5929 46.6 31.1 48.8 0.6 -2
K10009 0.8 2000 22 9110 35 21.5 28.8 0.7 -0.8
K10020 1.5 856 15.5 5520 ND ND ND ND -2.2
C20040 2 970 12 7865 ND ND ND ND -1.7
F20048 2.1 1185 23 5224 29.7 37.7 40 0.9 -1.2
G20042 2.2 631 27 2305 65.3 70.2 20.5 3.4 -2.6
H20027 2.4 716 29 3426 38.2 65.4 15.9 4.1 -1.1
Y10029 2.6 2000 13.3 7300 ND ND ND ND 0.2
S20030 2.6 743 25 2928 30.8 55.7 26.9 2.1 -2.2
W10016 2.7 681 26.5 2570 37.2 31.4 19.9 1.6 -2.3
Y10035 2.7 998 25 4000 ND ND ND ND -1.4
W20024 2.8 603 41 1484 11.6 44.7 28.3 1.6 -2.6
G10022 2.9 342 17.3 1980 16.7 20 53.1 0.4 -3.9
P10031 2.9 965 19.1 5060 ND ND ND ND -1.4
R10040 3.2 836 23.5 3560 40.6 35.6 36.6 1 -1.7
H20070 3.3 620 29 2110 27 42.7 45.7 0.9 -2.4
S20047 3.5 708 33 3288 38.7 44.5 30.5 1.5 -0.9
V20080 3.7 652 36 1824 24.6 56.6 40.9 1.4 -2.2
C10055 4 649 27.6 2350 37.5 20.9 34 0.6 -2.2
Y20096 4.2 622 30 2088 10.3 45.5 32.2 1.4 -2.3
A10054 4.3 623 27.9 2330 31.4 30.7 27.4 1.1 -2.2
G10151 4.7 603 21.6 2790 ND ND ND ND -2.3
P10075 5.6 380 27.3 1390 ND ND ND ND -3.7
Y10102 6.9 274 16.6 1650 ND ND ND ND -5
P20138 11.3 474 34 1397 21.9 50.7 41 1.2 -3
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5.3 The relationship between CD4 count and percentage in HIV infected
and uninfected children
As illustrated in Figure 5-3 a strong relationship between absolute CD4 and CD4
percentage in HIV infected children (groups 1 and 2) was demonstrated. This
correlation was still seen at CD4 counts <500 mm3 (Spearman’s correlation coefficient,
rho 0.64/0.45, both p<0.001). A weaker correlation was seen in the control groups
(Spearman’s correlation coefficient - rho 0.38/0.29 p<0.001/=0.02) although this may
have been as the data was observed over a narrower range.
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Figure 5-3. Scatter plots to show relationship between absolute CD4 and CD4
percentage.
A) HIV infected B) HIV infected, low CD4 and CD4% only C) HIV uninfected controls. Spearman
correlation used.
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5.4 Cardiovascular Results 1 – Intimal Medial Thickness (IMT)
5.4.1 Missing baseline IMT by site and group
Technical difficulties and uncooperative children meant some recruits could not be
scanned and this tended to be the younger children -Table 5-4. Comparing the median
age of children in groups 1 and 2 with their control groups respectively using a Wilcoxon
rank sum test showed that at UTH, children with IMT results in group 1 were
significantly older (median age 6.4 years) than their control group with IMT results
(median age 4.1 years) (p=0.001). This can be explained as the controls were recruited
later in the study when the clinical teams were more confident in scanning smaller
children and technically they were able to perform high quality scans quickly - so more
scans were performed on younger control children that were of acceptable quality. No
difference in age of children with IMT results was seen between Group 2 and controls at
UTH (p=0.78) nor at JCRC between Groups 1 and controls (p=0.46) or group 2 and
controls (p=0.65). Combining all children recruited from both sites no difference in age
was seen between Group 1 and controls (p=0.54) nor Group 2 and controls (p=0.61).
Thus comparisons of HIV infected versus controls cannot be confounded by age as a
whole; however any subsequent analyses which adjust for site will also be adjusted for
age.
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Table 5-4. Effect of missing baseline IMT scans.
Total recruited 89 89 52 52
Missing baseline
IMT (% total) 50 (56%) 30 (34%) 1 (2%) 8 (15%)
Age 2.9 (1.8 : 6.1) 3.4 (2.1 : 5.6) 7.0 (5.8 : 8.2) 6.9 (5.6 : 8.3)
Age with a
baseline IMT
6.4 (4.4 : 9.6) 4.1 (2.8 : 7.0) 7.0 (5.8 : 8.5) 6.9 (5.6 : 8.5)
Age with
baseline IMT
missing
1.8 (1.2 : 2.5) 2.5 (1.0 : 3.0) 5.5 6.2 (5.0 : 8.2)
Total recruited 119 120 22 23
Missing baseline
IMT (% total)
13 (11%) 12 (10%) 1 (5%) 0
Age 2.8 (1.6 : 4.0) 2.9 (2.1 : 4.1) 6.5 (5.9 : 9.9) 6.4 (5.5 : 9.1)
Age with a
baseline IMT
3.1 (1.8 : 4.2) 3.2 (2.1 : 4.2) 6.5 (6.0 : 9.9) 6.4 (5.5 : 9.1)
Age with
baseline IMT
missing
1.5 (1.1 : 2.2) 2.4 (1.7 : 3.0) 5.2 NA
UTH
HIV- controls
matched to
group 1
HIV- controls
matched to
group 2
HIV+ ART
experienced
(group 2)
HIV+ ART naïve
(group 1)
JCRC
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5.4.2 Baseline Intimal Medial Thickness (IMT)
As summarised in Table 5-5 and illustrated in Figure 5-4 baseline IMT was significantly
thicker in group 1 versus controls (p<0.001) with a similar trend for the smaller numbers
in group 2 versus the group 2 control group (p=0.09). Results were unchanged after
excluding 15 and 16 scans performed 2–12 weeks after enrolment in groups 1 and 2
respectively (p<0.001 / =0.09). There was also no evidence of a trend towards a
difference in IMT with increasing time after baseline when the scan was performed
(p=0.98/0.43). Therefore all scans (baseline and post baseline up to a maximum of 12
weeks) were included in further analyses.
Figure 5-4. Box plot of baseline IMT by group (median and IQR).
A) Results when all baseline scans are included in the analysis; B) Results when IMT scans
performed after week 0 are excluded.
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* missing scans – these were performed but accidently deleted prior to data transfer
Table 5-5. Summary of baseline IMT results by group
Wk 2 9 (6%) Wk 2 4 (6%)
Wk 6 4 (3%) Wk 6 8 (11%)
Wk 12 2 (1%) Wk 12 4 (6%)
Too young
(% missing)
Not done
Unanalysable
Missing*
Missing (% total)
Number performed
after week 0 (%
total)
16
Total number in
group
Overall mean (SD)
Median (IQR)
Number IMT scans
performed
Mean in mm (SD)
Range
74
HIV- controls
matched to Group 1
HIV+ ART naïve
group 1
HIV+ ART
experienced group 2
209
0.46 (0.05)
0.33 : 0.62
2 (3%)
2 (100%)
53 (84%)
6 (10%)
0.34 : 0.57
72
0.35 : 0.56
63 (30%)
167
0.44 (0.04)
42 (20%)
30 (71%)
0.45 (0.38)
0.45 (0.43 – 0.48)
HIV- controls
matched to Group 2
75
2 (3%)
2 (3%)
208
15
145
0.46 (0.04)
67
0.45 (0.04)
0.37 : 0.54
8 (11%)
1 (13%)
7 (87%)
2 (5%)
5 (12%)
5 (12%)
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5.5 Impact of variables on baseline IMT
5.5.1 Age
Comparing group 1 (ART naïve) and their control group in a full interaction model,
allowing the relationship between baseline IMT and age to vary by HIV infection,
estimates were that in the ART-naïve children baseline IMT was (-)0.001 lower for
every year older (95% CI -0.004 : +0.001) (p=0.20), and in the controls baseline IMT
was also (-)0.001 lower for every year older (95% CI -0.003 : +0.001) (p=0.39). There
was no evidence that the impact of age at baseline varied by HIV status (interaction
p=0.80). Fitting the same relationship between age and baseline IMT in both groups
there was still no evidence of a relationship between baseline IMT and age overall –
baseline IMT was (-)0.001 lower per year older (95% CI -0.003 ; +0.000) (p=0.13). The
Figure 5-5. Scatter plot to show effect of age on baseline IMT
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strong association between baseline IMT and HIV status persisted (IMT being
(-)0.016mm lower in controls than HIV-infected children (95% CI -0.024 : -0.008)
p<0.001).
In contrast in the ART experienced group, there was evidence that the impact of age on
baseline IMT varied by HIV status (p=0.01). In HIV infected ART experienced children
baseline IMT was (-)0.005mm lower per year older (95% CI -0.010 : +0.000) (p=0.06).
In controls, baseline IMT was (+)0.005 higher per year older (95% CI -0.000 : +0.010)
(p=0.06).
Normal values of IMT in young children are not available. To attempt to calculate
“normal range” IMT was plotted against age in all 234 HIV uninfected controls, Figure
5-6. Point estimate suggests that IMT is 0.001 mm higher per additional year of age but
there is no formal evidence for this (95% CI -0.001 : +0.002) (p= 0.40).
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Figure 5-6. Scatter plot to illustrate effect of age on IMT in HIV uninfected controls.
No significant impact of age on IMT (p=0.40) was seen.
Effect of age on IMT in HIV uninfected controls
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5.5.2 Impact of CD4 parameters on baseline IMT
CD4 counts were truncated at the 99th centile to avoid very high values having undue
influence in regression models. A significant association between CD4% and baseline
IMT was seen in ART naïve (group 1) children and controls (rho=0.17, p=0.003) (not
adjusting for other factors). No significant association was seen between CD4 count
and baseline IMT in ART naïve/controls, nor between CD4 count or percentage and
baseline IMT in ART experienced/controls - Figure 5-7.
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Figure 5-7. Scatter plots to demonstrate the relationship and Spearman correlation
between baseline IMT and CD4 count / CD4%
A) CD4 count in ART naïve patients (group 1) and controls, B) CD4 percentage in ART naïve
patients and controls C) CD4 count in ART experienced patients (group 2) and controls and D)
CD4 percentage in ART experienced patients and controls.
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5.5.3 Impact of other baseline variables on baseline IMT
A bivariable main effects and interaction model (allowing a different effect of each factor
depending on whether the child was HIV-infected or a control) were used to screen the
effects of other baseline variables on baseline IMT, Table 5-6. Variables such as
baseline urea and age started ART were not included in this model as these were not
available for the control group but were included in later models that assessed change
over 96 weeks in the HIV-infected children. Any variable or interaction which had p<0.2
in the main effects or interaction model was included in a multivariable model from
which a final multivariable model was identified using backwards elimination (exit
p=0.05). Case/control status, age and site of recruitment were included in all models
regardless of significance as the key exposure of interest (case vs control) or because
they were factors a priori considered to have potential influence. After a model had
been identified by backwards elimination, each rejected main effect and interaction term
was checked for additional prognostic importance given this model, and any factors with
p<0.05 retained.
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p value for main
effect adjusted
for group
p value for
interaction by
HIV status
p value for main
effect adjusted
for group
p value for
interaction by
HIV status
Age in years 0.13 0.80 0.98 0.01
Sex 0.08 0.30 0.06 0.73
Site 0.04 0.28 0.72 0.11
Weight-for-age Z 0.12 0.50 0.08 0.03
Height-for-age Z 0.19 0.44 0.80 0.23
BMI-for-age Z 0.40 0.03 0.001 0.17
Mean sBP 0.67 0.43 0.07 0.26
Mean dBP 0.27 0.69 0.35 0.11
Mean HR 0.65 0.06 0.55 0.59
Current WHO 0.69 NA 0.05 NA
Baseline log10 VL 0.28 NA NA NA
Duration on ART NA NA 0.25 NA
CD4 0.15 0.16 0.67 0.51
CD4% 0.96 0.47 0.35 0.03
CD4 z score 0.85 0.06 0.60 0.52
Lipids
Total cholesterol 0.01 0.21 0.32 0.34
Triglycerides 0.39 0.14 0.17 0.50
LDL 0.31 0.07 0.37 0.33
HDL 0.02 0.98 0.70 0.08
Controls were classed as WHO stage 1, viral load = 100 and for those matched to group 2 (ART
experienced) time on ART as 2 years. Main effects model included HIV status and factor of interest.
Interaction model includes main effects model and interaction between HIV status and factor of
interest. Absolute CD4 count and CD4 % were truncated at 99th centile. BMI, body mass index;
dBP, diastolic blood pressure; HDL, high density lipoprotein; HR, heart rate; LDL, low-density
lipoprotein; NA, not applicable; sBP, systolic blood pressure; VL, viral load.
ART naïve versus controls ART experienced versus controls
HIV related variables
Clinical variable
Immunological variable
Table 5-6. Results of a bivariate analysis, using a main effects and interaction model
to screen for the effects of variables on baseline IMT.
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The final multivariable model in ART naïve (group 1) v controls after backward
elimination (Table 5-7) found that total cholesterol was inversely related to baseline IMT
(IMT -0.006mm lower for every 1 mmol/L higher p=0.02). Age at baseline was not
significantly related to baseline IMT after adjusting for total cholesterol (p=0.33).
Despite the strong effect of total cholesterol, a residual effect of being an HIV infected
case vs uninfected control remained, with IMT 0.01mm higher in cases after adjustment
(p=0.02). After adjusting for total cholesterol and HIV status no significant effect of
recruitment site persisted (p=0.11).
Table 5-7. Final multivariable models for baseline IMT
Estimate of
impact on IMT
(mm)
p value
Mean at reference category 0.481 ( 0.464 : 0.498 ) <0.001
Total cholesterol (per 1 mmol/L higher) -0.006 ( -0.010 : - 0.001 ) 0.02
HIV-infected case vs uninfected control 0.010 ( 0.001 : 0.018 ) 0.02
Site (UTH vs JCRC) -0.008 ( -0.019 : 0.002 ) 0.11
Age (per 1 year older) -0.001 ( -0.003 : 0.001 ) 0.33
Mean at reference category 0.469 ( 0.438 : 0.500 ) <0.001
HIV-infected case vs uninfected control 0.033 ( 0.012 : 0.054 ) 0.03
Weight-for-age in cases (per 1 unit higher) 0.014 ( 0.002 : 0.030 ) 0.02
Weight-for-age in controls (per 1 unit higher) 0.000 ( - 0.008 : 0.010 ) 0.92
Site (UTH vs JCRC) 0.002 ( -0.013 : 0.017 ) 0.97
Age (per 1 year older) 0.001 ( -0.002 : 0.005 ) 0.44
95% CI
Naïve & controls
Experienced & controls
Reference category = age 0 and total cholesterol 0. IMT, Intimal Medial Thickness; JCRC, Joint Clinical
Research Centre, Kampala; UTH, University Teaching Hospital, Lusaka;
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The surprising and somewhat counterintuitive finding that a higher cholesterol was
significantly associated with a lower (healthier) IMT was looked at in more detail. The
graphs displayed in Figure 5-8 confirm that the same direction of effect is seen when
just total cholesterol is considered, so this finding is not due to over correcting in the
multivariable model.
Figure 5-8. Relationship between baseline IMT and cholesterol.
145
The final multivariable model in ART experienced (group 2) v controls after backward
elimination (Table 5-7) included weight-for-age which had effects that differed
significantly between HIV-infected cases and uninfected controls (interaction p=0.04). In
HIV-infected cases, IMT was +0.014mm higher per unit higher weight for age (95%CI
(+0.002 : +0.030), p=0.002); but there was no association between weight-for-age and
IMT in HIV-uninfected controls (p=0.92). Age at baseline was not significantly related to
baseline IMT after adjusting for weight for age z score (separately in cases and
controls) (p=0.44), that is any differences according to age in the bivariable analyses
could be explained by other variables. There was also no significant residual effect of
recruitment site in experienced children (p=0.97). Despite the strong effects of weight
for age z score, the residual effect of HIV case vs uninfected control remained, with IMT
0.033mm higher in HIV-infected cases after adjustment (p=0.03).
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5.6 Longitudinal changes in IMT
5.6.1 Impact of missing data
Table 5-8 summarises available data over time. As at baseline, the main reason for
missing scans was younger age and therefore completeness is higher in older children
(group 2 and group 1 at later time points). UTH also experienced more technical
difficulties in successfully scanning children, especially at earlier time points.
Consequently the regression models used for longitudinal analysis adjusted for age and
site.
Week 0 Week 48 Week 96
UTH
Number in trial 89 70 67
Number with IMT (%) 39 (44) 44 (63) 50 (75)
Number with missing IMT (%) 50 (56) 26 (37) 17 (25)
Died / LTFU 19 3
Number in trial 119 115 112
Number with IMT (%) 106 (89) 103 (90) 93 (83)
Number with missing IMT (%) 13 (11) 12 (10) 19 (17)
Died / LTFU 4 3
Number in trial 52 52 52
Number with IMT (%) 51 (98) 51 (98) 50 (96)
Number with missing IMT (%) 1 (2) 1 (2) 2 (4)
Number in trial 22 22 22
Number with IMT (%) 21 (96) 22 (100) 19 (86)
Number with missing IMT (%) 1 (5) 0 3 (14)
IMT, intimal medial thickness; LTFU, lost to follow up.
JCRC
UTH
JCRC
Group 2
Group 1
Table 5-8. Summary of scans performed by week of follow up.
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5.6.2 Longitudinal changes in IMT
Over 96 weeks from baseline significant improvements in IMT were demonstrated in
both ART naïve and ART experienced children. As summarized in Table 5-9 and
illustrated in Figure 5-9 a significant decrease of (-)0.02mm (sd 0.04) (p<0.001) and
(-)0.02mm (sd 0.06) (p=0.01) in the IMT from baseline was seen in ART naïve /
experienced children respectively.
Table 5-9. Summary of longitudinal changes in IMT by group.
Week 0 Week 48 Week 96
145 147 143
0.46 (0.04) 0.46 (0.04) 0.45 (0.03)
Mean change between week 0 and 48 n = 123
Mean change between week 0 and 96 n = 116
Week 0 Week 48 Week 96
72 73 69
0.46 (0.05) 0.45 (0.05) 0.44 (0.04)
Mean change between week 0 and 48 n = 72
Mean change between week 0 and 96 n = 68
-0.01 (0.05), p = 0.07
-0.02 (0.06), p = 0.01
Mean IMT (SD) in mm
Group 1 – ART naive
Total number IMT performed at time point
Mean IMT (SD) in mm
-0.004 (0.03), p = 0.25
-0.02 (0.04), p = 0.0001
Group 2 – ART experienced
Total number IMT performed at time point
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Figure 5-9. Change in IMT over 96 weeks
A) HIV infected, ART naïve (initiating ART) and controls and B) HIV infected, ART experienced
and controls.
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5.7 Impact of ART regimen on changes in IMT
Adjusted regression analysis was used to investigate any effects of randomized NRTI
on change in IMT over 48 and 96 weeks. All models included baseline IMT as a factor
to adjust for regression to the mean effects. As overall changes in IMT were similar in
naïve and experienced children (Figure 5-8), I pooled both groups to gain the greatest
power to detect any differences between randomized NRTI. I then checked that this
pooled analysis had not masked differential effects of randomized NRTI according to
whether the child was naïve or experienced by testing for significant interactions
between randomized NRTI and naïve/experienced strata. There was no evidence of
any interaction between randomized NRTI and naïve/experienced strata at either week
48 or 96 (p>0.05), and so results from main effects models are presented.
There was no evidence of a difference between randomized groups in change in IMT
from baseline to week 48 adjusting for site, age and baseline IMT (global test across
the three arms (p=0.27)). In particular there was no evidence of a difference between
ABC and d4T (p=0.98) or between ABC and ZDV (p=0.16).
Similarly there was no evidence of a difference between randomized groups in change
in IMT from baseline to week 96 adjusting for site, age and baseline IMT (global test
across the three arms p=0.77). In particular there was no evidence of a difference
between ABC and d4T (p=0.47) or between ABC and ZDV (p=0.76) - Figure 5-10.
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Figure 5-10. Changes in IMT over 96 weeks by NRTI randomisation arm.
A) ART naïve children and B) ART experienced children over the 96 weeks after
randomisation to either d4T, ZDV or ABC. No significant differences by NRTI randomisation
arm were demonstrated. Mean and SD shown .
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5.8 Impact of baseline variables on IMT at week 0, 48 and 96.
A univariable linear mixed effects model was used to model the absolute IMT values at
weeks 0, 48 and 96 jointly, including one single random effect per child (reflecting an
individual child’s value versus the population mean), in order to estimate a common
effect of other baseline factors on absolute IMT at the three time points. As listed in
Table 5-10 48 weeks of follow up (p=0.05), 96 weeks of follow up (p<0.001) and
baseline urea (p<0.001) were significantly associated with IMT at the measured time
points. As only time point and baseline urea had p<0.05 in univariable models, one final
multivariable model was fitted including these two variables (p<0.05) and other
variables known to provide important information for the study populations (age, sex,
site and HIV naïve/experienced). The highly significant effect of urea and no other
variable is surprising. When I added urea into the previous multivariable model
described in section 0, fitted only to the naïve HIV-infected children, urea did not have
an independent effect, suggesting that its highly significant effect in this model may be a
chance spurious finding, given the large number of statistical tests performed.
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Table 5-10. Association between the clinical characteristics of the study population on
IMT at week 0, 48 and 96 using a univariable linear mixed effects model.
Age (years) 0.00 (0.00 : 0.00 ) 0.31
Sex -0.01 (-0.01 : 0.00 ) 0.06
Site 0.00 (-0.01 : 0.01 ) 0.55
Week of follow up - 48 -0.01 (-0.01 : 0.00 ) 0.05
Week of follow up - 96 -0.02 (-0.02 : -0.01 ) <0.001
Baseline Weight-for-age Z 0.00 (0.00 : 0.00 ) 0.23
Baseline Height-for-age Z 0.00 (0.00 : 0.00 ) 0.21
Baseline BMI-for-age Z 0.00 (0.00 : 0.00 ) 0.71
Baseline mean sBP (per 5mmHg) 0.00 (0.00 : 0.00 ) 0.27
Baseline mean dBP (per 5mmHg) 0.00 (0.00 : 0.00 ) 0.32
Baseline mean HR 0.00 (0.00 : 0.00 ) 0.36
ART (naïve v experienced) 0.00 (-0.01 : 0.00 ) 0.47
NNRTI - NVP v EFV 0.00 (-0.01 : 0.01 ) 0.73
ARM – ZDV v d4T 0.00 (-0.01 : 0.01 ) 0.44
ARM – ABCv d4T 0.00 (-0.01 : 0.01 ) 0.67
Baseline CD4 0.00 (0.00 : 0.00 ) 0.40
Baseline CD4% 0.00 (0.00 : 0.00 ) 0.19
Baseline CD4 z score 0.00 (0.00 : 0.00 ) 0.62
Current WHO 2 v 1 0.00 (-0.01 : 0.01 ) 0.76
Current WHO 3 v 1 0.00 (-0.01 : 0.01 ) 0.58
Current WHO 4 v 1 -0.01 (-0.02 : 0.01 ) 0.39
Previous WHO grade 3/4 0.00 (-0.01 : 0.01 ) 0.77
Baseline VL 0.00 (0.00 : 0.00 ) 0.80
Age started ART (years) 0.00 (0.00 : 0.00 ) 0.47
Duration on ART (years) 0.00 (0.00 : 0.00 ) 0.44
Laboratory results
Baseline total cholesterol 0.00 (-0.01 : 0.00 ) 0.47
Baseline triglycerides 0.00 (0.00 : 0.01 ) 0.64
Baseline LDL 0.00 (-0.01 : 0.00 ) 0.41
Baseline HDL 0.00 (-0.01 : 0.01 ) 0.64
Baseline urea -0.01 (-0.01 : 0.00 ) <0.001
Baseline creatinine 0.00 (0.00 : 0.00 ) 0.47
Baseline MCV 0.00 (0.00 : 0.00 ) 0.11
Baseline haemaglobin 0.00 (0.00 : 0.00 ) 0.26
Baseline platelets 0.00 (0.00 : 0.00 ) 0.21
BMI, body mass index; sBP, systolic b lood pressure; dBP, diastolic b lood pressure; HR, heart
rate; NNRTI, non-nucleoside reverse transcriptase; NVP, nevirapine; EFV, efavirenz; ZDV,
zidovudine; d4T, stavudine; ABC, abacavir; WHO, World Health Organisation; VL, viral load;
LDL, low density lipoprotein HDL , high density lipoprotein; MCV, mean corpuscular volume.
Variable Estimate 95% CI p value
Patient details
HIV related
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In the multivariable analysis (Table 5-11), after adjusting for age, sex, site and HIV
naïve/experienced), IMT was significantly lower after 48 / 96 weeks by -0.01 / -0.02mm,
95% CI (-0.01 : 0.00 / -0.02 : -0.01), (p=0.04 / <0.001). Children at UTH had an IMT -
0.01mm lower than children at JCRC, 95% CI (-0.02: -0.00), (p=0.05). For every umol/l
higher baseline urea IMT was 0.01mm lower 95% CI (-0.01 : 0.00), (p<0.001). There
was no evidence of an interaction between HIV-infection and age or urea (p>0.05).
Table 5-11. Multivariable model for absolute IMT at week 0, 48 and 96 weeks.
Estimate p value
Patient details
Age (years) at baseline 0.00 ( 0.00 : 0.00 ) 0.14
Sex - female v male -0.01 ( -0.01 : 0.00 ) 0.07
Site - JCRC v UTH 0.01 ( 0.00 : 0.02 ) 0.05
Week of follow up - 48 v 0 -0.01 ( -0.01 : 0.00 ) 0.05
Week of follow up - 96 v 0 -0.02 ( -0.02 : -0.01 ) <0.001
HIV related
ART experienced v naïve 0.00 ( -0.01 : 0.01 ) 0.80
Laboratory results
Baseline urea -0.01 ( -0.01 : 0.00 ) <0.001
95% CIVariable
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5.9 Impact of baseline variables on the change in IMT from baseline to
week 96
The previous analysis considered all values of IMT together in one model. However, the
particular interest in this trial was the change from baseline to the primary endpoint time
of week 96. I therefore considered separate models just for this change (one
observation per child), following the previous modelling strategy used to identify
predictors of baseline IMT. Some additional factors were included in these models that
had not been measured in controls (e.g. biochemistry) and so were not considered in
the earlier models. Specifically, a bivariable main effects and interaction model
(allowing a different effect of each factor depending on whether the child was ART
naïve or experienced at baseline), also including baseline IMT to adjust for regression
to the mean, were used to screen the effects of other baseline variables on the change
in IMT over 96 weeks -Table 5-12. Any variable or interaction which had p<0.2 in the
main effects or interaction model was included in a multivariable model from which a
final multivariable model was identified using backward elimination (exit p=0.05). ART
naïve/experienced status, age, baseline IMT and site of recruitment were included in all
models regardless of significance as the key exposure of interest (ART naïve v
experienced) or because they were factors a priori considered to have potential
influence. After a model had been identified by backwards elimination, each rejected
main effect and interaction term was checked for additional prognostic importance given
this model, and any factors with p<0.05 retained.
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Table 5-12. Results of a bivariate analysis, using a main effects and interaction model to
screen for effects of baseline variables on the change in IMT from baseline to week 96.
p value for main effect
adjusted for group
Age in years 0.13
Sex 0.77
Site 0.96
Weight-for-age Z 0.84
Height-for-age Z 0.86
BMI-for-age Z 0.78
Mean sBP 0.31
Mean dBP 0.48
Mean HR 0.79
2 v 1 0.57
3 v 1 0.47
4 v 1 0.05
Baseline log10 VL 0.96
Wk 96 VL suppression 0.41
Duration on ART at baseline 0.76
NNRTI - NVP v EFV 0.47
ARM – ZDV v d4T 2 v 1 0.69
ARM – ABCv d4T 3 v 1 0.75
CD4 0.29
CD4% 0.43
CD4 z score 0.35
Total cholesterol 0.77
Triglycerides 0.68
LDL 0.87
HDL 0.50
Urea 0.06
Creatinine 0.87
MCV 0.26
Haemaglobin 0.57
Platelets 0.45
Lipids at baseline
Immunological variables at baseline
0.89
NA
NA
0.84
0.75
0.01
0.22
0.18
0.38
0.51
0.82
0.11
Laboratory markers at baseline
0.48
0.98
0.62
Main effects model included HIV status and factor of interest. Interaction model includes
main effects model and interaction between HIV status and factor of interest. Absolute
CD4 count and CD4 % were truncated at 99th centile. BMI, body mass index; dBP,
diastolic blood pressure; HDL, high density lipoprotein; HR, heart rate; LDL, low-density
lipoprotein; NA, not applicable; sBP, systolic blood pressure; Wk, week; VL, viral load.
0.51
0.16
Relationship to change in IMT over 96 week
p value for interaction by
ART naïve / experienced
Clinical variables at baseline
HIV related variables
Baseline WHO 0.37
0.45
0.29
0.15
1.00
0.41
0.66
0.34
0.98
0.86
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The final multivariable model after backward elimination (Table 5-13) looked at mean
change over 96 weeks in IMT compared to the reference category (reference category
age 3 years, triglycerides 1mmol/l, ART-naïve at baseline). For each 1 year older at
baseline, the change in IMT from baseline to week 96 was (+)0.003mm larger (p=0.04)
(i.e. any decline was smaller, or even an increase). Every 1 mmol/l higher baseline urea
was associated with an (-)0.07mm greater decline in IMT from baseline to week 96
(p=0.01).
WHO stage 4 HIV-disease at baseline was significantly associated with a greater
improvement (-)0.048 mm in IMT over 96 week in children who were ART experienced
at baseline (p=0.01). Despite the strong effect of total triglycerides, a residual effect of
being an ART naive vs ART experienced at baseline remained, the change in IMT over
96 weeks was an increase of 0.009mm for each 1mmol/l increase in triglycerides in
ART naïve children (p=0.05) and a decrease of (-)0.021mm for each 1 mmol/l increase
in triglycerides in ART experienced children (p=0.003).
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Table 5-13. Final multivariable models for change in IMT from baseline to week 96.
Variable
Estimate of impact
on change in IMT
(mm)
p value
Mean at reference category 0.319 ( 0.245 : 0.394 ) <0.001
ART at baseline - experienced v naïve 0.008 ( -0.013 : 0.029 ) 0.44
Age at baseline (per year older) 0.003 ( 0.000 : 0.006 ) 0.04
Site UTH v JCRC -0.002 ( -0.018 : 0.013 ) 0.77
Baseline urea (per 1 mmol/l increase) -0.007 ( -0.012 : -0.001 ) 0.01
Baseline WHO stage in children ART naïve at
baseline
2 v 1 0.004 ( -0.015 : 0.022 ) 0.68
3 v 1 0.000 ( -0.017 : 0.018 ) 0.96
4 v 1 0.023 ( -0.027 : 0.073 ) 0.37
Baseline WHO stage in children ARTexperienced at
baseline
2 v 1 -0.027 ( -0.060 : 0.007 ) 0.12
3 v 1 -0.015 ( -0.043 : 0.013 ) 0.29
4 v 1 -0.048 ( -0.082 : -0.013 ) 0.01
Baseline triglycerides in children ART naïve at
baseline (per 1 mmol/l increase) 0.009 ( 0.000 : 0.018 ) 0.05
Baseline triglycerides in children ART experienced
at baseline (per 1 mmol/l increase) -0.021 ( -0.035 : -0.007 ) 0.003
95% CI
Models were adjusted for baseline IMT. Reference category; age = 3 years, triglycerides = 1 mmol/l. ART,
anti-retroviral therapy; IMT, intimal medial thickness; JCRC, Joint Clinical Research Centre; UTH, university
teaching hopsital; WHO, World Health Organisation.
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5.10 Pulse Wave Velocity (PWV)
5.10.1 Missing baseline PWV by site and group
Technical difficulties and uncooperative children meant some recruits could not be
scanned; this tended to be the younger children, Table 5-14. Comparing the median
age of children in groups 1 and 2 with baseline PWV scans with their control group
respectively showed that at UTH the children with PWV results in group 1 were
significantly older (median age 6.3 years) than the control group (median age 4.2 years)
(p=0.002). This can be explained as the controls were recruited later in the study when
the clinical team was more confident in scanning smaller children. No differences were
seen between Group 2 and controls at UTH (p=0.59) nor at JCRC between both group
1/2 and controls (p=0.12/0.82). Combining all children recruited from both sites to group
1/2 no difference was seen between groups and controls (p=0.59/0.55). Thus whilst
comparisons of HIV infected versus controls cannot be confounded by age as a whole,
further analyses that adjust for site will also be adjusted for age.
Total recruited 89 89 52 52
Missing PWV (% total) 51 (57) 29 (33) 1 (2) 0
Age 2.9 (1.8 : 6.1) 3.4 (2.1 : 5.6) 7.0 (5.8 : 8.2) 6.9 (5.6 : 8.3)
Age with a baseline PWV 6.3 (4.5 : 9.6) 4.2 (3.0 : 6.4) 7.0 (5.8 : 8.5) 6.9 (5.6 : 8.3)
Age with missing baseline PWV 1.8 (1.2 : 2.6) 1.5 (0.9 : 2.7) 5.5
Total recruited 119 120 22 23
Missing PWV (% total) 16 (13) 25 (21) 0 0
Age 2.8 (1.6 : 4.0) 2.9 (2.1 : 4.1) 6.5 (5.9 : 9.9) 6.4 (5.5 : 9.1)
Age with a baseline PWV 3.2 (1.8 : 4.3) 3.3 (2.4 : 4.4) 6.5 (5.9 : 9.9) 6.4 (5.5 : 9.1)
Age with missing baseline PWV 1.5 (1.1 : 2.2) 1.8 (1.3 : 2.6)
UTH
JCRC
HIV- controls
matched to group 1
HIV- controls
matched to group 2
HIV+ ART naïve
(group 1)
HIV+ ART
experienced
(group 2)
Table 5-14. Summary of missing baseline PWV recordings by group and site.
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5.11 Baseline Pulse Wave Velocity
Two results from group 1 were excluded; these were both <3m/sec, performed in young
children on the same day and considered not to be physiologically possible. One
extremely high result (PWV – 9.9m/sec) was also obtained in group 1 at week six; this
could be biologically possible; the patient at that visit also had a raised CRP and was
febrile so potentially this was a true reading but reflecting an intercurrent infection.
However this could also heavily influence results so this result (and others >99th centile)
were truncated and replaced with the 99th centile value in subsequent analyses. To
determine the impact of scans performed after week 0 firstly the results were plotted -
Figure 5-11. Regression analysis confirmed there was no trend in baseline PWV by
time after randomization in either group 1 or group 2 (p=0.18/0.97) so all results were
included in the further analyses.
Figure 5-11. Baseline PWV results
A) ART naïve and B) ART experienced children by week after randomisation performed.
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As summarized in Table 5-15 and illustrated in Figure 5-12 baseline PWV was
significantly higher in group 1 versus controls (p=0.05). No significant difference was
seen between the smaller numbers in group 2 and controls (p=0.57). Results after
excluding nine and seven scans performed at weeks 2 -12 after enrollment in groups 1
and 2 respectively showed the same trend towards a significant difference between
group 1 and controls (p=0.09) and no difference between group 2 and controls (p=0.38)
As there was no significant time trend in PWV with increasing time post-enrolment, and
because power to detect differences between cases and controls will be reduced
restricting to the fewer children with scans at week 0, I have included all scans up to 12
weeks in further analyses.
IQR, interquartile range; PWV, pulse wave velocity; SD, standard deviation. * missing
recordings – were performed but accidently deleted prior to data transfer
Table 5-15. Baseline PWV results.
Wk 2 4 (3%) Wk 2 2 (3%)
Wk 6 2 (1%) Wk 6 4 (5%)
Wk 12 3 (2%) Wk 12 1 (1%)
Too young
(% missing)
Not done
Unanalysable
Missing*
7(10%) 5 (9%) 1 (100%)
3 (5%) 3 (6%)
67 (32%) 54 (26%) 1 (1%)
57 (85%) 46 (85%)
HIV- controls
matched to Group 2
75
5.85 (0.80) 5.67 (0.74) 5.63 (0.61) 5.69 (0.68)
4.12 : 9.89 4.13 : 7.26 4.34 : 7.15 4.07 : 7.33
5.673 (5.188 – 6.20)
141 155 73
208 209 74 75
5.723 (0.73)
Total number in
group
Overall mean (SD)
Median (IQR)
Number PWV
scans performed
Mean in m/sec
(SD)
Range
Number performed
after week 0 (%
total)
Missing (% total)
HIV+ ART naïve
group 1
HIV- controls
matched to Group 1
HIV+ ART
experienced group 2
9 7
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Figure 5-12. Boxplot of baseline PWV between the groups.
Median and IQR given. A) results when all baseline PWV results are included, B) results
when PWV recordings performed after week 0 are excluded.
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5.12 Impact of variables on baseline PWV
5.12.1 Age
Comparing group 1 (ART naïve) and their control group in a full interaction model,
allowing the relationship between baseline PWV and age to vary by HIV infection,
estimates were that in the ART-naïve children baseline PWV was (-)0.06 lower for
every year older (95% CI -0.08 : +0.13) (p=0.08), and in the controls baseline PWV was
0.03 higher for every year older (95% CI -0.03 : +0.08) (p=0.31). There was no
significant evidence that the impact of age at baseline varied by HIV status (interaction
p=0.08). Fitting the same relationship between age and baseline PWV in both groups
there was still no evidence of a relationship between baseline PWV and age overall –
Figure 5-13. Effect of age on baseline PWV by group.
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baseline PWV was (-)0.007 lower per year older (95% CI -0.04 : +0.03), (p=0.67). After
adjusting for age, there was a trend towards PWV being (-)0.16m/second lower in
controls (95% CI -0.32 : +0.01) (p=0.06).
Comparing group 2 (ART experienced) and their control group in a full interaction
model, allowing the relationship between baseline PWV and age to vary by HIV
infection, estimates were that in the ART-experienced children baseline PWV was 0.06
higher for every year older (95% CI -0.02 : +0.14) (p=0.13), and in the controls baseline
PWV was (-)0.01 lower for every year older (95% CI -0.08 : +0.07) (p=0.83). There was
no evidence that the impact of age at baseline varied by HIV status (interaction p=0.22).
Fitting the same relationship between age and baseline PWV in both groups there was
still no evidence of a relationship between baseline PWV and age overall – baseline
PWV was 0.03 higher per year older (95% CI -0.03 : +0.08), (p=0.37). No significant
association between baseline PWV and HIV status was seen after adjusting for age
(PWV 0.07m/second higher in controls (95% CI -0.15: 0.28) (p=0.54)).
In the ART experienced group, duration of ART prior to baseline ranged from 2 – 7.1
years (median 3.9 years, IQR (2.9 : 4.3)). As illustrated in Figure 5-14 the distribution of
age at baseline and duration of ART at baseline was varied (Spearman rho=0.02,
p=0.86) and therefore it was possible to estimate an effect of duration of ART on PWV
independently of any effect of age at enrolment. Regression analysis showed that for
each year on ART, after adjusting for age, PWV was (-)0.03m/sec lower but this was
not significant (95%CI (-0.16 : +0.11), p=0.71). There was also no effect in a univariable
analysis not adjusted for age (p=0.70).
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Scatter plot showing duration of ART by age.
Figure 5-14. The relationship between duration on ART and age at baseline.
A wide variation exists with no significant relationship (Spearman co-efficient = 0.02, p=0.86)
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5.13 Effect of age on PWV in HIV uninfected controls
As for IMT there are no published normal ranges of PWV in young children. To attempt
to calculate a normal range PWV was plotted against age in all 230 HIV uninfected
controls - Figure 5-15. The point estimate suggests that PWV increases by 0.01m/sec
for each additional year of age but there is no formal evidence that this is not
compatible with chance (95% CI -0.02 : 0.05), (p=0.45).
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Figure 5-15. Effect of age on PWV in HIV uninfected children,
No significant impact of age on PWV was demonstrated (95% CI -0.02 : 0.05), (p=0.45).
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5.13.1 Impact of baseline CD4 count on baseline PWV
No significant associations were demonstrated between absolute CD4 count and PWV
in either ART-naïve and controls or ART-experienced and controls (p=0.37/0.13
respectively). A significant inverse association was seen between CD4 percentage and
PWV in both ART-naïve and controls and ART-experienced and controls (r = -0.21 / -
0.20), (p<0.001/0.02) (not adjusting for other factors), Figure 5-16.
Figure 5-16. The relationship between baseline CD4 percentage and PWV
A) ART naïve children and their controls and B) ART experienced children and their controls.
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5.13.2 Impact of other variables on baseline PWV.
A bivariable main effects and interaction model were used to screen the effects of
variables on baseline PWV - Table 5-16. Any variable or interaction which had p<0.2 in
the main effects or interaction model was included in the multivariable analysis, using
backwards elimination to select a final model (exit p=0.05). Case/control status, age
and site of recruitment were included in all models regardless of significance as they
were the key exposure of interest (case vs control) or factors a priori considered to have
potential influence. After a model had been identified by backwards elimination, each
rejected main effect and interaction term was checked for additional prognostic
importance given this model, and any factors with p<0.05 retained.
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Table 5-16. Results of a bivariable analysis, using a main effects and interaction model
to screen for the effects of variables on baseline PWV.
p value for main
effect adjusted
for group
p value for
interaction by
HIV status
p value for main
effect adjusted
for group
p value for
interaction by
HIV status
Age in years 0.67 0.08 0.37 0.22
Sex 0.36 0.53 0.70 0.50
Site 0.01 0.02 <0.001 0.31
Weight-for-age Z <0.001 0.01 0.77 0.24
Height-for-age Z 0.002 0.01 0.27 0.51
BMI-for-age Z 0.02 0.03 0.29 0.35
Mean sBP 0.01 0.98 <0.001 0.58
Mean dBP 0.38 0.52 <0.001 0.60
Mean HR 0.12 <0.001 0.32 0.92
Current WHO 0.45 NA 0.05 NA
Baseline log10 VL 0.16 NA NA NA
Duration on ART NA NA 0.70 NA
CD4 0.92 0.42 0.26 0.21
CD4% 0.001 0.31 0.02 0.40
CD4 z score 0.26 0.62 0.56 0.24
Lipids
Total cholesterol 0.63 0.18 0.27 0.73
Triglycerides 0.004 0.77 0.54 0.98
LDL 0.43 0.35 0.50 0.75
HDL 0.88 0.06 0.09 0.96
ART naïve versus controls ART experienced versus controls
Clinical variable
HIV related variables
Immunological variable
Controls were classed as WHO stage 1, viral load = 100 and for those matched to group 2 (ART
experienced) time on ART as 2 years. Main effects model included HIV status and factor of
interest. Interaction model includes main effects model and interaction between HIV status and
factor of interest. Absolute CD4 count and CD4 % were truncated at 99th centile. BMI, body
mass index; dBP, diastolic blood pressure; HDL, high density lipoprotein; HR, heart rate; LDL,
low-density lipoprotein; NA, not applicable; sBP, systolic blood pressure; VL, viral load.
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HIV infected ART naïve versus control children
The final multivariate model in ART naïve (group 1) v controls after backward
elimination (Table 5-17) included baseline CD4 percentage (PWV -0.02m/sec lower for
every 1% higher CD4 percentage (p=0.002), baseline systolic blood pressure (PWV -
0.02m/sec lower for every 1mmHg higher, (p<0.001) and baseline triglycerides (PWV
0.16m/sec higher for every mmol/L higher triglycerides (p=0.01). There was a trend
towards higher PWV in HIV-infected children after adjusting for age, site, CD4
percentage, systolic blood pressure and triglycerides (p=0.06). Despite strong effects of
baseline CD4 percentage, triglycerides and systolic blood pressure there were still
residual effects of site; the PWV of children recruited at UTH was 0.28m/sec higher
than children recruited at JCRC (p=0.01) and age; PWV 0.14m/sec higher per year
older (p<0.001) in HIV-infected children. In HIV uninfected children no significant effect
of age was demonstrated (p=0.18; interaction p=0.08). There was no evidence of
collinearity between systolic blood pressure and the other variables included in the
model.
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Table 5-17. Final multivariable models for baseline PWV in HIV infected ART naïve
children and controls.
Estimate of
impact on
PWV (m/sec)
p value
Mean at reference category 7.921 ( 7.014 : 8.828 ) <0.001
HIV-infected case vs uninfected control 0.364 ( -0.012 : 0.740 ) 0.06
Site (UTH vs JCRC) 0.280 ( 0.059 : 0.501 ) 0.01
CD4 percentage (per 1% increase) -0.018 ( -0.029 : -0.007 ) 0.002
Systolic BP (per 1mmHg higher) -0.018 ( -0.026 : -0.009 ) <0.001
Triglycerides (per 1mmol/l higher) 0.155 ( 0.043 : 0.266 ) 0.01
Age in HIV infected (per 1 year older) 0.138 ( 0.065 : 0.211 ) <0.001
Age in controls (per year older) 0.039 ( -0.019 : 0.097 ) 0.18
95% CI
Naïve & controls
Reference category = age 0. BP. Blood pressure; IMT, Intimal Medial Thickness; JCRC, Joint
Clinical Research Centre, Kampala; UTH, University Teaching Hospital, Lusaka;
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HIV infected ART experienced versus control children
The final multivariate model in ART experienced (group 2) v controls after backward
elimination (Table 5-18) found a significant association of diastolic blood pressure with
baseline PWV; PWV was 0.03 m/sec higher for every 1mmHg higher diastolic blood
pressure (p<0.001). Despite the strong effect of diastolic blood pressure there was still
a residual effect of site, with children at UTH having a PWV that was 0.54m/sec higher
than at JCRC (95% CI 0.34 ; 0.75), p<0.001). After adjusting for age, site and diastolic
blood pressure no effect of being HIV infected vs control remained (p=0.29). There was
no effect of CD4 percentage on baseline PWV after adjusting for these other factors.
Table 5-18. Final multivariable models for baseline PWV in HIV infected, ART
experienced children and controls.
Estimate of
impact on
PWV (m/sec)
p value
Mean at reference category 3.578 ( 2.712 : 4.444 ) <0.001
HIV-infected case vs uninfected control 0.097 ( -0.085 : 0.280 ) 0.29
Age (per 1 year older) 0.022 ( -0.026 : 0.069 ) 0.37
Site (UTH vs JCRC) 0.544 ( 0.340 : 0.747 ) <0.001
Diastolic BP (per 1mmHg higher) 0.025 ( 0.011 : 0.039 ) <0.001
Reference category = age 0. BP. Blood pressure; IMT, Intimal Medial Thickness; JCRC, Joint
Clinical Research Centre, Kampala; UTH, University Teaching Hospital, Lusaka;
Experienced & controls
95% CI
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5.14 Longitudinal changes in PWV
5.14.1 Impact of missing data
Table 5-19 summarises the data available at the different time points. As at baseline,
the main reason for missing scans was younger age and therefore completeness was
higher in older children (group 2 and group 1 at later time points). UTH also
experienced more technical difficulties in successfully scanning children. Consequently
age and site of recruitment will be adjusted for in subsequent models.
Week 0 Week 48 Week 96
Number in trial 89 70 67
Number with PWV (%) 38 (43) 45 (64) 49 (73)
Number with missing PWV (%) 51 (57) 25 (36) 18 (27)
Died / LTFU 19 3
Number in trial 119 115 112
Number with PWV (%) 103 (87) 103 (90) 95 (85)
Number with missing PWV (%) 16 (13) 12 (10) 17 (15)
Died / LTFU 4 3
Week 48 Week 96
Number in trial 52 52 52
Number with PWV (%) 51 (98) 52 48 (92)
Number with missing PWV (%) 1 (2) 4 (8)
Number in trial 22 22 22
Number with PWV (%) 22 21 (95) 21 (95)
Number with missing PWV (%) 1 (5) 1 (5)
Group 1
UTH
UTH
JCRC
JCRC
Group 2
PWV, pulse wave velocity; LTFU, lost to follow up.
Table 5-19. Summary of available PWV recordings by week of
follow up.
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5.14.2 Changes in PWV over 96 weeks
As reported in Table 5-20 and illustrated in Figure 5-17, mean PWV significantly
decreased by -0.37 (SD 0.82) m/sec (p<0.001), in ART naïve children over 96 weeks
after starting ART. Conversely in ART experienced children a significant increase of
0.34 (SD 0.62) m/sec in PWV over 96 weeks (p<0.001); potentially this could reflect an
increase in PWV with increasing age in HIV-infected children on ART, although I did not
find evidence to support this in my previous model for baseline PWV.
Week 0 Week 48 Week 96
141 148 144
5.83 (0.73) 5.76 (0.81) 5.48 (0.71)
Mean change between week 0 and 48 n = 121
Mean change between week 0 and 96 n = 112
Week 0 Week 48 Week 96
73 73 69
5.63 (0.61) 5.77 (0.65) 5.96 (0.68)
Mean change between week 0 and 48 n = 72
Mean change between week 0 and 96 n = 68 0.34 (0.62), p < 0.001
Group 2 – ART experienced
Number PWV
Mean (SD) m/sec
0.13 (0.61), p = 0.08
Group 1 – ART naive
Number PWV
Mean (SD) m/sec
-0.11 (0.77), p = 0.12
-0.37 (0.82), p < 0.001
Table 5-20. Summary of PWV changes over time by group.
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Figure 5-17. Change in PWV over 96 weeks.
A) HIV-infected ART naïve (initiating ART) children and B) HIV infected, ART
experienced children.
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5.15 Impact of ART regimen on change in PWV over 96 weeks
Adjusted regression analysis was used to look for an effect of randomized NRTI on
change in PWV over 48 and 96 weeks. As overall changes in PWV were different in
naïve and experienced children (Figure 5-17) a separate model was fitted for each
group. Both models included baseline PWV as a factor to adjust for regression to the
mean effects.
Within the ART naïve group, after adjusting for site, age and baseline PWV there was
no evidence of a difference between randomized groups in change in PWV from
baseline to week 48 or week 96 (global test across the three arms p=0.71/0.29). In
particular there was no evidence of a difference between ZDV and d4T (p =0.95/0.82),
ABC and d4T (p=0.48/0.14) or between ABC and ZDV (p=0.49/0.24).
Within the ART experienced group, after adjusting for site, age and baseline PWV there
was no evidence of a significant difference between randomized groups in change in
PWV from baseline to week 48 or week 96 (global test across the three arms
p=0.09/0.21). Looking in detail by arm a borderline significant results was seen at week
48 comparing ZDV and d4T (p=0.05), with a trend towards a greater increase in PWV
from 0 to 48 weeks in the ZDV than the d4T group. However by week 96 no significant
difference was seen (p=0.69). Additionally there was no evidence of a difference
between ABC and d4T (p=0.07/0.09) or between ABC and ZDV (p=0.93/0.18). Week 48
differences were driven by a mean decrease in the d4T group compared to mean
increases in the ZDV and ABC groups. This is illustrated in Figure 5-18.
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Figure 5-18. Change in PWV over 96 weeks by NRTI randomisation arm.
A) ART naive and B) ART experienced children in the 96 weeks after randomisation to
either d4T, ZDV or ABC. Mean and SD given.
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5.16 Discussion
5.16.1 IMT results
This is the first report that changes in structural and arterial stiffness are present in very
young (median age 2.9 years) HIV infected ART naïve children compared to age
matched controls from the same community. These findings compliment the findings of
other paediatric studies (summarised in table 2.8) that have found structural changes of
the arterial wall in older children and adolescents. Unique to this study were the large
number of ART naïve children; the majority with severe immunosuppression (57% of
the ART naïve group were classed as WHO stage III/IV) or low CD4 percentage for age
(median CD4 percentage 18% (IQR 11 – 23%)).
The ART experienced children were older (median 6.9 years) and virologically
suppressed on first line, d4T containing ART, in contrast to other cohorts that have had
children taking a heterogeneous selection of ART regimens, including PIs, for variable
durations and with different proportions of virological suppression. Having children on a
single first line ART combination removed class of ART as a confounder. Two control
groups, well matched by age, sex and race – important as these are known to influence
IMT and PWV [329-332], added to the strength of the findings.
IMT assesses structural rearrangement of the arterial wall and is a well validated
surrogate marker of subclinical atherosclerosis. IMT reflects risk factor burden in
children from 10 years of age [274] and thickened IMT has been demonstrated in
children with known cardiovascular risk factors such as obesity, diabetes or metabolic
syndrome [245, 333, 334]. In non-HIV infected adults, increased IMT is an independent
predictor of adverse cardiovascular outcome and a marker of coronary artery disease
[290, 335, 336]. HIV infected adults have been shown to have increased IMT compared
to matched controls [207] and an increase in IMT over time has been described [337].
I have demonstrated a detrimental (thicker) 0.02mm difference in IMT between HIV
infected ART naïve children and age-matched controls and a 0.01mm difference
between ART experienced children and age-matched controls. This difference is at the
lower end of what other studies have found (differences in mean IMT between HIV
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infected and uninfected children ranging from 0.02 to 0.15mm), likely reflecting the
younger age and shorter duration of HIV infection in this cohort. Whilst the changes are
small and their clinical significance unknown, in the context of ART, when long-term
survival is predicted, small changes in vascular function before starting treatment may
become very significant over time.
Whilst other studies have shown that IMT increases with age in HIV uninfected children,
I did not find any association between age and baseline IMT in either HIV infected or
uninfected children. Ishizu et al demonstrated in a group of 60 healthy children aged 5 –
14 years a linear increase in IMT with age [IMT in millimeters = (0.009 x age in years)
+0.35] [332]. Charakida et al found an increase of 0.005 mm (95% CI, 0.0003 to 0.01)
per additional year of age in HIV infected children but not their controls, in this study the
mean age of HIV-infected controls was 11.0 /12.2 years (SD 3.1 / 2.8) [241]. The lack of
age effect in the CHAPAS-3 cohort may be a reflection of the young age of the children
(only 38% of uninfected controls were >5 years, and 5% > 10 years); it may be that age
only starts to impact IMT after the end of the first decade, or that in the older
experienced children, whom started ART at an early age (median 3.2 years), this was
sufficient to prevent the HIV related increases described by Charakida.
Multivariable regression analysis suggested that in ART naïve HIV infected children and
age matched controls, the finding that for each 1mmol/l higher total cholesterol IMT was
0.006mm lower, is at first surprising. When the final model is run replacing total
cholesterol with HDL-C very similar results are obtained, such that higher HDL-C is
associated with a lower IMT (co-efficient -0.008 95% CI (-0.019, 0 .004)) but this does
not reach statistical significance (p=0.19). This is complementary to data from adult
cohorts in whom higher HDL-C levels were associated with a thinner IMT [338, 339].
The role of lipids is not straightforward and recent work has shown that interactions
between the components of HDL cholesterol is more complex than initially thought and
affected by low grade and chronic inflammation [340].
I did not demonstrate an independent association between IMT and absolute CD4
count, CD4 percentage or CD4 z score in either group. In this study a limited set of
parameters were studied but further studies looking at naïve/memory ratios and
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CD4/CD8 ratios could be informative. In adolescent and adult studies a lower CD4
count and CD4 nadir and in adolescents a lower CD4 nadir is a risk factor for increased
IMT although the other variables that were adjusted for differed by study [208, 245,
341]. One possibility is that the CD4 percentage in naïve children does not correlate
with baseline IMT as the ratio of naïve to memory cells is altered and it is the ratio that
is important.
A trend towards a difference in IMT between ART experienced children and controls
(p=0.09) was seen in this CHAPAS-3 cohort but did not reach conventional levels of
statistical significance. This is complementary to the findings of the Thai cohort in whom
no difference in IMT was described in 100 asymptomatic HIV-infected adolescents who
had been on ART (52% on NNRTI based regimen) for a median of 10 years, the
majority of whom were virologically suppressed and with a CD4 count above
500cells/uL [240]. In the Thai study, it appears early ART, commenced at a mean age
of 3.2 years and continued for a median of 3.9 years, virological suppression, with a
CD4≥500 cells/mm3 could be sufficient to reverse/prevent the detrimental changes in 
IMT reported in other cohorts.
Conversely Sainz et al showed IMT to be higher in a cohort of 150 Spanish HIV infected
children compared to 150 controls, 96% of the cohort were on ART although 26% had a
detectable VL. Even when removing the patients with a detectable VL a significant
difference between HIV+ and HIV- persisted [245]. This may however be a reflection of
time with a detectable VL; in the Spanish cohort the median duration of time with a
detectable viral load was 10.8 years before ART was commenced so these adolescents
were started on ART much later than in the CHAPAS 3 cohort and the Thai cohort
[240]. The Spanish cohort also had a large proportion on PIs with a median cumulative
exposure of 8.2 years (IQR 3.2 – 11.3 years); a sub analysis of non-smoking vertically
infected adolescents in this cohort found PI use to be associated with an increased IMT
although no detrimental effects of PI on IMT were seen when the whole cohort was
analysed. Finally in the Spanish cohort only a small proportion of children were of
African descent (73% white).
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This is the first longitudinal cardiovascular data from children living with HIV in Africa. It
shows that detrimental changes in IMT can, at least in part, be reversed with ART.
Findings that the ART experienced children, who had already been on ART for a mean
of 3.9 years, had ongoing improvements in their IMT after a further 2 years ART,
suggest a longer duration of ART could continue to be beneficial.
On multivariable analysis the variables found to be associated with significant
improvements in IMT were duration of follow up, as discussed above longer ART
duration is important and surprisingly baseline urea, in that for every umol/l higher in
urea at enrolment a (-)0.01mm greater decrease in IMT was seen over 96 weeks. No
association of urea and IMT has been reported previously, this could be reflecting
muscle wasting or underlying renal failure, in adult populations an association between
renal failure and increased IMT has been reported [342].
Three of the paediatric studies have implicated the use of d4T [243] and protease
inhibitors [240, 249] with a thickened IMT when compared to HIV infected adolescents
on a regimen containing alternative antiretroviral drugs. All of the 74 ART experienced
children were on d4T based treatment at baseline and 22/74 (30%) remained on d4T
for the duration of the trial. No difference in IMT was seen between ART experienced
children whom remained on d4T or were randomised to ZDV/ABC; similarly in ART
naïve children commencing ART there was no difference in the change in IMT over 96
weeks by randomised NRTI arm. Of additional reassurance, given the adverse reports
of ABC in the adult population, no difference in IMT was seen in the children
randomised to ABC.
5.16.2 PWV results
Arterial stiffness can be an important determinant of the vascular load to the heart and
has been associated with adverse cardiovascular outcomes. Aorto-femoral pulse wave
velocity (PWV), a measure of arterial elasticity, predicts incident cardiovascular events
in asymptomatic adults [335] and is a gold-standard marker of subclinical
atherosclerosis [343]. To date little has been published on PWV in vertically HIV-
infected children.
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I have demonstrated that perinatally HIV-infected ART naïve children have increased
arterial stiffness, assessed by measuring PWV, compared to age matched controls,
which improves after 2 years of ART. Conversely older children who have been on ART
for a median of 3.9 years have similar PWV to healthy HIV uninfected controls but an
increase in PWV is seen in the HIV infected children over 2 years follow up; an increase
that is not fully explained in terms of increasing age and has been reported in another
HIV infected paediatric cohort [242].
In the ART naïve group I found that triglycerides were positively associated with
baseline PWV. CD4 percentage and, surprisingly, systolic blood pressure were
inversely related with PWV. The later, an inverse relationship between systolic blood
pressure and PWV was also seen in the ART naïve children in the original bivariable
model (co-efficient -0.012, 95% CI (-0.020, -0.004) p=0.01) suggesting this correlation
is real rather than an effect of overcorrecting. In the ART experienced group diastolic
blood pressure was positively associated with baseline PWV (co-efficient 0.025, 95% CI
(0.011, 0.039) p<0.001).
Charakida et al [242] did not find a difference in PWV between ART naïve and control
children, whilst children on ART had a higher PWV than ART naïve despite no
significant difference in age, (median age 11 years). There may be some unaccounted
for bias as the children with the more severe disease would be treated first and hence
had have longer exposure to ART, on multivariate analysis HIV disease severity was an
independent predictor of PWV. No significant effect of PI use on PWV was seen in this
study.
The importance of early ART is highlighted in a study of South African HIV infected
children who were recruited into the CHER study. Innes et al. studied 59 children aged
7 years whom had commenced lopinavir/ritonavir based ART before 3 months of age.
91% had an undetectable VL. Compared to age matched controls there was no
difference in PWV (4.8m/sec versus 4.9m/sec p=0.20) after adjustment for age, gender
and systolic blood pressure (which was not significantly different between HIV infected
children and controls). This was despite significantly elevated lipids in the HIV infected
group and prolonged (median 7.1 years) PI based ART [246]. Conversely in a cross
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sectional study of 230 HIV infected children aged 6 – 18 years living in Ethiopia, a
higher PWV was noted in children on a PI containing regimen [238]. Reassuring I found
no difference in change in PWV over 96 weeks between children randomised to d4T,
ZDV or ABC.
A further study in HIV infected adolescents has measured PWV in 101 older HIV
infected youths (median (IQR) age 19 (14, 23) years) although the majority of this
cohort were not vertically infected. Compared to age, sex and race matched controls
there was no difference in PWV between HIV infected youths and controls. In the HIV
infected group PWV was only associated on multivariate analysis with current alcohol
use, although the duration of HIV infection in this study was short (median 8 years). In
the control group PWV was positively associated with systolic and diastolic blood
pressure, age, BMI, current smoking, marijuana and alcohol use of which age and BMI
remained significant on multivariable analysis [247].
An association of higher weight, height and BMI, in HIV uninfected children correlated
with an increased IMT has been previously made [240, 249, 344]. Increased body fat
accumulation has also been associated with reduced flow mediated dilation [345].
5.16.3 Limitations of the study
One criticism of my study may be the choice of measuring the IMT only in the common
carotid artery. Whilst no consensus exists over the gold standard technical protocol for
IMT measurement, it can be argued that there are several advantages of taking
measurements from the ICA, in that changes may appear here first or be more
pronounced [260, 346]. In the only other longitudinal paediatric / adolescent study,
significant changes in both the CCA and ICA were observed [249]. From a pragmatic
view the training required to reach technical competence for measuring IMT within the
ICA would have been far greater and actually getting accurate and reproducible results
on children of such a young age whose carotid bulb is higher compared to adults would
have been very challenging.
A further limitation is the lack of longitudinal measurements in the HIV-uninfected
children. Indeed the natural progression of IMT in healthy young children has not been
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studied and whilst improvements in IMT following interventions such as increasing
exercise or improved diets have been reported [347-349] it may be that natural changes
in IMT are more dynamic than previously thought. In the longitudinal study performed
by Ross et al [248] a decrease in the IMT (measured in the ICA) was seen over 48
weeks in the control group despite no interventions, suggesting there may be normal
fluctuations in cIMT among this age group (median age 10 years). The lack of normal
ranges in this age range and in African children makes prediction of “normality” difficult.
Future work needs to focus on the natural progression of IMT and PWV in HIV
uninfected African children. Secondly the natural progression of IMT and PWV changes
in HIV infected, ART naïve children who are not started on ART is not known. Given
that since 2013 WHO has recommended that all children under 5 years should be on
ART as soon as a diagnosis is made it is unlikely that the longitudinal effects of
untreated paediatric HIV on the cardiovascular system will ever be able to be
determined.
Being overweight causes adverse changes in the metabolic profile, insulin resistance
and full metabolic syndrome can develop: increased IMT and PWV are well described
in such patients. In our cohort the other end of the spectrum – malnutrition – was
common and to date the limited literature that exists suggests adult survivors of
malnutrition have lower PWV and IMT compared to adults who have not suffered from
malnutrition [350]. Equally low birth weight and rapid weight gain in early childhood has
been proposed to increase the risk of later cardiovascular disease. Unfortunately
although we tried to collect data about gestational age at delivery and birth weight this
information was generally not available in either the HIV infected children or uninfected
controls. In a study of 19 year olds who had been born prematurely, IMT was unrelated
to gestational age, birth weight standard deviation score and early postnatal weight gain
but was positively associated with late infancy weight gain, although the relationship
disappeared after correction for current height [351].
Contradictory results to the CHAPAS-3 from previous studies may reflect the smaller
sample size in many of these other studies, study design (heterogeneous ART
exposure), limited follow up and lack of comparability of controls. By limiting
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confounders, for example smoking or obesity, it has been possible to demonstrate the
impact of HIV disease and ART treatment. The CHAPAS 3 data supports a role for HIV
infection per se rather than for HIV related factors or ART as suggested by other
studies [241, 249]. One theory postulated is that chronic HIV infection leads to vascular
endothelial damage, ongoing low level sustained inflammation leading to an increase in
vessel wall thickness [352]. The CHAPAS-3 findings suggest that uncontrolled HIV
infection plays a major role in the pathogenesis of the cardiovascular changes. In
chapter 6 this will be explored in more detail.
The CHAPAS 3 study has several advantages. It is the first to study a significant
proportion of very young children. Secondly the control group was carefully matched for
age, sex and ethnicity. However of the control children a proportion were uninfected
ART exposed children (absolute number not collected) and the influence of in utero
ART exposure to cardiovascular parameters remains to be fully determined.
5.17 Conclusions
From a very young age detrimental changes in markers of cardiovascular structure and
arterial stiffness are seen in untreated HIV infected children living in Zambia and
Uganda. Using ART to suppress viral replication and inflammation, while improving
immune function appears to be protective and can reverse some of the detrimental
atherogenic structural and functional changes. No differential effects of three different
NRTI backbones were demonstrated on the effect on the cardiovascular system. With
long term survival expected for vertically infected infants and children this evidence
adds to the known benefits of ART. Longitudinal monitoring of cardiovascular structure
and arterial stiffness needs to be undertaken, especially looking at the effects of newer
ART regimens on cardiovascular structure and arterial stiffness.
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Chapter 6 Results: The impact of ART on markers of
inflammation, vascular dysfunction and disordered
thrombogenesis
6.1 Introduction
Adverse cardiovascular outcomes in HIV infection and potential underlying mechanisms
have been described in chapter 2. In summary, despite extensive investigation, the
pathophysiology underlying the changes in vascular function associated with HIV
infections have yet to be fully elucidated. Important factors include, increased
inflammation, classical cardiovascular risk factors (although in children the traditional
risk factors are unlikely to be operating by themselves, if at all), disordered vascular
repair mechanisms and ART-related metabolic toxicities. Inflammation may be key, as
evidenced by increased levels of pro-inflammatory cytokines such as IL-6 and CRP,
even when virological suppression is achieved and maintained [80]. For this study 19
biomarkers were selected that have been associated with vascular diseases. These
were measured in the CHPAS 3 cohort and then analysed in the context of a range of
parameters that could be important in HIV and vascular pathogenesis. The majority of
available evidence is derived from adult studies. Paediatric data is sparse and
contradictory. Table 6-1 summarises the key actions of each of the 19 biomarkers, the
effects of HIV on the biomarkers and known associations with cardiovascular disease in
adults.
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Number
recruited
Setting % patients on
ART
Parameters
measured
Findings Ref
83 HIV +
59 HIV –
Aged 5.4 –
17.7 years
UK. 33% ART
naïve
67% on ART
(31/56 PI
25/56 non PI)
cIMT, FMD, BP,
anthropometry,
total cholesterol,
HDL, apoB, LPa,
LDL, hsCRP
Lipid abnormality not
associated with IMT /
FMD. Increased hsCRP
in HIV +
[241]
64 HIV +
30 HIV –
mean age
14.1 years
Spain All on ART,
83% with VL
<50
copies/mL
IMT, IL-6, CRP.
MPO. tPA,
sVCAM-1, P-
selectin, sCD14,
lipid profile
HIV + higher sCD14,
sVCAM. No relationship
between biomarkers
and VL.
No effect HIV status for
CRP, IL-6, MPO, MCP-
1, P-selectin and tPA.
No correlation between
biomarkers and IMT.
[244]
77 HIV +
32 HV –
13%
horizontally
infected
Median age
16.2 years
Spain 70% with
undetectable
VL
30% with VL
> 50
hsCRP, D-dimer,
β2-microglobulin, 
HLA-DR+CD38+,
LPS, microbial
16srDNA, sCD14
HIV+ higher CRP, d-
dimer, β2microglobulin; 
no ART class effect.
HLA DR+CD38+ cells
increased in viraemic
children. Higher levels
of LPS, 16s RNA and
sCD14 independent of
viraemia.
[439]
31 HIV+
stable on
ART for >6
months
31 HIV -
USA 84% VL < 400
copies/ml
16/31on PI
based ART
cIMT,
homocysteine,
hsCRP,
myeloperoxidase,
lipids
HIV+ higher cholesterol,
triglycerides, MPO and
lower homocysteine
levels. BMI significant
predictor of IMT in HIV-,
duration of ART
predictive of IMT in
HIV+
[249]
106 HIV+,
mean age
14.8 years,
5%
horizontally
infected
55 HIV -,
mean age
12.3 years
USA 86% on ART CRP, IL-6, MCP-1,
fibrinogen, P-
selectin, sICAM<
sVCAM, E-
selectin, leptin,
anthropometry
HIV+; higher sICAM,
sVCAM, MCP-1, IL-6,
fibrinogen. Higher IL-6,
MCP-1, CRP and
sICAM correlated with
higher waist:hip,
sVCAM, MCP-1, IL-6,
fibrinogen and CRP
inversely related to
CD4%.
[440]
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Table 6-1. Markers of inflammation and vascular injury tested in this study
Actions Effect of HIV infection
Association with
cardiovascular
disease
Markers of inflammation
IL-6
Pro and anti-
inflammatory actions
Secreted early in the
inflammatory pathway,
stimulates acute phase
protein synthesis,
neutrophil production,
supports B cell
development
Antagonistic actions
against regulatory T
cells,
inhibits TNFa / IL-1
activates IL-1Ra / IL-10
Higher levels in HIV+
adults that do not
normalise with ART / viral
load suppression [78, 80,
353-355]
Higher levels related to
increased risk of
opportunistic infections
[356], disease
progression [357] non-
AIDS defining events
[316] and all-cause
mortality [78, 358, 359].
Higher levels in obese
HIV+ adults [360]
Conflicting impact of ART
e.g. current ABC use; no
effect on IL-6 [176] or
higher IL-6 levels [151]
HIV+:
Higher levels
associated with CVD
[3] conversely in a
cohort study no
significant difference
between cases and
controls [361]
HIV-:
Higher levels
associated with CVD,
endothelial
dysfunction [362],
increased risk of
coronary events [363,
364] and subclinical
atherosclerotic lesions
independent of
traditional risk factors
[365-367]
IL-8
Produced by
macrophages and
epithelial cells
A potent chemotactic
factor for granulocytes
and T cells to
phagocytose antigens
which trigger toll-like
receptors.
Higher levels in HIV+
adults unrelated to
disease activity, co-
infections or other
medications [368]. A small
study failed to
demonstrate an impact of
HIV status on IL-8 levels,
however levels were
higher with active TB co-
infection [369].
Limited in vitro
evidence suggestive a
link between higher
levels and increased
CVD risk but minimal
in vivo evidence [370]
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Actions Effect of HIV infection
Association with
cardiovascular
disease
IL-10
Anti-inflammatory and
anti-atherosclerotic
cytokine
produced by monocytes
and lymphocytes
Inhibits synthesis of pro-
inflammatory cytokines
including TNFα and 
suppresses the antigen
presentation capacity of
antigen presenting cells
Enhances B cell
survival, proliferation,
and antibody production
Conflicting results;
Higher levels in HIV+,
increase with disease
progression and fall with
ART but not to normal
levels [371]. Levels
correlate with viral load
[372] and inversely
correlate to CD4 [373]
Conversely a small study
showed that levels
increase after starting
ART and fall following
treatment interruption
[374]
No relation
demonstrated with CV
events [361], lower
levels associated with
increased
cardiovascular risk
[375] and thickened
IMT [376]
TNFα 
Produced by activated
macrophages, lymphoid
cells, endothelial cells,
cardiac myocytes and
adipose tissue.
Stimulates the acute
phase reaction,
promotes expression of
adhesion molecules on
endothelial cells and
inhibits viral replication.
A potent chemo-
attractant for
neutrophils, stimulates
macrophage
phagocytosis and
production of IL-1.
Alters intracellular
calcium homeostasis
and induces nitric oxide
synthesis which can
injure myocardial cells
Higher levels early in HIV
infection and correlate
with viral load [372],
disease progression
[377], being overweight
[10], poor prognosis [378]
and ART failure [379].
Levels remain elevated
despite effective ART
[354, 379-382] - not fully
understood but reduction
with effective ART
reported in a small study
[383]
HIV+: adults on ART
higher levels related
to increased coronary
arterial calcification
[384]
HIV-: Higher levels in
patients with abnormal
ECG or symptomatic
heart disease [364].
IL-1Ra
Inhibits the pro-
inflammatory actions of
IL-1, IL-1α and IL-1β, 
secreted by epithelial
cells and adipocytes
Significantly elevated in
HIV+ unaffected by
disease stage or CD4 cell
count [385] or inversely
related to CD4 count [373]
Early release at sites
of ruptured plaque,
elevated following
myocardial infarction
[386]
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Actions Effect of HIV infection
Association with
cardiovascular
disease
CRP
A pro-inflammatory
acute-phase reactant
stimulated by IL-6
Produced mainly by the
liver and within
atherosclerotic plaques
by activated vascular
cells
Induces adhesion
molecule expression in
human endothelial cells,
may play a direct role in
promoting the
inflammatory component
of atherosclerosis [387]
Higher levels associated
with increased BMI [360],
dyslipidaemia [388], male
sex, opportunistic
infections [356],
cardiovascular disease
[389] and all-cause
mortality [78, 390-393].
No association with ART,
viral load or CD4 count
[80, 394].
Conflicting effect of ART -
ABC use no difference
[176] or raised levels
seen[151]
Persistently elevated CRP
with suppressed VL
associated with clinical
failure [395]
HIV+ adults higher
levels associated with
increased risk of
coronary events [363,
396-398], adverse
IMT changes [84, 354,
366], measuring CRP
helps identify those at
high risk of CVD [399]
HIV- adults elevated
levels an independent
factor associated with
CVD [400-402].
ICAM-3
(CD50)
A transmembrane
glycoprotein that binds a
leukocyte adhesion
protein (LFA-1), an
important step in the
initiation of the immune
response.
No associations found No associations found
Serum
amyloid
A
An acute phase protein
produced by
hepatocytes and
adipocytes, that assists
cell recruitment to the
sites of inflammation
and induces enzymes
that degrade the
extracellular matrix.
A non-significant increase
in HIV-infected patients
who have died [78]
Increased in HIV+
patients whom had a
cardiovascular event
compared to HIV
infected patients with
no history of a
cardiovascular event
[361]
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Actions Effect of HIV infection
Association with
cardiovascular
disease
Markers of vascular injury
E-selectin
(CD62E)
A cell adhesion
molecule expressed by
activated endothelial
cells which has a pro-
inflammatory role and
involved in the
pathogenesis of
atherosclerosis [403]
Conflicting results - levels
higher in HIV+ adults and
correlate with disease
progression, levels
increased in seronegative
controls with bacterial and
protozoal infections [404].
No difference from
controls [82]
Higher levels seen in
patients with CHD and
independently predict
risk of CHD [405]
P-selectin
Cell adhesion molecule
stored in endothelial
cells and platelet
granules that promotes
leucocyte adherence
to the endothelium
A marker of platelet
activation
Levels fall following
initiation of ART [374]
although another study
suggested elevated levels
on ART related to
dyslipidaemia [406, 407].
Elevated levels
proposed as a strong
correlate of
platelet/endothelial
abnormalities in
patients with major
atherosclerotic risk
factors [408]
sVCAM1
(CD106)
Adhesion molecule
released in endothelial
dysfunction and
activation
Stimulated by TNFα 
and IL-1
Has a role in
inflammatory
component of
atherosclerosis [403]
Higher levels in HIV+
[409]; not associated with
disease stage [354, 410]
nor related to CD4 or
CRP [82], higher levels if
have lipodystrophy [411]
Levels fall with starting
ART and increase
following treatment
interruption [374, 412,
413].
HIV+ levels increased
up to 2 years before a
cardiovascular event
[361]
In HIV- population no
association with higher
levels and future risk
of MI [405, 414]
.
ICAM-1
(CD54)
An endothelial and
leukocyte-associated
transmembrane protein
stimulated by IL-1 and
TNFα.  
Important in stabilizing
cell-cell interactions,
facilitating leukocyte
endothelial
transmigration and in
the inflammatory
component of
atherosclerosis [403]
Higher in HIV+ [415, 416],
in patients with advanced
disease and proportional
to CD4 count [410], not
related to CRP levels [82].
Levels increase following
treatment interruption
[412]
Higher levels in ART
naïve which normalized
with treatment but not to
normal levels[417], levels
related to serum lipid
levels [406].
In HIV+ levels are not
related to CV
events[361]
In HIV- higher levels
associated with
presence of
atherosclerotic
plaques [365] and
independently predict
risk of CHD
independent of other
known risk factors
[405]
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Actions Effect of HIV infection
Association with
cardiovascular
disease
MCP-1
Pro-inflammatory
Recruits monocytes,
memory T cells, and
dendritic cells to sites of
tissue injury, infection
and inflammation.
Implicated in the
pathogenesis of
atherosclerosis
Higher levels seen in HIV
infection [418], TB co-
infection [369] and
treatment interruption
[413, 419].
Levels related to degree
of lipodystrophy [420] and
inversely related to CD4
[373].
Higher CSF levels
correlate with HIV
associated dementia
[421].
In HIV+, higher levels
seen with increased
IMT [420, 422], pre-
atherosclerotic
changes [418] and
increased coronary
calcification [384]
HIV-: higher levels
correlate with
subclinical
atherosclerosis [423],
significant associations
with age, smoking
status, and serum
triglyceride
concentrations [423]
VEGF
A signal protein that
stimulates
vasculogenesis and
angiogenesis
Serum levels increased in
HIV-associated
neurological disease
[424], higher levels with
higher CD4 counts,
implicated in
pathogenesis of Kaposi’s
sarcoma [425]
Unclear
Angio-
poietin
A protein growth factor
that promotes
angiogenesis,
Implicated in
pathogenesis of Kaposi’s
sarcoma [426]. An
increase in the ANG-
2:ANG-1 ratio is observed
during acute HIV infection
and ANG-1 falls with
chronic HIV infection [427]
Disequilibrium of ratio
described in cardiac
failure [428]
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Actions Effect of HIV infection
Association with
cardiovascular
disease
Markers of disordered thrombogenesis
Tissue
factor
(CD142)
A glycoprotein
expressed on vascular
smooth muscle cells
and on atherosclerotic
plaques
Primary initiator of the
extrinsic coagulation
pathway leading to
conversion of
prothrombin to
thrombin and fibrin clot
formation.
.
Involved in non-
haemoastatic
processes e.g.
inflammation,
angiogenesis, tumour
growth and metastasis.
Increased expression on
monocytes correlated,
levels correlated with VL
and indices of immune
activation, [429]
Elevated levels seen in
HIV- patients with
cardiovascular risk
factors such as
hypertension,
diabetes, dyslipidemia,
and smoking as well
as in those with acute
coronary syndromes
[430]
d-dimer
Fibrin degradation
products, a specific
marker of fibrin clot
formation and
fibrinolysis
Higher levels with higher
VL [80, 415], advancing
age [357, 381], severe
immunosuppression,
inflammatory disease or
malignancy [431].
Higher levels related to
all-cause mortality [78,
316] but only modestly
affects risk reclassification
[88]
Higher levels in ART
naïve, normalized with
treatment but not to
normal levels [374, 417,
432],
No effect of ABC [176]
HIV+, higher levels
independently
associated with
increased risk of CVD
[361, 389]
HIV-, higher levels are
associated with an
increased risk of MI
but this is not an
independent risk [433]
thrombo-
modulin
(CD141)
An integral membrane
protein expressed on
endothelial cells which
functions as a cofactor
in the thrombin-
induced activation of
protein C in the
anticoagulant pathway
Elevated in HIV+ ART
naive, non-significant
reduction with ART,
significant increase in
levels significantly higher
if have peripheral
lipoatrophy [411]
Preliminary results
suggest that
thrombomodulin
dysfunction may be
implicated in the
pathogenesis of
myocardial infarction
[434]
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6.2 Methods
An extensive panel of 19 biomarkers, reflecting markers of inflammation, disordered
thrombogenesis and vascular injury and repair was performed on all samples (HIV
infected and controls) at baseline and in the HIV infected children at weeks 48 and 96.
Methods of the techniques used are described in chapter 3.
6.2.1 Analysis
As expected, the absolute biomarker concentrations were highly skewed. Whilst I can
compare the different groups using non-parametric rank-sum tests, these have lower
power than parametric tests (like the t-test). Further, I wish to investigate the effects of
different baseline factors on the biomarkers which require a regression model. To use a
standard normal linear regression, the outcome (dependent) variable needs to be
approximately normally distributed. I used a “boxcox” regression to estimate the best
power transformation to obtain approximate normality. This suggested that a log
transformation was the closest simple power transformation for a regression model: I
used log10 since this is what is commonly used for HIV viral load. 16/19 biomarkers
were truncated at the 99th percentiles, and IL-6, IL-8 and TNFa were truncated at the
95th percentile, to avoid outliers having undue influence on results. A small number of
results below the limits of detection were set to the lower limit of detection of each
assay (8/4 tissue factor from (control) groups 3/4 respectively, and 8/15/5/10 d-dimer
from groups 1/2/3/4 respectively). Where VL was <100 copies/ml, a value of 100
copies/ml was used for analysis; effectively therefore this factor measures the impact of
log10 increases above detectable with undetectable as the reference category. Z
scores for weight/height/BMI for age were obtained from UK 1990 cohort data [435],
WHO z-scores were not used as these do not cover the age range of CHAPAS-3
children for weight. Z scores for CD4 were obtained from [436].
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6.3 Results
Reproducibility of the Assays
Between 43 and 57 (20%-28%) of baseline samples were run in duplicate to ensure
reproducibility between plates. Where samples were run twice the results from the first
run were used for the analysis. Results from the second run were used for the purpose
of validation only.
Bland Altman plots were constructed for each biomarker and the mean difference,
confidence intervals, limits of agreement and difference in variance calculated for each
marker, Table 6-2, Figure 6-1. For nine of the nineteen biomarkers (P-selectin, ICAM-3,
thrombomodulin, Ang-2, IL-1Ra, IL-10, IL-6, MCP-1 and VEGF) the mean difference
between duplicates was significantly different from zero (Bland Altman plots shown
below Table 6.1). However the mean differences were relatively small, compared to the
spread of the data, with limits of agreement within +/- 0.4 except for IL-10 and IL-8
which were within +/- 0.45, and IL-6, CRP and VEGF which were within +/- 0.6. Further
there was no evidence of systematically poorer agreement at low or high values,
suggesting that the values have more random variation in observed values across the
data range. Therefore using one measurement per sample would increase the random
error, and reduce my ability to detect genuine associations, but should not to lead to
bias. I was not able to run all assays in duplicate due to funding constraints.
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Table 6-2. Summary of results from biomarker validation study.
Mean difference (log10) and 95% confidence intervals given
Biomarker
Number
tested
Mean
difference
E-selectin 57 0.00 -0.05 0.04 -0.34 0.34
P-selectin 57 0.04 0.01 0.07 -0.18 0.26
ICAM-3 43 -0.05 -0.09 -0.01 -0.28 0.18
Thromb 57 0.04 0.02 0.06 -0.13 0.22
Ang-1 57 -0.01 -0.03 0.01 -0.15 0.13
Ang-2 43 -0.11 -0.15 -0.07 -0.37 0.16
DD 43 0.01 -0.03 0.05 -0.20 0.22
TF 43 0.03 -0.02 0.09 -0.20 0.26
IL1-RA 43 0.03 0.01 0.05 -0.09 0.15
IL-10 57 -0.09 -0.14 -0.05 -0.44 0.25
IL-6 43 -0.14 -0.20 -0.07 -0.53 0.26
IL-8 57 -0.03 -0.08 0.02 -0.44 0.38
MCP-1 43 -0.03 -0.05 -0.01 -0.14 0.08
TNFa 57 -0.02 0.00 0.04 -0.15 0.19
CRP 57 0.01 -0.08 0.10 -0.61 0.63
SAA 43 -0.02 -0.07 0.04 -0.35 0.32
SICAM1 57 0.00 -0.06 0.05 -0.39 0.38
VCAM-1 57 -0.02 -0.07 0.03 -0.36 0.31
VEGF 57 -0.12 -0.19 -0.05 -0.63 0.40
IL-1Ra, interleukin-1 receptor antagonist; CRP, C reactive protein; TNFa, tumour necrosis factor A; IL-10,
interleukin-10; IL-6, interleukin-6; IL-8, interleukin-8; ICAM-3, intracellular adhesion molecule-3; SAA, soluble
amyloid A; MCP, Monocyte chemoattractant protein-1; Angio 1, angiopoietin-1; Angio 2, angiopoietin-2, Ang
2: Ang 1, ratio of angiopoietin 2:1; sICAM, soluble intracellular adhesion molecule; VCAM, soluble vascular cell
adhesion molecule-1; VEGF, vascular endothelial growth factor; TF, tissue factor; TM, thrombomodulin.
95% CI Limits of agreement
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Figure 6-1. Results of the biomarker validation study.
Scatter plots to show correlation and limits of agreement for nine of the
nineteen biomarkers.
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6.3.1 Missing samples
As summarised in Table 6-3, the majority of patients had blood samples available at
each time point. A few patients did not have samples available due either to difficulties
with venesection or mislabeling of samples. All analyses are based on observed data.
Table 6-3. Summary of blood samples available by week.
Group 1 HIV
infected
ART naïve
HIV
uninfected
matched to
group 1
Group 2 HIV
infected
ART
experienced
HIV
uninfected
matched to
group 2
Total 208 209 74 75
Samples available 205 202 73 73
Missing (%) 3 (1) 7 (3) 1 (1) 2 (3)
Total 185 74
Samples available 185 73
Missing 0 1 (1)
Total 178 74
Samples available 174 74
Missing 4 (2)
Total 31 21
Week 144 Samples available 31 21
Missing 0 0
Week 0
Week 48
Week 96
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6.4 Baseline biomarker results
Baseline results are summarised in Table 6-4. In summary:
Inflammatory markers (IL-1Ra, CRP, TNFa, IL-10, IL-6, IL-8, ICAM-3, SAA)
IL-1Ra and IL-10 have anti-inflammatory actions; levels of both were significantly higher
in the ART naïve children compared to their controls and compared to ART experienced
children (p<0.001). IL-1Ra levels in ART experienced children and their controls did not
differ significantly (p=0.49) whilst IL-10 levels were significantly higher in ART
experienced children compared to their controls (p<0.001)
201
Figure 6-2. Baseline differences between Il-1Ra between ART naïve (group 1) and
controls and ART experienced (group 2) and controls. Median and IQR given.
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6 pro-inflammatory markers (CRP, TNFa, IL-6, IL-8, ICAM-3, SAA) were measured.
Comparing ART naïve children to controls all 6 pro-inflammatory markers were
significantly higher in the ART naïve children (p<0.001). All 6 biomarkers were also
significantly higher in ART naïve children compared to the ART experienced group
(p≤0.008). Comparing ART experienced children to their control group CRP, IL-6, IL-8 
and ICAM-3 levels were higher in the ART experienced group (p≤0.04). TNFa levels 
were significantly higher in the control group compared to the ART experienced group
(p=0.02) (although absolute differences were relatively small) whilst SAA levels were
comparable between ART experienced and their controls (p=0.61), Figure 6-3.
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Figure 6-3. Examples of the baseline differences between 3 pro- inflammatory
biomarkers.
A) TNFa levels were significantly higher in ART naïve children compared to their
controls and compared to ART experienced children. However levels in ART experienced
children were significantly lower than their controls.
B) CRP levels were significantly higher in ART naïve children compared to controls and
ART experienced children. ART experienced children also had significantly higher leve ls then
their controls
C) Serum amyloid A levels were significantly higher in ART naïve compared to controls
and ART experienced children, however levels in ART experienced and their controls were
similar.
204
Markers of cardiovascular injury and repair (MCP-1, Ang-1, Ang-2, E-selectin, P-
selectin, sICAM-1, VCAM, VEGF)
Comparing ART naïve children to controls, with the exception of Ang-2, all markers of
cardiovascular injury were higher in ART naïve children (p≤0.03). Ang-2 levels were 
significantly higher in the control group compared to the ART naïve group (p<0.001).
Comparing ART naïve to ART experienced children 7 of the 8 cardiovascular markers
were higher in ART naïve children; Ang-1 levels were comparable between these
groups. Comparing ART experienced children to controls, 5 of the 8 markers of
cardiovascular injury were higher in ART experienced children. Levels of Ang-2 and E-
selectin were higher in controls compared to the ART experienced children (p≤0.002) 
whilst sICAM-1 levels were similar between ART experienced and control children.
Examples are given Figure 6-4.
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Figure 6-4. Examples of the baseline differences between 3 markers of cardiovascular
injury and repair.
A) MCP-1 levels were significantly higher in ART naïve children compared to their controls
and compared to ART experienced children. ART experienced children also had significantly
higher levels than their controls.
B) E-selectin levels were significantly higher in ART naïve children compared to controls
and ART experienced children. ART experienced children had significantly lower levels then their
controls
C) Soluble ICAM-1 levels were significantly higher in ART naïve compared to controls and
ART experienced children, however levels in ART experienced and HIV uninfected children were
similar.
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As a consequence of higher Ang-1 and lower Ang-2, the Ang2:Ang-1 ratio was
significantly lower in ART naïve children compared to controls and in ART experienced
children compared to controls. The ratio was higher in ART naïve children compared to
ART experienced children - Figure 6-5.
Figure 6-5. Baseline differences in Ang-1, Ang-2 and Angiopoietin 2:1 ratio
between ART naïve, ART experienced and controls.
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Markers of disordered thrombogenesis (d-dimer, TF, TM):
Comparing ART naïve children to controls, D-dimer levels were significantly higher in
the ART naïve group (p<0.001) whilst thrombomodulin (TM) and tissue factor (TF)
levels were more similar, although there was a trend to marginally lower
thrombomodulin in controls (p=0.08). Comparing ART naïve to ART experienced D-
dimer and TM levels were higher in the ART naïve group (p<0.001), conversely TF
levels were higher in the ART experienced group (p=0.003). Levels of D-dimer and TF
were higher in the ART experienced group compared to controls (p<0.001). Levels of
TM were higher in controls compared to the ART experienced children (p<0.001),
Figure 6-6.
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Figure 6-6. Examples of the baseline differences between the 3 markers of
disordered thrombogenesis.
A) D-dimer levels were significantly higher in ART naïve children compared to their
controls and compared to ART experienced children. Levels in ART experienced children
were also significantly higher than their controls.
B) Tissue factor levels were comparable between ART naïve children and their controls.
Levels in ART experienced children were significantly higher levels than their controls and
ART naïve children
C) Thrombomodulin levels were significantly higher in ART naïve compared to ART
experienced children but there was only a marginal trend towards a difference between ART
naïve children and their controls (p=0.08). ART experienced children had higher levels than
their controls.
209
Table 6-4. Summary of baseline biomarker results by group.
No Median No Median
IL-1Ra 205 586 357 1150 202 381 283 604 p < 0.001
CRP 205 8675 2823 34410 202 1623 533 6461 p < 0.001
TNFa 205 9.6 7.1 13.0 202 5.6 4.2 7.1 p < 0.001
IL-10 205 7.8 4.7 18.0 202 1.8 1.3 2.8 p < 0.001
IL-6 205 11.9 7.0 20.8 202 0.9 0.6 1.6 p < 0.001
IL-8 205 12.1 5.7 27.3 202 4.3 2.3 7.0 p < 0.001
ICAM-3 204 11.9 8.6 16.1 199 1.4 1.1 1.6 p < 0.001
SAA 205 5583 1592 27357 202 3110 966 12529 p < 0.001
MCP 205 203 155 267 202 85 66 105 p < 0.001
Angio 1 197 10579 4011 17581 187 7066 2881 14580 p = 0.03
Angio 2 197 6485 5120 9039 188 8023 6199 10426 p < 0.001
Ang 2:Ang 1 197 0.72 0.39 1.86 187 1.12 0.59 2.92 p = 0.001
E-selectin 204 25.3 16.1 38.2 199 17.6 12.4 27.0 p < 0.001
P-selectin 204 78.4 54.2 114.9 199 51.7 40.1 67.4 p < 0.001
sICAM 205 1612 1113 2602 202 966 695 1839 p < 0.001
VCAM 205 2549 1820 4009 202 1056 710 1751 p < 0.001
VEGF 205 356 158 725 202 66 36 118 p < 0.001
D-dimer 204 101 37 247 200 5.9 5.9 61.7 p < 0.001
TF 203 41.1 33.6 49.7 199 40 29 54 p = 0.34
TM 204 5.0 3.9 6.4 199 4.7 3.8 5.7 p = 0.08
Note: patterns seen in >1 biomarker indicated by shading
* using Mann-Whitney U test; IL-1Ra, interleukin-1 receptor antagonist; CRP, C reactive protein; TNFa, tumour
necrosis factor A; IL-10, interleukin-10; IL-6, interleukin-6; IL-8, interleukin-8; ICAM-3, intracellular adhesion
molecule-3; SAA, solub le amyloid A; MCP, Monocyte chemoattractant protein-1; Angio 1, angiopoietin-1; Angio 2,
angiopoietin-2, Ang 2: Ang 1, ratio of angiopoietin 2:1; sICAM, soluble intracellular adhesion molecule; VCAM,
solub le vascular cell adhesion molecule-1; VEGF, vascular endothelial growth factor; TF, tissue factor; TM,
thrombomodulin.
Significantly higher in ART-naïve vs controls, ART-experienced vs controls and ART-naïve vs experienced
Significantly (or marginally) higher in ART-naïve vs controls and vs ART-experienced; significantly lower in ART-
experienced vs controls
Significantly higher in ART-naïve vs controls and vs ART-experienced; no evidence of difference between ART-
experienced vs controls
Significantly lower in ART-naïve vs controls and in ART-experienced vs controls; significantly higher in ART-naïve
vs experienced
Cardiovascular injury and repair
Disordered thrombogenesis
IQR IQR
Inflammatory
HIV infected ART naïve
(Group 1)
HIV uninfected
matched to group 1
difference
between
group 1
and
controls*
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No Median No Median
IL-1Ra 73 289 178 652 73 328 230 589 p = 0.49 p < 0.001
CRP 73 3791 1283 10781 73 830 333 3283 p < 0.001 p < 0.001
TNFa 73 3.7 3.1 5.1 73 4.5 3.6 5.3 p = 0.02 p < 0.001
IL-10 73 2.7 1.8 7.2 73 1.4 1.0 2.4 p < 0.001 p < 0.001
IL-6 73 6.4 4.6 10.3 73 0.8 0.6 1.5 p < 0.001 p < 0.001
IL-8 73 6.8 3.1 11.6 73 3.4 2.0 8.7 p = 0.04 p < 0.001
ICAM-3 73 4.4 3.4 5.3 73 1.5 1.2 1.8 p < 0.001 p < 0.001
SAA 73 2368 1207 11843 73 2172 933 6856 p = 0.61 P = 0.008
MCP 73 124 110 156 73 71 59 89 p < 0.001 p < 0.001
Angio 1 72 13203 5930 20999 67 4138 1308 8299 p < 0.001 P = 0.14
Angio 2 72 3293 2421 4382 67 5744 4586 7970 p < 0.001 p < 0.001
Ang 2:Ang 1 72 0.27 0.16 0.46 67 1.51 0.67 3.5 p < 0.001 p < 0.001
E-selectin 73 13.7 10.2 21.5 73 20.7 12.9 26.1 p = 0.002 p < 0.001
P-selectin 73 59.0 49.0 82.6 73 45.0 37.3 61.4 p < 0.001 p = 0.001
sICAM 73 1070 728 1863 73 1069 715 1653 p = 0.57 p < 0.001
VCAM 73 1408 954 2516 73 1184 765 1796 p = 0.04 p < 0.001
VEGF 73 216 65 413 73 43 22.7 78.5 p < 0.001 p = 0.001
D-dimer 73 27.7 5.9 196 73 5.9 5.9 53.6 p = 0.01 p < 0.001
TF 73 44.2 38.0 58.6 71 39.8 27.7 46.9 p = 0.001 p = 0.003
TM 73 4.2 3.4 5.2 73 4.5 3.9 5.1 p = 0.02 p < 0.001
* using Mann-Whitney U test; IL-1Ra, interleukin-1 receptor antagonist; CRP, C reactive protein; TNFa, tumour necrosis factor A;
IL-10, interleukin-10; IL-6, interleukin-6; IL-8, interleukin-8; ICAM-3, intracellular adhesion molecule-3; SAA, solub le amyloid A;
MCP, Monocyte chemoattractant protein-1; Angio 1, angiopoietin-1; Angio 2, angiopoietin-2, Ang 2: Ang 1, ratio of angiopoietin
2:1; sICAM, soluble intracellular adhesion molecule; VCAM, solub le vascular cell adhesion molecule-1; VEGF, vascular
endothelial growth factor; TF, tissue factor; TM, thrombomodulin.
Note: patterns seen in >1 biomarker indicated by shading
Significantly higher in ART-naïve vs controls, ART-experienced vs controls and ART-naïve vs experienced
Significantly higher in ART-naïve vs controls and vs ART-experienced; no evidence of difference between ART-experienced vs
controls
Significantly (or marginally) higher in ART-naïve vs controls and vs ART-experienced; significantly lower in ART-experienced vs
controls
Significantly lower in ART-naïve vs controls and in ART-experienced vs controls; significantly higher in ART-naïve vs experienced
Disordered thrombogenesis
Cardiovascular injury and repair
Inflammatory
Difference
between
Group 1 v
Group 2*
IQR IQR
HIV infected ART experienced
(Group 2)
HIV uninfected
matched to group 2
difference
between
group 2
and
controls*
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6.5 Relationship between the different biomarkers.
Associations between different biomarkers, viral load, IMT and PWV were
investigated in each group (ART naïve, ART experienced and HIV uninfected) at
baseline using univariable Spearman correlation co-efficients.
ART naive
As illustrated in Figure 6-7A, baseline IL-10, MCP-1, TNFa, Angiopoeitin-2, E-
selectin, thrombomodulin and viral load were all significantly higher in the younger
children within the ART-naïve group, with TNFa, thrombomodulin and viral load
each having a correlation coefficient r>0.35 (Figure 6-7B). In this group of children,
age is equivalent to duration of untreated HIV infection. The only factor associated
with baseline viral load with r>0.35 was age. All correlations between IMT, PWV and
the biomarkers were r<0.35 in magnitude. However, the other biomarkers
demonstrated groupings that did not completely reflect what might have been
predicted. There were strong positive correlations between:
 CRP, IL-6 and serum amyloid A
 VCAM and soluble ICAM; which were more closely related to CRP and
serum amyloid A than E-selectin and P-selectin, the other markers of
endothelial injury
 VEGF, P-selectin, angiopoietin-1 and IL-8; which were not closely related to
angiopoietin-2
 IL-8 and IL-1Ra; IL-1Ra in particular was the common link between the
CRP/IL-6/ serum amyloid A / sICAM / VCAM cluster above, the IL-8 / VEGF /
angiopoietin-1 / P-selectin cluster above, and a cluster containing slightly
more weakly linked factors including age, HIV viral load, E-selectin, TNFa,
thrombomodulin, IL-10, MCP-1 and angiopoietin-2.
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Figure 6-7. Relationship between biomarkers, viral load, age, IMT and PWV at
baseline in ART naïve HIV-infected children.
In the correlation matrix (A) the strength of positive relationships are demonstrated using
blue scale and negative correlations on the red scale. In the nodal diagram (B) relationships
with a spearman correlation of >0.35 are demonstrated, positive correlations shown in
green and negative correlations in red.
IL1R, interleukin-1 receptor antagonist; CRP, C reactive protein; TNF, tumour necrosis
factor A; IL10, interleukin-10; IL6, interleukin-6; IL8, interleukin-8; ICA, intracellular
adhesion molecule-3; SAA, soluble amyloid A; MCP, Monocyte chemoattractant protein-1;
ANG1, angiopoietin-1; ANG2, angiopoietin-2; SIC, soluble intracellular adhesion molecule;
VCA, soluble vascular cell adhesion molecule-1; VEG, vascular endothelial growth factor;
TF, tissue factor; THR, thrombomodulin; ESE, E-selectin; IBL, baseline viral load; DD, d-
dimer; PSE, P-selectin; IMT, intimal medial thickness; PWV, pulse wave velocity.
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ART experienced
As illustrated in Figure 6-8A, age was much less strongly associated with
biomarkers in HIV-infected, ART experienced children (all correlations <0.35), who
had been on ART for at least two years as well as being older than the ART naïve
children (medium age 2.9 versus 6.9 years). No significant correlations were seen
between IMT and any biomarker, however PWV was higher in children with lower
angiopoietin-2 and ICAM-3 levels. Several groups of biomarkers were significantly
positively correlated with each other, some similarly to patterns observed in naïve
children and others in contrast:
Similarly to naïve children
 Serum amyloid A, sICAM, CRP and VCAM
 TNFa, IL-10 and MCP-1
 IL-8, VEGF and angiopoietin-1
 IL-1Ra was highly associated with IL-8, and was also the common node
linking the three clusters above
In contrast to naïve children
 P-selectin was highly associated with E-selectin (rather than VEGF /
angiopoietin-1 in naïve children); E-selectin was still most associated with
thrombomodulin
 IL-6 was now most strongly associated with IL-10, with little association with,
IL-1Ra, IL-8. P-selectin, E-selectin, tissue factor, thrombomodulin, VEGF or
angiopoietin-1.
 A more complex set of relationships existed between angiopoietin-2 and
other factors including PWV
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Figure 6-8. Relationship between biomarkers, viral load, age, IMT and PWV at
baseline in ART experienced HIV-infected children.
In the correlation matrix (A) the strength of positive relationships are demonstrated
using blue scale and negative correlations on the red scale. In the nodal diagram (B)
relationships with a spearman correlation of >0.35 are demonstrated, positive
correlations shown in green and negative correlations in red.
IL1R, interleukin-1 receptor antagonist; CRP, C reactive protein; TNF, tumour necrosis
factor A; IL10, interleukin-10; IL6, interleukin-6; IL8, interleukin-8; ICA, intracellular
adhesion molecule-3; SAA, soluble amyloid A; MCP, Monocyte chemoattractant
protein-1; ANG1, angiopoietin-1; ANG2, angiopoietin-2; SIC, soluble intracellular
adhesion molecule; VCA, soluble vascular cell adhesion molecule-1; VEG, vascular
endothelial growth factor; TF, tissue factor; THR, thrombomodulin; ESE, E-selectin;
IBL, baseline viral load; DD, d-dimer; PSE, P-selectin; IMT, intimal medial thickness;
PWV, pulse wave velocity.
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HIV uninfected controls
As illustrated in Figure 6-9, older uninfected control children had significantly lower
values of angiopoietin-2 and TNFa. IMT had only a weak positive correlation with
thrombomodulin and PWV a weak positive correlation with P-selectin and E-selectin.
Interestingly, the same sets of biomarkers were significantly positively correlated
with each other as observed in both naïve and experienced HIV-infected children:
 Serum amyloid A, soluble ICAM, CRP and VCAM
 IL-8, VEGF, angiopoeitin-1
 TNFa, IL-10 and MCP-1
 IL-1Ra was also the common node linking the three clusters above
Other strong associations reflected a mixture of those seen in ART-naïve or
experienced children
 IL-6 was strongly associated with CRP, serum amyloid A and IL1-Ra, as
seen in naïve but not experienced children
 E-selectin was strongly associated with P-selectin, as seen in experienced
but not naïve children
In contrast to both groups of HIV-infected children, thrombomodulin was not strongly
associated with any other biomarker in naïve children.
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Figure 6-9. Relationship between biomarkers, viral load, age, IMT and PWV at
baseline in HIV uninfected children.
In the correlation matrix (A) the strength of positive relationships are demonstrated using
blue scale and negative correlations on the red scale. In the nodal diagram (B) relationships
with a spearman correlation of >0.35 are demonstrated, positive correlations shown in
green and negative correlations in red.
IL1R, interleukin-1 receptor antagonist; CRP, C reactive protein; TNF, tumour necrosis
factor A; IL10, interleukin-10; IL6, interleukin-6; IL8, interleukin-8; ICA, intracellular adhesion
molecule-3; SAA, soluble amyloid A; MCP, Monocyte chemoattractant protein-1; ANG1,
angiopoietin-1; ANG2, angiopoietin-2; SIC, soluble intracellular adhesion molecule; VCA,
soluble vascular cell adhesion molecule-1; VEG, vascular endothelial growth factor; TF,
tissue factor; THR, thrombomodulin; ESE, E-selectin; IBL, baseline viral load; DD, d-dimer;
PSE, P-selectin; IMT, intimal medial thickness; PWV, pulse wave velocity.
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6.6 Effect of age in HIV uninfected children
As little data on normal levels of these biomarkers in HIV-uninfected children are
available I investigated correlations in more detail. Looking at the biomarker levels
by age in the HIV uninfected controls, only certain patterns emerged. For 7/8
inflammatory biomarkers a significant negative correlation with increasing age
existed (p all≤0.01). No significant difference by age was seen for serum amyloid A 
levels (p=0.35), Figure 6-10.
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Figure 6-10. Effect of age on inflammatory biomarker level in HIV uninfected
children.
With the exception of serum amyloid A a significant negative correlation with lower values
observed in older children
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A similar pattern was observed for 8/9 markers of cardiovascular injury and repair
with a significant negative correlation with lower values observed in older children
(p≤0.04). No significant difference by age was seen for angiopoietin-1 levels 
(p=0.11), Figure 6-11.
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Figure 6-11. Effect of age on biomarkers of cardiovascular injury and repair in
HIV uninfected children.
With the exception of angiopoeitin-1 all biomarker levels have a significant negative
correlation with increasing age.
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Looking at markers of disordered thrombogenesis, D-dimer and thrombomodulin
levels decreased significantly with increasing age (p<0.001). No significant effect of
age on tissue factor levels was seen (Figure 6-12).
Figure 6-12. Effect of age on biomarkers of disordered thrombogenesis in
HIV uninfected children.
D-dimer and thrombomodulin levels were significantly negatively corerlated with
increasing age. No significant relationship between tissue factor levels and age
were demonstrated.
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6.7 Effect of age on biomarkers in HIV infected v HIV uninfected
children
The above models simply look at pairwise correlations separately in each group of
children. However, just as for IMT and PWV in Chapter 5, I can consider separately
the ART-naïve children and their controls, and the ART-experienced children and
their controls. First, I investigated the associations between age and biomarker
values within each case-control group similarly to Chapter 5. In each case the
biomarker is the dependent variable (outcome), and age and case-control group are
independent variables (exposures). From the analyses above, in naïve children I
would expect to find negative associations between age and TNFa, thrombomodulin
and angiopoetin-2, with potentially different effects in cases vs controls for the latter
two. Additional associations with age may also become evident due to greater
power from combining cases and controls. In the smaller group of ART-experienced
children and controls, I may find no associations due to lower power to detect
effects, or possibly associations previously evident in the larger control group overall
with TNFa and angiopoetin-2.
The results of the multivariate models are presented in Table 6-5. Within the smaller
ART experienced group and their controls no significant effects of age or
interactions dependent upon HIV status were found. In the larger ART-naïve group,
in addition to the expected significant effect of age on TNFa levels, significant
associations between age and levels of IL-1Ra, IL-10, MCP-1, VCAM, VEGF and d-
dimer were demonstrated. Additionally the levels of angiopoietin-2, thrombomodulin,
CRP, IL-6 and E-selectin were significantly associated with age, with differing effects
of age in cases and controls.
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Table 6-5. Results of multivariate analyses using a main effects and
interaction model to screen for the effects of HIV status and age on each of
the baseline biomarkers.
p value for main
effect of age
adjusted for
group
p value for
interaction by
age and HIV
status
p value for main
effect of age
adjusted for
group
p value for
interaction by
age and HIV
status
IL-1Ra 0.01 0.10 0.06 0.65
CRP NA 0.02 0.61 0.51
TNFa <0.001 0.70 0.37 0.14
IL-10 <0.001 0.57 0.46 0.36
IL-6 NA 0.03 0.57 0.97
IL-8 0.70 0.23 0.53 0.72
ICAM-3 0.96 0.42 0.13 0.98
SAA 0.48 0.07 0.73 0.86
MCP-1 <0.001 0.16 0.78 0.71
Angio 1 0.39 0.46 0.23 0.67
Angio 2 NA 0.03 0.38 0.96
Ang 2 : Ang 1 0.23 0.67 0.08 0.43
E-selectin NA 0.02 0.13 0.44
P-selectin 0.10 0.62 0.44 0.34
sICAM 0.42 0.24 0.28 0.31
VCAM 0.04 0.75 0.07 0.14
VEGF 0.002 0.55 0.56 0.37
TM NA 0.02 0.99 0.15
D-DIMER 0.004 0.09 0.17 0.61
TF 0.37 0.34 0.82 0.66
Cardiovascular injury and repair
Disordered thrombogenesis
IL-1Ra, interleukin-1 receptor antagonist; CRP, C reactive protein; TNFa, tumour necrosis factor A; IL-10,
interleukin-10; IL-6, interleukin-6; IL-8, interleukin-8; ICAM-3, intracellular adhesion molecule-3; SAA, soluble
amyloid A; MCP, Monocyte chemoattractant protein-1; Angio 1, angiopoietin-1; Angio 2, angiopoietin-2, Ang 2:
Ang 1, ratio of angiopoietin 2:1; sICAM, solub le intracellular adhesion molecule; VCAM, soluble vascular cell
adhesion molecule-1; VEGF, vascular endothelial growth factor; TF, tissue factor; TM, thrombomodulin.
Expected associations from the univariable analaysis
ART naïve v controls ART experienced v controls
Inflammatory
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Table 6-6 shows the multivariate models for the seven biomarkers which were
associated with age but with no evidence that this age association varied by case-
control status. All biomarkers decreased as age at ART initiation increased (inverse
association), and were independently significantly lower in controls than cases.
Table 6-6. Results of a linear regression without interaction terms to look at effect
of age and HIV status on baseline biomarker results.
Biomarker and factor
Co-
efficient p value
Baseline age (increase per year) -0.019 ( -0.034 : -0.004 ) 0.01
ART naïve v control -0.206 ( -0.278 : -0.135 ) <0.001
Constant 2.914 ( 2.842 : 2.986 ) <0.001
Baseline age (increase per year) -0.029 ( -0.035 : -0.023 ) <0.001
ART naïve v control -0.234 ( -0.264 : -0.204 ) <0.001
Constant 1.082 ( 1.052 : 1.112 ) <0.001
Baseline age (increase per year) -0.047 ( -0.061 : -0.033 ) <0.001
ART naïve v control -0.654 ( -0.723 : -0.586 ) <0.001
Constant 1.136 ( 1.067 : 1.204 ) <0.001
Baseline age (increase per year) -0.014 ( -0.021 : -0.008 ) <0.001
ART naïve v control -0.380 ( -0.412 : -0.346 ) <0.001
Constant 2.357 ( 2.324 : 2.390 ) <0.001
Baseline age (increase per year) -0.011 ( -0.022 : -0.001 ) 0.04
ART naïve v control -0.355 ( -0.407 : -0.304 ) <0.001
Constant 3.459 ( 3.407 : 3.511 ) <0.001
Baseline age (increase per year) -0.026 ( -0.042 : -0.010 ) 0.002
ART naïve v control -0.680 ( -0.758 : -0.603 ) <0.001
Constant 2.602 ( 2.524 : 2.680 ) <0.001
Baseline age (increase per year) -0.040 ( -0.067 : -0.013 ) 0.004
ART naïve v control -0.671 ( -0.802 : -0.539 ) <0.001
Constant 2.094 ( 1.961 : 2.226 ) <0.001
IL-1Ra, interleukin-1 receptor antagonist; TNFa, tumour necrosis factor A; IL-10, interleukin-10; MCP-1,
Monocyte chemoattractant protein-1; VCAM, soluble vascular cell adhesion molecule-1; VEGF, vascular
endothelial growth factor.
IL-1Ra
TNFa
IL-10
MCP-1
VCAM
VEGF
d-dimer
95% CI
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Table 6-7 shows the multivariate models for the five biomarkers which were
associated with age and with evidence that this age association varied by case-
control status. For 3 biomarkers (angiopoietin-2, E-selectin and thrombomodulin)
levels significantly decreased as age at ART initiation increased in HIV infected
patients (p≤0.03). In controls similar significant decreased levels were seen with 
increasing age for IL-6, angiopoietin-2 and thrombomodulin (p≤0.02). 
Table 6-7. Results of a linear regression with interaction terms to look at effect of
age and HIV status on baseline biomarker results
Biomarker and factor
Co-
efficient p value
Increase per year older in HIV infected 0.023 ( -0.015 : 0.068 ) 0.20
Increase per year older in controls -0.044 ( -0.090 : 0.017 ) 0.06
Increase per year older in HIV infected 0.008 ( -0.011 : 0.026 ) 0.41
Increase per year older in controls -0.022 ( -0.043 : -0.002 ) 0.03
Increase per year older in HIV infected -0.018 ( -0.039 : -0.007 ) 0.002
Increase per year older in controls -0.036 ( -0.050 : -0.023 ) <0.001
Increase per year older in HIV infected -0.034 ( -0.047 : -0.020 ) <0.001
Increase per year older in controls -0.009 ( -0.024 : 0.007 ) 0.26
Increase per year older in HIV infected -0.023 ( -0.031 : -0.016 ) <0.001
Increase per year older in controls -0.010 ( -0.019 : -0.002 ) 0.02
Thrombomodulin
CRP, C reactive protein; IL-6, interleukin-6; Angio 2, angiopoietin-2.
95% CI
CRP
IL-6
Angio-2
E-selectin
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6.8 The influence of baseline viral load and age on the biomarkers in
HIV infected, ART naïve children?
To investigate the impact of baseline viral load and age on biomarker levels a
bivariable analysis was performed on children in group 1 (HIV+ ART naïve) only,
since these were the only children within this study with any variation in VL. As
shown in Table 6-8 older children had significantly lower levels of TNFa (p<0.001)
and serum amyloid A (p=0.02) with no significant effect of age on these biomarkers.
A higher baseline viral load was significantly associated with higher baseline levels
of IL-6 (p=0.04), ICAM-3 (p<0.001), MCP-1 (p=0.03) and tissue factor (p=0.04) with
no evidence of an independent effect of age on these biomarkers. In particular, the
significant effects of age on MCP-1 shown in Table 6-6 are therefore due to
confounding between VL and age, with VL being the more important predictor of
these biomarkers. Both age and baseline viral load significantly influenced levels of
IL-10 (p≤0.01), E-selectin (p≤0.02) and thrombomodulin (p≤0.04). 
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co-efficient p value co-efficient p value
IL-1Ra -0.002 ( -0.028 : 0.024 ) 0.88 0.044 ( -0.046 : 0.133 ) 0.34
CRP 0.041 ( -0.002 : 0.084 ) 0.06 0.123 ( -0.027 : 0.272 ) 0.11
TNFa -0.026 ( -0.036 : -0.017 ) <0.001 0.033 ( 0.000 : 0.067 ) 0.05
IL-10 -0.042 ( -0.065 : -0.018 ) 0.001 0.106 ( 0.024 : 0.188 ) 0.01
IL-6 0.014 ( -0.005 : 0.034 ) 0.14 0.070 ( 0.004 : 0.137 ) 0.04
IL-8 0.012 ( -0.016 : 0.040 ) 0.40 0.071 ( -0.027 : 0.169 ) 0.15
ICAM-3 0.003 ( -0.009 : 0.015 ) 0.62 0.082 ( 0.040 : 0.124 ) <0.001
SAA 0.053 ( 0.008 : 0.098 ) 0.02 0.111 ( -0.046 : 0.268 ) 0.16
Cardiovascular injury and repair
MCP-1 -0.006 ( -0.017 : 0.006 ) 0.32 0.043 ( 0.004 : 0.083 ) 0.03
Angio 1 -0.002 ( -0.031 : 0.027 ) 0.89 0.027 ( -0.073 : 0.127 ) 0.59
Angio 2 -0.013 ( -0.027 : 0.000 ) 0.05 0.033 ( -0.014 : 0.079 ) 0.17
Ang 2: Ang 1 -0.097 ( -0.289 : 0.096 ) 0.32 0.066 ( -0.602 : 0.733 ) 0.85
E-selectin -0.027 ( -0.043 : -0.011 ) 0.001 0.064 ( 0.009 : 0.119 ) 0.02
P-Selectin -0.005 ( -0.019 : 0.008 ) 0.43 0.026 ( -0.020 : 0.072 ) 0.26
sICAM 0.000 ( -0.016 : 0.016 ) 0.99 0.015 ( -0.039 : 0.070 ) 0.59
VCAM -0.010 ( -0.026 : 0.006 ) 0.20 0.028 ( -0.026 : 0.083 ) 0.30
VEGF -0.021 ( -0.048 : 0.005 ) 0.11 0.026 ( -0.065 : 0.117 ) 0.58
Disordered thrombogenesis
D-dimer -0.005 ( -0.046 : 0.036 ) 0.81 0.131 ( -0.012 : 0.274 ) 0.07
TF -0.004 ( -0.012 : 0.004 ) 0.30 0.028 ( 0.001 : 0.055 ) 0.04
TM -0.021 ( -0.030 : -0.012 ) <0.001 0.033 ( 0.002 : 0.064 ) 0.04
Inflammatory
IL-1Ra, interleukin-1 receptor antagonist; CRP, C reactive protein; TNFa, tumour necrosis factor A; IL-10, interleukin-10; IL-6,
interleukin-6; IL-8, interleukin-8; ICAM-3, intracellular adhesion molecule-3; SAA, soluble amyloid A; MCP, Monocyte
chemoattractant protein-1; Angio 1, angiopoietin-1; Angio 2, angiopoietin-2, Ang 2: Ang 1, ratio of angiopoietin 2:1; sICAM, soluble
intracellular adhesion molecule; VCAM, solub le vascular cell adhesion molecule-1; VEGF, vascular endothelial growth factor; TF,
tissue factor; TM, thrombomodulin.
95%CI
Age
95%CI
log baseline VL
Table 6-8. Influence of age and baseline viral load on baseline biomarkers in HIV
infected, ART naive children.
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6.9 Is there a relationship between angiopoietin 1/2 and VEGF?
Angiopoietin 1 and 2 and VEGF are involved in remodelling and endothelial cell
migration; an imbalance in the relationships between these three biomarkers
associated with HIV infection may reflect ongoing vascular injury. As illustrated in
Figure 6-13 a significant relationship exists between the ratio of angiopoietin 2:1 and
VEGF levels. Additionally a trend by group also appears with the majority of HIV
infected ART naïve children having higher VEGF and Angiopoietin 2:1 ratios whilst
HIV infected, ART experienced children have generally lower VEGF and
angiopoietin 2:1 ratios.
Figure 6-13. Relationship between the ratio of angiopoietin 2 to 1 with VEGF by
group.
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A significant relationship between VEGF and the angiopoietin ratio was
demonstrated, in that for every 1 log higher VEGF, the angiopoietin ratio was
(-)0.609 log lower (95%CI -0.680 ; -0.538), p<0.001). In an interaction model, there
was no evidence that the relationship between the VEGF and angiopoietin ratio
differed by group (HIV+ART naïve, HIV+ ART experienced or their controls), p≥0.13.  
To determine whether the effect of age confounds the relationship between VEGF
and the angiopoietin ratio, I included age as an independent factor in this model.
First there was no evidence that the impact of age on the log angiopoetin 2:1 ratio
varied according to case control status, but there was strong evidence that, overall,
the log angiopoetin 2:1 ratio was (-)0.029 lower for every year older (95% CI -0.043
to -0.016) p<0.001). In the HIV-infected, ART naive and HIV-infected, ART
experienced groups, the association between age and log angiopoetin 2:1ratio was
similar (heterogeneity p=0.76), with log angiopoetin 2:1 ratio being (-)0.757 and
(-)0.723 lower for every year older, respectively. However, overall log angiopoetin
2:1ratio levels were significantly lower in HIV-infected, ART experienced group, by
(-)0.530 log (p=0.04). In contrast, overall levels were similar in HIV-infected, ART
naive and control groups (p=0.99), but log angiopoetin 2:1 ratio declined more
quickly with older age in control group, by (-)0.944 log for every year older
(heterogeneity p=0.046).
To determine whether the relationship is further modified by the baseline viral load
this was added to the model but was not significant (p=0.87).
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6.10 Longitudinal changes in biomarkers.
The effects over 96 weeks of commencing ART or continuing ART were looked at.
In naïve children 16/19 biomarkers at week 96 were significantly lower than the
baseline levels (p≤0.001). The remaining 3 biomarkers had no significant change 
from baseline. In experienced children 12/19 biomarkers fell significantly over 96
weeks (p≤0.02) whilst 3/19 had significant increases and 4/19 had no significant 
differences over 96 weeks. The changes over 96 weeks in each biomarker are
summarised in Table 6-9 and illustrated in Figures 6-14 to 6-17.
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Group No Median No Median No Median Median
log10
difference p value
1 205 586 357 1150 185 314 247 515 174 262 181 418 -213 -0.32 <0.001
2 73 289 178 652 73 271 184 396 74 209 168 372 -57 -0.12 0.01
1 205 8675 28223 3441 185 5829 1620 23736 174 2919 1120 13053 -2333 -0.31 <0.001
2 73 3791 1283 10781 73 1945 827 11517 74 1162 414 3939 -1097 -0.38 <0.001
1 205 9.6 7.1 13 185 5.7 4.7 7 174 4.4 3.4 5.8 -4.8 -0.32 <0.001
2 73 3.7 3.1 5.1 73 3.8 3 5 74 3.1 2.8 4 -0.6 -0.08 0.01
1 205 7.8 4.7 18 185 2.4 1.5 4.1 174 1.3 0.9 2.5 -5.8 -0.72 <0.001
2 73 2.7 1.8 7.2 73 2.1 1.6 4.1 74 1 0.7 1.5 -1.4 -0.4 <0.001
1 205 11.9 7 20.8 185 1.6 0.8 6.7 174 0.9 0.6 1.5 -9.9 -1.09 <0.001
2 73 6.4 4.6 10.3 73 5.2 2.2 9.7 74 0.7 0.5 1.1 -5.7 -1.02 <0.001
1 205 12.1 5.7 27.3 185 4.6 2.9 9.6 174 4.7 2.6 9.2 -5.6 -0.35 <0.001
2 73 6.8 3.1 11.6 73 5.9 2.5 10.3 74 3.8 2.5 5.9 -1.2 -0.13 0.02
1 204 11.9 8.6 16.1 184 2 1.3 5.3 174 1.1 0.8 1.4 -11 -1.03 <0.001
2 73 4.4 3.4 5.3 73 3.7 2.3 5.2 74 1 0.8 1.2 -3.4 -0.65 <0.001
1 205 5583 1592 27357 185 4225 1418 23962 174 2370 949 8719 -810 -0.19 <0.001
2 73 2368 1207 11843 73 2616 1161 7310 74 1324 529 3631 -618 -0.25 0.01
1 205 202.6 155 267.1 185 95.2 71.4 128.4 174 63.8 52.8 81.3 -123 -0.48 <0.001
2 73 124.2 109.6 155.6 73 114.2 88.1 136.4 74 55 46.5 64.6 -68 -0.35 <0.001
1 197 10579 4011 17581 181 6137 3199 14112 167 8691 3299 1785 371 0.05 0.91
2 72 13203 5930 20999 73 10375 4725 18240 71 9279 4164 14897 -2291 -0.08 0.08
1 197 6485 5120 9039 181 6127 4232 9141 167 6337 4838 9369 461 0.03 0.96
2 72 3293 2421 4382 73 3532 2292 4984 71 5726 4467 7127 2290 0.25 <0.001
1 197 -0.14 -0.41 0.27 181 -0.007 -0.38 0.33 167 -0.08 -0.43 0.3 -0.07 -0.05 0.89
2 72 -0.57 -0.79 -0.33 73 -0.47 -0.66 -0.15 71 -0.14 -0.46 0.18 0.24 0.37 <0.001
1 204 25.3 16.1 38.2 184 18.5 12.8 32.2 174 16.1 11.5 26.3 -8.6 -0.19 <0.001
2 73 13.7 10.2 21.5 73 18.4 12.1 26.5 74 18.3 11.3 28.5 3.3 0.1 0.002
1 204 78 54 115 184 46 35 61 174 55 39 91 -14 -0.13 <0.001
2 73 59.1 49.1 82.6 73 46.4 36 58.2 74 67 51 95 8.3 0.05 0.16
1 205 1613 1113 2603 185 980 680 1298 174 628 504 873 -1011 -0.45 <0.001
2 73 1071 728 1863 73 869 647 1152 74 542 451 659 -511 -0.29 <0.001
1 205 2549 1820 4009 185 1016 726 1542 174 632 490 877 -1901 -0.63 <0.001
2 73 1408 954 2516 73 1038 700 1445 74 498 450 630 -863 -0.46 <0.001
1 205 3564 158 725 185 94 45 169 174 63.3 29 126 -215 -0.67 <0.001
2 73 216 65 413 73 120 44 274 74 45 25 78 -158 -0.6 <0.001
1 204 101 37 247 184 39 6.6 144 174 20 4.4 117 -41 -0.58 <0.001
2 73 28 5.9 196 73 37 5.5 128 74 10.3 6.6 76 -5.7 -0.31 0.09
1 203 41 34 50 184 42 33 53 174 46 37 59 4.9 0.04 0.06
2 73 44 38 59 73 41 35 51 74 44 34 61 -1.6 -0.02 0.16
1 204 5 3.9 6.4 184 3.9 3.1 5 174 4.2 3.2 5.4 -0.5 -0.05 <0.001
2 73 4.2 3.4 5.2 73 3.7 3 4.5 74 4.8 3.8 5.6 0.9 0.09 0.004
Note: patterns seen in >1 biomarker indicated by shading
Significant reduction in week 96 levels compared to baseline
Significant increase in week 96 levels compared to baseline
Change over 96 weeks
IL-6
Week 0 Week 48 Week 96
IQR IQR IQR
TM
Paired t-test on log10 values used to calculate changes over time.
Angio 2
Ang 2:
Ang 1
E-
selectin
P-
Selectin
sICAM
VCAM
VEGF
Disordered thrombogensis
D-dimer
TF
IL-8
ICAM-3
SAA
Cardiovasular injury and repair
MCP-1
Angio 1
Inflammatory
IL-1Ra
CRP
TNFa
IL-10
Table 6-9. Changes in biomarkers over 96 weeks by group.
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Inflammatory markers (IL-1Ra, CRP, TNFa, IL-10, IL-6, IL-8, ICAM-3, SAA)
Significant decreases in the levels of all 8 markers of inflammation were
demonstrated over the 96 weeks in both ART naïve and ART experienced children -
Figure 6-14.
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Figure 6-14. Examples of changes over 96 weeks in 3 of the inflammatory
biomarker panel studied by baseline ART exposure.
Levels seen in HIV uninfected children shown at baseline where they are matched for age
to each infected groups. A) TNFa, B) IL-8, C) IL-6
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Markers of cardiovascular injury and repair (MCP-1, Ang-1, Ang-2, E-selectin,
P-selectin, sICAM-1, VCAM, VEGF)
Significant decreases were seen in the levels of MCP-1, VEGF, sICAM, and VCAM
in both ART naïve and ART experienced children over 96 weeks to levels lower than
those of HIV uninfected controls. E-selectin levels fell significantly in in ART naïve
children and increased significantly in ART experienced children over 96 weeks.
Conversely P-selectin levels fell significantly over 96 weeks in ART naïve children
whilst no significant difference was seen in ART experienced children between week
96 and baseline - Figure 6-15.
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Figure 6-15. Examples of changes over 96 weeks in 3 of the biomarkers reflecting
cardiovascular injury and repair by baseline ART exposure.
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Angiopoietin 1 levels did not change significantly over 96 weeks in either ART naïve
or ART experienced children. Angiopoietin 2 levels did significantly increase over 96
weeks in ART experienced children, but did not change significantly in ART-naïve
children. As expected therefore, the Angiopoietin 2:1 ratio did not significantly
change in ART naïve children over 96 weeks however a significant increase was
seen in ART experienced children - Figure 6-16
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Figure 6-16. Changes in the ratio of Angiopoietin 2 to angiopoietin 1 over 96
weeks by ART exposure at baseline.
HIV uninfected control results shown at baseline.
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Markers of disordered thrombogenesis (d-dimer, TF, TM)
A small but significant increase in tissue factor levels over 96 weeks was seen in the
ART naïve group, no significant differences were seen over time in the ART
experienced group. A significant decrease in ART naïve children and a significant
increase in ART experienced children in thrombomodulin was observed. D-dimer
levels significantly fell in both ART naïve and experienced groups - Figure 6-17.
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Figure 6-17. Examples of changes over 96 weeks in biomarkers reflecting
disordered thrombogenesis by baseline ART exposure.
Levels seen in HIV uninfected children shown at baseline
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6.11 Effect of randomized NRTI on change in biomarkers over 96
weeks
The Kruskal–Wallis non-parametric test was used to compare any differences
across the three randomized NRTIs in the changes from baseline to week 96 in
each of the log of the 19 biomarkers, separately in ART-naïve and ART-experienced
strata (total 36 tests). Where the Kruskal-Wallis test had p<0.1, I then conducted
pairwise tests between each pair of randomized NRTIs using the ranksum test. Two
Kruskal Wallis p-values were <0.05 (change in CRP from baseline in ART-naive
p=0.047 and change in IL-10 from baseline in ART-experienced p=0.02). There
were a further 3 results where the p value was between 0.05-0.1 suggesting a trend
towards a difference by NRTI - Table 6-10. If there were no differences between
randomized NRTI groups, I would expect 0.05*36=1.8 tests to have p<0.05, and
0.1*36=3.6 tests to have p<0.1 by chance; therefore these results likely reflect
multiple testing rather than genuine differences.
d4T v ZDV ZDV v ABC d4T v ABC
IL-1Ra 2 p = 0.07 p = 0.12 p = 0.37 p = 0.03
CRP 1 p = 0.05 p = 0.27 p = 0.13 p = 0.02
IL-10 2 p = 0.02 p = 0.003 p = 0.19 p = 0.24
IL-8 2 p = 0.08 p = 0.86 p = 0.08 p = 0.03
SAA 1 p = 0.06 p = 0.19 p = 0.23 p = 0.02
Group KruskalWallis
Mann Whitney
Table 6-10. Biomarkers with borderline significant results suggesting effect of
arm affecting change from baseline
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6.12 The impact of viral load suppression on the change in
biomarkers
To determine the influence of week 96 virological suppression separate models
were fitted for both ART naïve and ART experienced - Table 6-11 and Table 6-12.
Table 6-11. Results of multivariate models investigating the effect of age,
baseline viral load and virological suppression on change in each biomarker over
96 weeks in children who were ART naïve at baseline.
Each model also adjusted for log10 baseline biomarker (to adjust for possible regression
to the mean).
NAIVE
Co-efficient p Co-efficient p Co-efficient p
IL1-Ra 0.01 0.87 0.05 0.22 -0.23 <0.001
CRP -0.02 0.41 0.06 0.47 -0.26 0.05
TNFa 0.04 0.32 0.02 0.37 -0.19 <0.001
IL-10 -0.04 0.001 0.03 0.50 -0.13 0.05
IL-6 -0.01 0.71 0.06 0.24 -0.23 0.01
IL-8 0.01 0.46 0.02 0.78 -0.20 0.02
ICAM-3 0.01 0.36 0 0.98 -0.22 <0.001
SAA -0.03 0.29 0.15 0.08 -0.20 0.14
MCP-1 -0.01 0.05 0.02 0.31 -0.12 <0.001
Angio 1 -0.01 0.05 0.02 0.31 -0.04 0.58
Angio 2 -0.01 0.20 0.03 0.20 -0.13 <0.001
E-selectin 0.00 0.95 -0.05 0.10 -0.11 0.02
P-Selectin 0.00 0.72 -0.04 0.14 -0.08 0.08
sICAM -0.01 0.16 0.02 0.40 -0.13 <0.001
VCAM -0.01 0.05 0.02 0.35 -0.15 <0.001
VEGF -0.03 0.01 -0.02 0.68 -0.13 0.03
D-dimer 0.01 0.81 0.04 0.76 -0.53 0.01
TF -0.01 0.21 0.01 0.58 0.12 <0.001
TM 0.00 0.46 -0.02 0.19 0.00 0.19
VL, viral load; IL-1Ra, interleukin-1 receptor antagonist; CRP, C reactive protein; TNFa, tumour necrosis factor A; IL-10, interleukin-
10; IL-6, interleukin-6; IL-8, interleukin-8; ICAM-3, intracellular adhesion molecule-3; SAA, soluble amyloid A; MCP, Monocyte
chemoattractant protein-1; Angio 1, angiopoietin-1; Angio 2, angiopoietin-2; sICAM, soluble intracellular adhesion molecule;
VCAM, soluble vascular cell adhesion molecule-1; VEGF, vascular endothelial growth factor; TF, tissue factor; TM,
thrombomodulin.
Cardiovascular injury and repair
Disordered thrombogenesis
Inflammatory
Age Baseline VL Virological suppression
at wk 96
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Table 6-12. Results of multivariate models investigating the effect of age and
virological suppression on change in each biomarker over 96 weeks in children
who were ART experienced at baseline.
Model adjusted for log10 baseline biomarker values to adjust for potential
regression to the mean.
Co-efficient p Co-efficient p
IL1-Ra 0.01 0.71 -0.25 0.09
CRP 0.08 0.07 -1.10 0.001
TNFa 0.00 0.89 -0.12 0.14
IL-10 0.03 0.29 -0.39 0.06
IL-6 0.07 0.002 -0.30 0.12
IL-8 -0.01 0.55 -0.38 0.04
ICAM-3 0.01 0.38 0.00 0.99
SAA 0.12 0.01 -1.32 0.001
MCP-1 0.02 0.12 -0.07 0.38
Angio 1 -0.02 0.55 -0.29 0.18
Angio 2 0.01 0.08 -0.10 0.10
E-selectin 0.01 0.57 -0.17 0.17
P-Selectin 0.01 0.54 -0.04 0.70
sICAM 0.02 0.06 -0.24 0.01
VCAM 0.12 0.04 -0.18 0.02
VEGF 0.02 0.33 -0.39 0.02
D-dimer -0.02 0.63 -0.46 0.33
TF -0.01 0.42 0.01 0.84
TM 0.01 0.15 -0.13 0.07
VL, viral load; IL-1Ra, interleukin-1 receptor antagonist; CRP, C reactive protein; TNFa, tumour
necrosis factor A; IL-10, interleukin-10; IL-6, interleukin-6; IL-8, interleukin-8; ICAM-3,
intracellular adhesion molecule-3; SAA, soluble amyloid A; MCP, Monocyte chemoattractant
protein-1; Angio 1, angiopoietin-1; Angio 2, angiopoietin-2; sICAM, soluble intracellular
adhesion molecule; VCAM, soluble vascular cell adhesion molecule-1; VEGF, vascular
endothelial growth factor; TF, tissue factor; TM, thrombomodulin.
Cardiovascular injury and repair
Disordered thrombogenesis
EXPERIENCED Age Virological suppressionat wk 96
Inflammatory
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For each biomarker, a model that then included age, baseline viral load, whether
ART naïve or experienced at trial entry and week 96 virological suppression was
then fitted in all children. As shown in Table 6-13 week 96 suppression was the
fundamental factor significantly affecting change in 16/19 of the biomarkers, in all
cases with virological suppression associated with larger decreases from baseline.
There was no significant effect of virological suppression at week 96 on change in
angiopoietin-1 (p=0.39), whilst for both P-selectin and thrombomodulin there was
marginal evidence of an association in the same direction as for other biomarkers
(p=0.08). Having adjusted for virological suppression at week 96, the only
biomarkers whose change remained associated with age were ICAM-3 and IL-10.
Older children had smaller decreases in ICAM-3, but larger decreases in IL-10.
There were no additional effects of children being ART-naïve vs experienced at
enrolment or of baseline VL.
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Table 6-13. Results of a multivariable regression model to look at the effect of
baseline age, ART naïve/experienced, baseline viral load and virological
suppression at week 96.
Model adjusted for log10 biomarker results.
Co-efficient p Co-efficient p Co-efficient p Co-efficient p
IL1-Ra 0.010 0.27 0.220 0.41 0.050 0.20 -0.240 <0.001
CRP 0.003 0.90 -0.040 0.90 0.070 0.38 -0.350 0.003
TNFa 0.040 0.20 0.020 0.83 0.020 0.26 -0.190 <0.001
IL-10 -0.020 0.05 0.130 0.40 0.030 0.56 -0.180 0.01
IL-6 0.011 0.35 0.120 0.35 0.080 0.12 -0.240 0.002
IL-8 0.007 0.62 -0.070 0.69 0.009 0.86 -0.220 0.004
ICAM-3 0.160 0.01 0.020 0.80 -0.001 0.97 -0.190 <0.001
SAA 0.008 0.72 0.440 0.72 0.170 0.05 -0.330 0.01
MCP-1 -0.006 0.30 0.090 0.21 0.030 0.19 -0.120 <0.001
Angio 1 -0.008 0.52 0.110 0.53 0.030 0.57 -0.060 0.39
Angio 2 -0.003 0.62 0.200 0.62 0.030 0.10 -0.120 <0.001
E-selectin 0.002 0.84 -0.080 0.44 -0.050 0.08 -0.110 0.01
P-Selectin 0.005 0.53 -0.060 0.57 -0.040 0.13 -0.070 0.08
sICAM -0.003 0.63 0.080 0.29 0.020 0.27 -0.130 <0.001
VCAM -0.005 0.37 0.070 0.34 0.030 0.20 -0.150 <0.001
VEGF -0.020 0.07 0.050 0.70 -0.010 0.81 -0.160 0.01
D-dimer -0.001 0.94 0.300 0.45 0.030 0.78 -0.520 0.002
TF -0.007 0.15 -0.001 0.99 0.007 0.70 0.110 <0.001
TM 0.060 0.17 -0.020 0.74 -0.020 0.16 -0.040 0.08
Inflammatory
Cardiovascular injury and repair
Disordered thrombogenesis
VL, viral load; IL-1Ra, interleukin-1 receptor antagonist; CRP, C reactive protein; TNFa, tumour necrosis factor A; IL-10, interleukin-10; IL-6,
interleukin-6; IL-8, interleukin-8; ICAM-3, intracellular adhesion molecule-3; SAA, soluble amyloid A; MCP, Monocyte chemoattractant protein-1;
Angio 1, angiopoietin-1; Angio 2, angiopoietin-2; sICAM, soluble intracellular adhesion molecule; VCAM, soluble vascular cell adhesion molecule-
1; VEGF, vascular endothelial growth factor; TF, tissue factor; TM, thrombomodulin.
Age at baseline Baseline log viral load Viral load suppression at
week 96
Effect of ART naïve /
experienced at baseline
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6.13 Discussion
The biomarker panels were put together a priori based upon existing literature
focusing upon the way people classically thought about pathogenesis in terms of
markers of inflammation, vascular damage / repair and disordered thrombogenesis
but the results presented within this chapter have shown some interesting
relationships and many markers span more than one group. This study represents,
to my knowledge, the first systematic and prospective longitudinal study of
biomarkers in HIV-infected African children, which is matched to cardiovascular and
immunological markers. Children received a limited repertoire of ART combinations,
the majority of children were virologically supressed at week 96 and the population
studied allowed the effects of HIV and ART to be looked at without confounders
such as a diverse ethnic population, co-morbidities multiple ART combinations and
obesity influencing levels [437, 438].
Results from other paediatric HIV studies are summarised in Table 6-14 and whilst
interesting, the populations studied are diverse in terms of geographical location,
ART history and several include horizontally infected adolescents. Studies were
conducted in populations with a high incidence of severe HIV and ART related
metabolic disturbances. The use of different biomarker panels, techniques and small
sample sizes may explain some of the irreproducibility of results. Without exception
all studies to date have studied older children / adolescents. As I have clearly
demonstrated a clear inverse relationship with age and biomarkers exists for the
majority of the biomarkers studied (except SAA, Ang-1 and tissue factor) so that all
comparisons with the existing literature must consider the impact of age.
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Table 6-14. Summary of studies of changes in biomarkers in HIV infected children
Number
recruited
Setting % patients on
ART
Parameters
measured
Findings Ref
83 HIV +
59 HIV –
Aged 5.4 –
17.7 years
UK. 33% ART
naïve
67% on ART
(31/56 PI
25/56 non PI)
cIMT, FMD, BP,
anthropometry,
total cholesterol,
HDL, apoB, LPa,
LDL, hsCRP
Lipid abnormality not
associated with IMT /
FMD. Increased hsCRP
in HIV +
[241]
64 HIV +
30 HIV –
mean age
14.1 years
Spain All on ART,
83% with VL
<50
copies/mL
IMT, IL-6, CRP.
MPO. tPA,
sVCAM-1, P-
selectin, sCD14,
lipid profile
HIV + higher sCD14,
sVCAM. No relationship
between biomarkers
and VL.
No effect HIV status for
CRP, IL-6, MPO, MCP-
1, P-selectin and tPA.
No correlation between
biomarkers and IMT.
[244]
77 HIV +
32 HV –
13%
horizontally
infected
Median age
16.2 years
Spain 70% with
undetectable
VL
30% with VL
> 50
hsCRP, D-dimer,
β2-microglobulin, 
HLA-DR+CD38+,
LPS, microbial
16srDNA, sCD14
HIV+ higher CRP, d-
dimer, β2microglobulin; 
no ART class effect.
HLA DR+CD38+ cells
increased in viraemic
children. Higher levels
of LPS, 16s RNA and
sCD14 independent of
viraemia.
[439]
31 HIV+
stable on
ART for >6
months
31 HIV -
USA 84% VL < 400
copies/ml
16/31on PI
based ART
cIMT,
homocysteine,
hsCRP,
myeloperoxidase,
lipids
HIV+ higher cholesterol,
triglycerides, MPO and
lower homocysteine
levels. BMI significant
predictor of IMT in HIV-,
duration of ART
predictive of IMT in
HIV+
[249]
106 HIV+,
mean age
14.8 years,
5%
horizontally
infected
55 HIV -,
mean age
12.3 years
USA 86% on ART CRP, IL-6, MCP-1,
fibrinogen, P-
selectin, sICAM<
sVCAM, E-
selectin, leptin,
anthropometry
HIV+; higher sICAM,
sVCAM, MCP-1, IL-6,
fibrinogen. Higher IL-6,
MCP-1, CRP and
sICAM correlated with
higher waist:hip,
sVCAM, MCP-1, IL-6,
fibrinogen and CRP
inversely related to
CD4%.
[440]
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Number
recruited
Setting % patients on
ART
Parameters
measured
Findings Ref
226 HIV +
median
age 12.3
years
140 HEU
median
age 10.3
years
USA
and
Puerto
Rico
89% on ART,
65% VL < 400
copies / mL
CRP
IL-6
MCP-1
Fibrinogen
P-selectin
sICAM-1, sVCAM,
E-selectin,
adiponectin
HIV+ higher MCP-1,
fibrinogen, sICAM and
sVCAM. BMI z score
associated with higher
CRP and fibrinogen but
lower MCP-1 and sVCAM.
Higher VL associated with
higher levels of MCP-1,
CRP, sICAM and sVCAM.
[407]
88 HIV+,
10%
horizontal
transmissi
on mean
age 13.5
years
Italy 86% on ART,
72% VL <
1000 copies /
mL
Protein S, protein C
anticoagulant,
antithrombin,
fibrinogen, d-dimer,
hsCRP and
homocysteine.
High prevalence of
thrombophilic
abnormalities. Low protein
S levels and high d-dimers
associated with detectable
VL. CRP unrelated to VL
[441]
27 HIV+
30 HIV-
mean age
11 years
USA 4%
horizontally
infected, 96%
on ART, 70%
VL < 50
copies / mL
IMT, fasting lipids,
insulin, TNFα, 
sTNFR-I, II, IL-6,
hsCRP, MPO,
ICAM-1, sVCAM,
VWF
No difference except for
higher hsCRP in HIV+.
CRP, age and female sex
positively associated with
increased IMT.
[442]
97 HIV +
81 HIV –
horizontall
y infected
adolescent
s
USA 67 on ART,
9% with VL
suppression
30 ART naive
Lipids, hsCRP,
sVCAM-1,
myeloperoxidase
and neopterin.
HIV+ on ART lower HDL
and apoprotein A
compared to HIV -,
hsCRP not elevated and
not predictive of risk.
sVCAM-1 elevated in
HIV+ in both ART naïve
and experienced.
[409]
49 HIV+
aged 1
month to
13 years
No
controls
USA 29% ART
naïve
22% on ART
starting PI
49%
switching
ART due to
treatment
failure
2% VL < 400
VL, CD4, lipids, apo
A and B, IGF-1,
IGFBP-1, IGFBP-3,
anthropometry,
biochemical
impedence, TNFA,
IL-1B, IL-6
No drug class effect
TNFα, levels fall with ART 
and related to CD4% –
increase 10%CD4 count
fall of 26% TNFα. Non-
significant reduction in IL-
6 with ART, inverse
relationship between IL-6
and CD4%
[443]
100 HIV +
50 HIV –
Aged 12 –
20 years
Thailand All on ART,
48% PI
based, 82%
undetectable
VL
fasting lipid profiles,
hs-CRP, NT-pro-
BNP,
echocardiogram,
cIMT.
hsCRP no different from
controls
[240]
sTNFR-I; soluble TNF receptors, MPO; myeloperoxidase
250
6.13.1 Baseline results in HIV infected, ART naïve children
In HIV infected, ART naïve 16 of the 19 biomarkers were higher than levels in age
matched HIV uninfected controls. Angiopoeitin-2 levels were lower than seen in HIV
uninfected controls and thrombomodulin and tissue factor levels were comparable in
HIV infected and uninfected controls.
Compared to HIV infected children on ART 17/19 biomarkers were higher in the
ART naïve children, Ang-1 levels were comparable regardless of ART status whilst
tissue factor levels were lower in HIV infected children not on ART. However the
ART experienced children were older than the ART naïve children.
Taken together these results add support to earlier initiation of ART, as advocated
by current WHO guidelines, to reduce levels of inflammation and vascular injury.
6.13.2 The effects of ART and changes in biomarkers
At baseline ART experienced children, despite a median of 3.5 years of effective
ART, had significant differences in 16/19 biomarkers compared to HIV uninfected
controls. 12 (CRP, IL-10, IL-6, IL-8, ICAM-3, MCP-1, Ang-1, P-selectin, VCAM,
VEGF, d-dimer and tissue factor) remained elevated compare to controls whilst
TNFα, Ang-2, E-selectin and thrombomodulin levels were significantly lower than 
controls. IL-1Ra, serum amyloid A and sICAM levels were not significantly different
between controls and cases.
Analysis of changes following 96 weeks of treatment revealed that in the children
who were ART naïve and then commenced ART 16/19 biomarkers had significant
decreases in levels; Ang-1, Ang-2 and tissue factor levels did not significantly
change. In those children who were ART experienced at baseline 12/19 biomarkers
continued to fall, 3 had significant increases in levels (Ang-2, E-selectin and
thrombomodulin) whilst 4 had no significant change (Ang-1, P-selectin, D-dimer and
tissue factor). This suggests that despite viral suppression further improvements are
seen with ongoing ART. These findings add to literature showing that ART has been
shown to decrease, although not completely normalise inflammatory biomarkers [77,
107, 444, 445]. The acknowledgement that ART does not or cannot normalise all of
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these biomarkers may suggest that either children are not starting ART early
enough or in spite of viral suppression, abnormalities remain.
Published paediatric results which suggest a role for active viral replication and
elevated cardiovascular biomarkers have been published [407]. This is encouraging
as with viral suppression pro-atherogenic mechanisms may be attenuated. Sainz
and colleagues did not detect any significant association between biomarkers and
VL [244]. Other studies have shown VL to be associated with markers of
inflammation (MCP-1, CRP) and endothelial dysfunction (sICAM, sVCAM) [407].
6.13.3 What do biomarkers add to our understanding of paediatric HIV?
Extensive work in adults has examined the addition of multiple biomarkers to
traditional risk prediction scores (such as the Framlington Risk Score) for
cardiovascular disease. Whilst a number of circulating, genetic, and imaging
biomarkers are robustly associated with cardiovascular risk the evidence that these
biomarkers can improve individual cardiovascular risk prediction is limited [446,
447].
Pre-ART changes
Inflammation in early HIV disease progression is not well characterized. Ninety
adults with untreated primary HIV-1 infection were studied to determine associations
of inflammatory proteins with early disease progression. High TNF-α levels were 
significantly associated with an increased viral load set point and shorter times to
ART initiation. The increased risk of reaching a CD4+ T-cell count of <500
cells/mm3 in the group with high TNF-α levels was driven by viral load but was 
independent of concurrent CD4+ T-cell count. Thus, TNF-α appears to be an 
important mediator of inflammation in patients with poor viral control and early HIV-1
disease progression [378]. Pre-ART inflammation and coagulation activation have
not been shown to predict CD4 count response to ART in adults [448].
CRP
Elevated CRP has been shown in the general adult population to be consistently
correlated with CVD, especially MI. CRP levels are positively correlated with BMI,
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glycated haemoglobin levels, female sex and greater numbers of metabolic
syndrome markers whilst negatively correlated with HDL cholesterol levels [449].
Several studies have reported a trend towards increased CRP in HIV infected
children compared to HIV uninfected controls [241, 249].
Relationship between biomarkers and markers of cardiovascular structure
and arterial stiffness
IMT and PWV are research tools that can provide insight into those patients who
have increased cardiovascular risk. In order to perform both techniques equipment
and training are required and they are both unlikely to be incorporated into routine
clinical care. Measurement of a circulating biomarker as a surrogate marker is
attractive however results to date are in keeping with other findings that no
biomarker has been found that is predictive of cardiovascular changes [450, 451].
Studies of healthy children have reported an association of hsCRP and IMT [442]. In
keeping with two other paediatric HIV studies [240, 244] we did not find an
association between CRP and IMT. In an adult population soluble VCAM-1 was
associated with higher CIMT independently of age and blood pressure in HIV-1
infected, virologically suppressed adults at risk for CVD [452], we were unable to
demonstrate such an association.
Prediction of morbidity and mortality once on ART
The use of a biomarker to predict morbidity and mortality is attractive. Several
studies have tried to do this for example after successful ART therapy d-dimer levels
remain elevated and are significantly associated with HIV associated non AIDS
events [453]. Higher IL-6 level and D-dimer levels at baseline and year 1 were
associated with the occurrence of a non–AIDS-defining event [316]. The mortality
and morbidity in CHAPS 3 was low and so the significance of elevated levels in
these biomarkers in children could not be determined.
In conclusion I have shown that there are significant differences between
biomarkers in HIV infected African children on and off ART compared to HIV
uninfected children. For the first time in an African setting a large scale study of the
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normal range of biomarker levels has been determined and this paves the way for
future studies within an African setting.
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Chapter 7 Results: Immunophenotyping
7.1 Introduction
7.1.1 Immune activation
In the early 1990s Giorgi et al showed that immune activation by HIV, as
demonstrated by expression of CD38 on CD8 T-cells, was a very strong predictor of
accelerated progression to AIDS [308]. Attention since has focused upon HLA DR+
and CD38+ expression on CD4+ and CD8+ T-cells as markers of activation in
adults. Higher levels of activation are related to viral load, disease progression,
increased morbidity and mortality from both AIDS and non AIDS related disease [94,
309-317, 454, 455]. ART reduces immune activation but higher levels of residual
inflammation can remain despite a good virological response to ART; the greater the
degree of immunosuppression at the time of commencing ART the higher the
degree of residual inflammation and this can limit immune reconstitution. Less is
known in HIV-infected children.
7.1.2 Thymic output
T-cells can be divided into naïve and memory subsets based upon the expression of
CD45 isoforms. CD45 is a leukocyte common antigen of which 2 isoforms, RA and
RO, exist. Naïve cells are characterized by CD45RA expression and are yet to ‘see’
antigen whilst CD45RO positive cells are usually memory cells. As introduced in
section 3.9.1 early thymic output is crucial in establishing and maintaining the
peripheral naïve T-cell pool in children [456]. In healthy children thymic output peaks
at one year of age and then gradually decreases as increased peripheral T-cell
division maintains the naive T-cell repertoire [456-458]. T-cells recently released
from the thymus are CD31+, naïve (CD45RA+) CD31+ T-cells are called recent
thymic emigrants (RTE) whereas T-cells that have proliferated in the periphery but
without encountering antigen are (CD45RA+) CD31- and called central naïve cells.
7.1.3 Unregulated proliferation
Unregulated T cell proliferation is described in HIV infection due to an imbalance of
immune activation and T-cell depletion [459-461]. Whilst ART reduces T-cell
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proliferation, abnormally high levels of proliferation can persist despite viral
suppression [462], similarly to immune activation. Ki67 is a marker of peripheral T-
cell division; with untreated HIV large proportions of cells are actively proliferating
which usually falls with effective ART.
To date little work has been published looking at these markers in large populations
of HIV-infected children living in Africa. To address this, 2 immunophenotyping
panels looking at markers of immune activation (HLA DR and CD38 expression in
CD4+ and CD8+ T-cells) and proliferation (Ki67 expression in CD4+ sub populations
classified according to CD45RA and CD31) were performed at baseline, week 48
and week 96. Methods of the techniques used are described in section 3. 9.
7.2 Results
7.2.1 Analysis
Markers were truncated at the 1st and 95th centile, to avoid outliers having undue
influence on results.
7.2.2 Missing samples
As summarised in Table 7-1, 80-90% of children had available immunophenotying
data available at each time point. A few patients did not have data available due
either to 1) no sample available or the sample not being processed (difficulties with
venesection, no laboratory personnel available or lack of reagents) or 2) due a
problem with the processing of the sample such that the results were unanalyzable,
specifically:
a) Antibody problem; incorrect antibodies added or one left out (the DR panel was
pre-mixed, the Ki67 had to be hand mixed), antibodies damaged by light.
b) Sample processing; left for too long before processing (4 hour window), poor lysis
or mixing or ran too fast / slow.
c) Machine problem; incorrect settings used, fluidics flow disturbed by blocked
probe, cracked tube, inadequate pressure or loose line.
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d) Insufficient events captured; anything with less than 1000 events was not
analysed.
All analyses are based on observed data.
Table 7-1. Summary of samples available for immunophenotyping analysis.
Group 1 HIV
infected ART
naïve
HIV uninfected
matched to group 1
Group 2 HIV
infected ART
experienced
HIV uninfected
matched to group 2
Total 208 209 74 75
Samples available 177 162 60 62
Sample unavailable (%) 31 (15%) 47 (22%) 14 (19%) 13 (17%)
No sample processed1 23 31 11 4
Sample unanalysable2 8 16 3 9
Samples available 187 161 60 63
Sample unavailable (%) 21 (10%) 48 (23%) 14 (19%) 12 (16%)
No sample processed1 19 32 13 3
Sample unanalysable2 2 16 1 9
Total 185 74
Samples available 161 61
Sample unavailable (%) 24 (13%) 13 (18%)
No sample processed1 20 10
Sample unanalysable2 4 3
Samples available 157 63
Sample unavailable (%) 28 (15%) 11 (15%)
No sample processed1 24 10
Sample unanalysable2 4 1
Total 178 74
Samples available 141 63
Sample unavailable (%) 37 (21%) 11 (15%)
No sample processed1 35 10
Sample unanalysable2 2 1
Samples available 150 62
Sample unavailable (%) 28 (16%) 12 (16%)
No sample processed1 26 11
Sample unanalysable2 2 1
(1) No sample processed; insufficient blood taken, no laboratory personnel available to process sample or no reagents available.
(2) Sample unanalysable; failed antibody staining, antibodies damaged by light, delay in processing sample, incorrect settings
used or insufficient events (<1000) captured.
Week
48
Ki67
Week
96
Ki67
DR
DR
Week
0
Ki67
DR
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7.3 Baseline immunophenotyping results
Markers of activation
Based upon the surface expression of HLA DR and CD38, CD4+ and CD8+ T-cells
can be divided into 4 sub-populations, as illustrated in Figure 7-1. Quadrant 2 (Q2)
represents the CD38+ HLA DR + or “double positives” that are markers of activated
cells; in this example A) shows a HIV uninfected 7 month old infant with 3.35% of his
CD4+ T-cells expressing CD38 and HLA DR whilst B) shows a 4 year 10 month old
HIV-infected child who is not on ART; he has high levels of activation with 47.8% of
his CD4+ cells expressing CD38 and HLA DR.
Figure 7-1. CD4+ (and CD8+) T-cells can be divided into 4 groups based upon the
surface expression of CD38 and HLA DR.
These examples show the CD4+ population of A) a 7 month old HIV uninfected baby and B)
a 4 year 10 month HIV-infected, ART naïve boy. Quadrant 1 (Q1) contains the HLA DR-
CD38+ sub population, Q2 contains the HLA DR+CD38+ “double positives”, markers of
immune activation. In this example the effects of uncontrolled HIV are clearly demonstrated;
in B 47.8% of the child’s CD4+ T-cells are HLA DR+ CD38+ , an highly activated population
compared to just 3.35% of the young HIV uninfected infant in A. Q3 contains HLA
DR+CD38- and Q4 contains “ double negatives” HLA DR-CD38-.
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Results are summarised in Table 7-2 and illustrated in Figure 7-2. The proportion of
CD4+ T-cells expressing HLA DR+CD38+ (“double positives”) was significantly
higher in HIV-infected, ART naïve children compared to both HIV uninfected controls
and HIV-infected, ART experienced children (p<0.001). The proportion of CD4
double positives was significantly lower in HIV-infected, ART experienced children
compared to controls (p=0.004). A similar pattern was seen in the proportion of
CD8+ double positives that were significantly higher in HIV-infected ART naïve
children compared to both their HIV uninfected controls and HIV-infected ART
experienced children (p<0.001). There was no evidence of a difference in the
proportion of CD8+ double positives in HIV-infected ART experienced children
compared to their controls (p=0.17).
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Figure 7-2. Baseline differences in percentage of activated (HLA DR+ CD38+)
CD4+ and CD8+ T-cells between groups.
A. Significant differences are seen in the percentage of activated CD4+ T-cells
between HIV-infected, ART naïve (group 1) and controls (p<0.001), between
HIV-infected ART naïve and HIV-infected ART experienced (group 2) and
between group 2 and their HIV uninfected control group (p<0.001).
B. Significant differences were also seen the percentage of activated CD8+ T-cells
between group 1 and controls, between group 1 and group 2 (p<0.001) but no
significant difference was seen between group 2 and their controls (p=0.17).
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HIV infected
ART naïve
(group 1)
HIV uninfected
matched to
group 1
difference
between
group 1
and
controls *
HIV infected
ART
experienced
(group 2)
HIV uninfected
matched to
group 2
difference
between
group 2
and
controls *
difference
between
group 1 and
group 2 *
Number of results 177 162 60 62
Lymphocytes 27 (18 : 35) 34 (25 : 41) p<0.001 31 (26 : 37) 33 (24 : 38) p = 0.88 p = 0.002
% CD3+ 71 (62 : 78) 67 (59 : 72) p<0.001 69 (61 : 73) 67 (61 : 74) p = 0.40 p = 0.11
% CD4+ 16 (11 : 22) 37 (32 : 43) p<0.001 34 (28 : 39) 35 (30 : 44) p = 0.10 p < 0.001
% CD3+ CD8+ 61 (53 : 71) 30 (26 : 35) p<0.001 40 (33 : 47) 33 (28 : 39) p <0.001 p < 0.001
CD4:CD8 0.45 (0.20 : 0.75) 1.57 (1.03 : 2.19) p<0.001 0.79 (0.56 : 1.35) 1.28 (0.9 : 1.94) p <0.001 p < 0.001
% CD4+ DR- CD38+ (Q1) 83 (68 : 91) 82 (69 : 91) p=0.95 65 (50 : 80) 66 (56 : 88) p = 0.34 p < 0.001
% CD4+ DR+ CD38+ (Q2) 4.24 (1.9 : 8.0) 1.24 (0.76 : 2.24) p<0.001 0.83 (0.39 : 1.64) 1.51 (0.84 : 2.8) p = 0.004 p < 0.001
% CD4+ DR+ CD38- (Q3) 0.25 (0.07 : 0.83) 0.20 (0.08 : 0.51) p=0.53 0.41 (0.10 : 0.90) 0.34 (0.12 : 1.68) p = 0.41 p = 0.23
% CD4+ DR- CD38- (Q4) 10 (4 : 22) 17 (7 : 28) p<0.001 32 (17 : 49) 29 (9 : 42) p = 0.15 p < 0.001
% CD8+ DR- CD38+ (Q1) 80 (64 : 88) 84 (72 : 91) p=0.01 66 (52 : 82) 72 (55 : 82) p = 0.59 p = 0.01
% CD8+ DR+ CD38+ (Q2) 12.1 (6.7 : 20.4) 3.8 (2.2 : 6.2) p<0.001 2.9 (1.5 : 4.8) 3.4 (2.3 : 6.2) p = 0.17 p < 0.001
% CD8+ DR+ CD38- (Q3) 0.11 (0.02 : 0.56) 0.10 (0.02 : 0.48) p=0.41 0.20 (0.06 : 0.91) 0.41 (0.13 : 1.28) p = 0.14 p = 0.09
% CD8+ DR- CD38- (Q4) 4.2 (1.6 : 9.5) 10.5 (4.9 : 21.6) p<0.001 24.7 (12.5 : 43.4) 20.4 (9.9 : 31.9) p = 0.39 p < 0.001
General
Markers of activation
* using Mann Whitney U test. Where a significant difference exists between HIV+ and uninfected controls the higher value is written in red. Where a
significant difference exists between ART naïve and ART experienced the higher value is underlined. Q1 - 4 refer to the quadrants illustrated in figure 7.1.
CD4
CD8
Table 7-2. Summary of baseline immunophenotyping results: markers of activation
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Cut offs to define low / intermediate / high levels of activation were set arbitrarily at
5% and 10% and the percentage of children in each group, as defined by the
proportion of CD4+ and CD8+ T-cells that are expressing both HLA DR+ and
CD38+, calculated as summarised in Table 7-3. Of special interest are the small
proportion (16%) of HIV-infected, ART naïve children who have low levels of
activated CD8+ T-cells and also the 17% / 8% of ART experienced children who
remain with medium / high levels of activated CD8+ cells despite a median of 3.7
years of ART and a supressed viral load. However, 24% / 10% of HIV uninfected
children had medium / high levels of activated CD8+ cells, suggesting this could be
due to non-HIV factors.
HIV uninfected
<5 % 371 ( 80% ) 103 ( 58% ) 56 ( 93% ) 212 ( 95% )
5 - 10% 56 ( 12% ) 44 ( 25% ) 5 ( 7% ) 8 ( 4% )
≥ 10% 34 ( 7% ) 30 ( 17% ) 0 ( 0 ) 4 ( 2% )
<5 % 223 ( 48% ) 29 ( 16% ) 45 ( 75% ) 149 ( 67% )
5 - 10% 104 ( 23% ) 41 ( 23% ) 10 ( 17% ) 53 ( 24% )
≥ 10% 134 ( 29% ) 107 ( 60% ) 5 ( 8% ) 22 ( 10% )
CD4+ HLA DR + CD38 +
CD8+ HLA DR + CD38 +
ART experiencedART naïveAll groups
Table 7-3. Proportion of children who have low / medium / high levels of activation
by group.
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Markers of proliferation
CD4 T-cells were subdivided into 4 populations based upon the surface expression
of CD45RA and CD31 as illustrated in Figure 7-3. The proportions of naïve cells (all
CD45RA+) and memory cells (all CD45RA-) were calculated. For each
subpopulation the proportion of cells expressing Ki67 was determined; Figure 7-4
illustrates the differences seen in Ki67 expression between HIV-infected children on
and off ART. All results are given in Table 7-4.
Figure 7-3. CD4+ T-cells can be divided into 4 groups based upon the surface
expression of CD45 RA and CD31.
This is an example of a 7 month old HIV-infected baby not on ART. 59.1% of his CD4+ T-
cells are recent thymic emigrants expressing CD45 RA+ CD31+ (Quadrant 2)
Quadrant 1 (Q1) contains the CD45 RA- CD31+ sub population, these are an abnormal
population of memory cells, seen at low frequencies in uninfected children
Q2 contains the CD45 RA+ CD31+ “double positives”, recent thymic emigrants (RTE)
Q3 contains CD45 RA+ CD31–; these are central naïve cells
Q4 contains “double negatives” CD45 RA- CD31-; these are true memory cells.
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Figure 7-4. Examples of Ki67 expression on CD4+ CD45RA- T-cells.
An HIV-infected, ART naïve child who has a 46.5% of his CD4+ CD45RA- T-cells
expressing Ki67
An HIV-infected, ART experienced child who has less than 0.7% of CD4+CD45RA- T-cells
expressing Ki67
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Table 7-4. Summary of baseline immunophenotyping.
Naïve, memory cells and proportion of proliferating by sub-population, median and IQR
given.
HIV infected
ART naïve
(group 1)
HIV uninfected
matched to
group 1
difference
between
group 1
and
controls *
HIV infected
ART
experienced
(group 2)
HIV uninfected
matched to
group 2
difference
between
group 2
and
controls *
difference
between
group 1
and group
2 *
% CD4+ Ki67+ 6.4 (3.9 : 9.2) 2.5 (1.6 : 3.7) p < 0.001 3.6 (2.7 : 4.7) 3 (2.2 : 3.9) p = 0.02 p < 0.001
% CD45 RA+ 57.9 (46.6 : 67.8) 69.3 (61.8 : 76.8) p < 0.001 59.0 (51.6 : 67.9) 66.4 (54.4 : 71.7) p = 0.01 p = 0.68
% CD45 RA+ Ki67+ 1.9 (1.1 : 4.1) 1.0 (0.6 : 2.3) p < 0.001 1.5 (1.0 : 2.7) 2.4 (0.8 : 3.6) p = 0.48 p = 0.15
% CD45RA+ CD31+ (Q2) 48 (38 : 60) 60 (52 : 67) p < 0.001 51 (44 : 60) 56 (47 : 62) p = 0.10 p = 0.21
% CD45RA+ CD31+ Ki67+ 1.36 (0.96 : 2.39) 0.94 (0.54 : 1.78) p < 0.001 1.2 (0.75 : 1.54) 1.41 (0.74 : 3.1) p = 0.35 p = 0.08
% CD45RA+ CD31- (Q3) 8.1 (4.6 : 11.8) 8.6 (6.5 : 11.8) p = 0.09 5.3 (3.6 : 8.0) 9.6 (5.8 : 12.9) p <0.001 p = 0.01
% CD45RA+ CD31- Ki67+ 1.55 (0.48 : 4.05) 0.75 (0.35 : 1.92) p < 0.001 1.09 (0.59 : 2.57) 2 (0.54 : 4.0) p = 0.20 p = 0.22
% CD45 RA- 41.8 (32.2 : 50.4) 30.6 (23.2 : 38.2) p < 0.001 40.5 (31.6 : 47.4) 33.6 (28.3 : 44.8) p = 0.01 p = 0.62
% CD45 RA- Ki67+ 12.2 (8.5 : 16.6) 5.4 (2.8 : 8.0) p < 0.001 6.5 (5.0 : 8.0) 4.9 (3.5 : 7.2) p = 0.01 p<0.001
% CD45RA- CD31+ (Q1) 17 (12 : 23) 12 (8 : 17) p < 0.001 17 (10 : 23) 14 (10 : 20) p = 0.30 p = 0.60
% CD45RA- CD31+ Ki67+ 11.9 (7.3 : 16.1) 5 (2.8 : 8.6) p < 0.001 5.6 (4.1 : 7.5) 4.1 (3.3 : 7) p = 0.04 p < 0.001
% CD45RA- CD31-(Q4) 22.7 (13.3 : 33.4) 17 (11.9 : 23.3) p < 0.001 23.3 (16.9 : 27.8) 17.9 (11.7 : 23.4) p = 0.01 p = 0.71
% CD45RA- CD31- Ki67+ 11.9 (7.2 : 16.6) 4.3 (1.8 : 7) p < 0.001 6.4 (5.0 : 8.2) 4.6 (2.5 : 6.5) p <0.001 p < 0.001
Memory cells
Median and IQR given * using Mann Whitney U test. Where a significant difference exists between HIV+ and uninfected controls the higher value
is written in red. Where a significant difference exists between ART naïve and ART experienced the higher value is underlined. Q1 - 4 refer to the
quadrants illustrated in figure 7.3.
Naïve cells
Markers of proliferation in CD4+ T-cells
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Naïve and memory cells
As illustrated in Figure 7-5 and summarised in Table 7-4, HIV-infected ART naïve
and experienced children have significantly lower proportions of naïve CD4+ cells
compared to their control groups (p<0.001). There is no evidence of a difference in
the proportion of naïve cells in HIV-infected ART naïve and ART experienced
children (p=0.68). The HIV-infected ART naïve children have significantly higher
percentage of proliferating naïve cells compared to their control group (p<0.001).
There is no evidence of a difference in proliferating naïve cells between HIV-infected
ART experienced and their control group or HIV-infected ART naïve children
(p≥0.15). 
A similar pattern is seen in the proportions of memory cells; HIV-infected ART naïve
and experienced children have significantly higher proportions of memory CD4+
cells compared to their control groups (p≤0.01), whereas there is no evidence of a 
difference in the proportion of memory cells between HIV-infected ART naïve and
ART experienced children (p=0.62). The HIV-infected ART naïve and ART
experienced children have significantly higher percentage of proliferating memory
cells compared to their respective control groups (p≤0.01). HIV-infected ART naïve 
children have a significantly higher proportion of proliferating memory cells
compared to HIV-infected ART experienced children (p<0.001).
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Figure 7-5. Differences in the proportions of subpopulations of naïve and
memory cells by group.
A) Naïve CD4+ T-cells
B) Proliferating naïve CD4+ T-cells
C) Memory CD4+ T-cells
D) Proliferating memory CD4+ T-cells
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The naïve CD4+ T-cell subpopulations
As illustrated in Figure 7-6, ART naïve children have significantly lower levels of
CD31+ naïve (RTEs) cells compared to controls (p<0.001), but more similar
proportions of central naïve (CD31-) cells to controls (p=0.09). However, both the
CD31+ and CD31- naive sub populations have significantly higher levels of
proliferation compared to controls (p<0.001). ART increases the proportion of RTEs
to similar levels to controls (p=0.10), but in contrast central naïve T-cells are
significantly lower than controls (p<0.001). In ART experienced children proliferation
in the recent thymic emigrants and central naïve cells is similar to uninfected
controls (p≥0.1). As overall, there was no evidence of a difference between HIV-
infected naïve and ART-experienced children in the proportions of proliferating cells
within each naïve subpopulation (p>0.08).
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Figure 7-6. Differences by groups of the proportions of sub-populations of the
CD4+ CD45RA+ naïve T-cells and proliferating cells.
A) Total recent thymic emigrants
B) Proliferating recent thymic emigrants
C) Total central naïve cells
D) Proliferating central naïve cells.
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The memory CD4+ T-cell subpopulations
As illustrated in Figure 7-7, the CD45RA- CD31+ subpopulation is significantly larger
in HIV-infected, ART naïve children compared to their control group (p<0.001). No
significant differences are seen between HIV-infected ART experienced and their
control group nor between HIV-infected children on and off ART (p≥0.30). The 
proportions of CD45-CD31+ expressing Ki67 were significantly higher in HIV-
infected, ART naïve children compared to their control group, HIV-infected ART
experienced compared to their control group and in HIV-infected ART naïve
compared to ART experienced (p≤0.04).  
Proportions of the true memory population (CD45RA- CD31-) were significantly
higher in HIV-infected ART naïve and ART experienced children compared to their
respective control groups (p<0.001). No significant differences were seen between
HIV-infected, ART naïve and ART experienced children (p=0.71). The proportion of
true memory cells expressing Ki67 was significantly higher in HIV-infected, ART
naïve compared to controls and to HIV-infected, ART experienced; additionally the
proportion expressing Ki67 was also higher in HIV-infected, ART experienced
compared to their control group (all p<0.001).
270
Figure 7-7. Differences between groups of the proportions of different sub-
populations of the CD4+ CD45RA- memory T-cells and the proportions of
proliferating cells.
A) CD45 RA- CD31+ T-cells
B) Proliferating CD45 RA- CD31+ T-cells
C) CD45 RA-CD31- T-cells
D) Proliferating CD45 RA-CD31- T-cells
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Table 7-5 summarises overall and by group the proportion of children with low /
medium / high levels of proliferating CD4+ subpopulations, categorised by the CD45
RA, CD31 and Ki67 expression using arbitrary thresholds.
Table 7-5. Proportions of children with low / medium / high levels of proliferating
CD4+ naïve and memory sub populations.
<25 % 20 ( 4% ) 17 ( 9% ) 3 ( 5% )
25 - 50% 158 ( 34% ) 85 ( 45% ) 25 ( 42% ) 48 ( 21% )
≥ 50% 293 ( 62% ) 85 ( 45% ) 32 ( 53% ) 176 ( 79% )
<2.5 % 372 ( 79% ) 141 ( 75% ) 52 ( 87% ) 179 ( 80% )
2.5 - 5% 68 ( 14% ) 29 ( 16% ) 4 ( 7% ) 35 ( 16% )
≥ 5% 31 ( 7% ) 17 ( 9% ) 4 ( 7% ) 10 ( 5% )
<5 % 112 ( 24% ) 55 ( 29% ) 24 ( 40% ) 33 ( 15% )
5 - 10% 200 ( 42% ) 72 ( 39% ) 26 ( 43% ) 102 ( 46% )
≥ 10% 159 ( 34% ) 60 ( 32% ) 10 ( 17% ) 89 ( 40% )
<2.5 % 327 ( 69% ) 117 ( 63% ) 44 ( 73% ) 166 ( 74% )
2.5 - 5% 82 ( 17% ) 31 ( 17% ) 11 ( 18% ) 40 ( 18% )
≥ 5% 62 ( 13% ) 39 ( 21% ) 5 ( 8 ) 18 ( 8% )
<10 % 127 ( 27% ) 34 ( 18% ) 15 ( 25% ) 78 ( 35% )
10 - 20% 213 ( 45% ) 86 ( 46% ) 24 ( 40% ) 103 ( 46% )
≥ 20% 131 ( 28% ) 67 ( 36% ) 21 ( 35% ) 43 ( 19% )
<5 % 162 ( 34% ) 21 ( 11% ) 24 ( 40% ) 117 ( 52% )
5 - 10% 142 ( 30% ) 47 ( 25% ) 30 ( 50% ) 65 ( 29% )
≥ 10% 167 ( 35% ) 119 ( 64% ) 6 ( 10% ) 42 ( 19% )
<10 % 71 ( 15% ) 31 ( 17% ) 5 ( 8% ) 35 ( 16% )
10 - 20% 173 ( 37% ) 51 ( 28% ) 15 ( 25% ) 107 ( 48% )
≥ 20% 227 ( 48% ) 105 ( 56% ) 40 ( 67% ) 82 ( 37% )
<5 % 163 ( 35% ) 26 ( 14% ) 13 ( 22% ) 124 ( 55% )
5 - 10% 179 ( 38% ) 52 ( 28% ) 42 ( 70% ) 85 ( 38% )
≥ 10% 129 ( 27% ) 109 ( 58% ) 5 ( 8% ) 15 ( 7% )
CD45RA+ CD31+ Ki67+
CD45RA+ CD31- Ki67+
CD45RA- CD31+ Ki67+
HIV
uninfected
CD45RA- CD31- Ki67+
CD45RA+ CD31+
CD45RA+ CD31-
CD45RA- CD31+
MEMORY T-CELLS
All groups ART naïve ARTexperienced
CD45RA- CD31-
NAÏVE T-CELLS
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7.4 The ratio of CD4 to CD8 cells.
A healthy CD4:CD8 ratio in children is generally considered to be greater than 1. A
reversal of the ratio is seen with CD4+ T-cell depletion or CD8 expansion, causes of
which include infection with HIV, EBV or CMV and other conditions including
malignancies. As summarised in Table 7-6, the majority (77%) of ART naïve
children had a CD4:CD8 ratio of less than one reflecting their low CD4 count.
Despite a median of 3.7 years on ART 49% of ART experienced children still had a
ratio under one, predominantly reflecting high CD8 counts as their CD4s were good,
and surprisingly 21% of “normal” healthy children had a low ratio; 25/60 of these
children had a low CD4 count as described in section 5. 2 whilst in the remaining
35/60 this was due to CD8 expansion possibly reflecting current EBV or CMV
infections, both extremely common in young African children. Within the population
of ART experienced children, there was no evidence that either prior duration of
ART or age at starting ART were associated with a CD4:CD8 ratio of under one (p≥ 
0.29).
Table 7-6. Summary of the ratio of CD4:CD8 T-cells at baseline overall and by
group.
< 1 256 ( 45% ) 160 ( 77% ) 36 ( 49% ) 60 ( 21% )
>1 310 ( 55% ) 48 ( 23% ) 38 ( 51% ) 224 ( 79% )
All groups ART naïve ARTexperienced
CD4 : CD8
HIV
uninfected
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7.5 Effect of age, CD4 and viral load on baseline immunophenotyping
results
7.5.1 Activation
There was no convincing evidence of a relationship between viral load, age, CD4
count, CD4 percentage or CD4 z score and activated (HLA DR+ CD38+) CD4+ and
CD8+ T-cells in the separate groups of HIV-infected, ART experienced or HIV
uninfected children (p≥0.05,Table 7-7).  
In the HIV-infected, ART naïve children, there was a trend towards a lower
percentage of CD4+ HLA DR+ CD38+ expressing CD4+ T-cells with increasing CD4
/ CD4 percentage / CD4 z score but this was weak in magnitude and did not reach
significance (r -0.14 / -0.13 / -0.13), (p=0.07 / 0.09 / 0.05) (Figure 7-8).
Table 7-7. Relationship of baseline viral load, age and CD4 count / CD4
percentage and CD4 z score with percentage of activated CD4+ and CD8+ T-cells.
r p r p r p r p r p
ART naïve 0.14 0.07 0.08 0.29 -0.14 0.07 -0.13 0.09 -0.13 0.05
ART experienced NA NA -0.09 0.48 0.08 0.55 -0.07 0.57 0.06 0.63
HIV uninfected NA NA 0.12 0.07 -0.10 0.14 -0.08 0.24 -0.01 0.90
ART naïve 0.01 0.88 0.01 0.88 0.01 0.92 0.10 0.19 0.01 0.87
ART experienced NA NA -0.08 0.53 0.12 0.38 -0.06 0.65 0.11 0.40
HIV uninfected NA NA 0.01 0.83 -0.01 0.87 -0.03 0.66 0.01 0.84
CD8+
HLA DR+
CD38+
CD4+
HLA DR+
CD38+
CD4 z
scoreViral load Age CD4
CD4
percentage
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Figure 7-8. Influence of baseline viral load, age and CD4 percentage on markers
of activation in HIV-infected, ART naïve children.
The strength of the correlations was determined by Spearman’s rank coefficient
(r) and the level of statistical significance given (p).
275
7.5.2 Proliferation
The relationship between the proportions of total naïve and memory CD4+ T-cells
(based upon the surface expression of CD45RA and CD31) and the proportion that
was proliferating (expressing Ki67) and baseline viral load, age and CD4 count are
presented in Table 7-8.
Naïve T-cells
No significant relationship between baseline viral load and proportions of naïve T-
cells subpopulations or level of proliferation was demonstrated in HIV-infected naïve
children.
Age was significantly inversely related to the proportion of recent thymic emigrants
(CD45RA+ CD31+) in ART naive and HIV uninfected children (p<0.001). An inverse
relationship was also seen in HIV-infected naïve children between age and the
proportion of central naïve cells (CD45RA+ CD31-) (p=0.03), with a similar
magnitude of negative association in the smaller number of HIV-infected ART-
experienced children (p=0.20). Proliferating RTEs and proliferating central naïve
cells were higher with increasing age in HIV uninfected controls (p=0.001), but were
not associated with age in either HIV-infected group (p>0.1).
Proportions of RTEs increased with increasing CD4 percentage in all groups (p≤ 
0.03), but there was no association between central naïve proportions and CD4
percentage in any group (p>0.1). CD4 percentage and the proportion of proliferating
RTEs and central naïve cells were inversely associated in ART naïve and HIV
uninfected children (p<0.001), but there was no evidence of any relationship in HIV-
infected children on ART (p>0.7).
Memory T-cells
No significant relationship between baseline viral load and proportions of memory T-
cells subpopulations or level of proliferation was demonstrated (p>0.06).
Age was significantly associated with proportions of true memory cells (CD45RA-
CD31-) in HIV naïve and HIV uninfected children (p≤0.01) with a similar magnitude 
of negative association in the smaller number of HIV-infected ART-experienced
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children (p=0.21). In HIV uninfected children age was also significantly associated
with the proportion of CD31+ memory cells (p=0.02) with a similar trend in HIV-
infected naïve children (p=0.05). Lower levels of proliferation in CD31+ memory
cells were associated with increasing age in HIV uninfected children only.
CD4 percentages were significantly inversely related to the proportion of CD31+ and
CD31- memory cells in HIV uninfected and HIV-infected ART-naive children
(p≤0.04), with a similar trend in ART experienced (p=0.07, 0.10). Higher CD4 
percentages were also associated with decreased proliferation in these
subpopulations in ART naïve children and in HIV uninfected children (p≤0.05). 
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r p r p r p
NAÏVE T-CELLS
ART naïve 0.05 0.55 -0.30 <0.001 0.48 <0.001
ART experienced NA NA -0.11 0.42 0.28 0.03
HIV uninfected NA NA -0.24 <0.001 0.32 <0.001
ART naïve -0.04 0.58 0.11 0.12 -0.28 <0.001
ART experienced NA NA -0.03 0.79 -0.04 0.75
HIV uninfected NA NA 0.18 0.001 -0.27 <0.001
ART naïve 0.12 0.10 -0.16 0.03 -0.11 0.13
ART experienced NA NA -0.17 0.20 0.06 0.64
HIV uninfected NA NA 0.03 0.74 -0.06 0.38
ART naïve -0.04 0.55 0.02 0.76 -0.17 0.02
ART experienced NA NA -0.09 0.49 0.05 0.70
HIV uninfected NA NA 0.21 0.001 -0.23 0.001
MEMORY T-CELLS
ART naïve 0.14 0.06 0.14 0.06 -0.26 <0.001
ART experienced NA NA 0.09 0.48 -0.24 0.07
HIV uninfected NA NA 0.16 0.02 -0.14 0.04
ART naïve 0.09 0.25 0.01 0.90 -0.15 0.04
ART experienced NA NA 0.03 0.80 0.06 0.66
HIV uninfected NA NA -0.14 0.03 -0.13 0.05
ART naïve -0.08 0.31 0.30 <0.001 -0.29 <0.001
ART experienced NA NA 0.17 0.21 -0.22 0.10
HIV uninfected NA NA 0.17 0.01 -0.22 0.001
ART naïve 0.04 0.57 -0.01 0.87 -0.17 0.02
ART experienced NA NA -0.07 0.59 0.05 0.72
HIV uninfected NA NA 0.00 0.93 -0.20 0.003
CD45RA+
CD31+
CD45RA+
CD31+
Ki67+
CD45RA+
CD31-
CD45RA+
CD31-
Ki67+
CD45RA-
CD31+
CD45RA-
CD31+
Ki67+
CD45RA-
CD31-
CD45RA-
CD31-
Ki67+
Viral load Age CD4percentage
Table 7-8. Relationship between the proportion of total and proliferating CD4+
sub-populations (based upon expression of CD45 RA and CD31) and viral load,
age and CD4 percentage.
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As discussed above both age and CD4 percentage were significantly related, on
univariate analysis, to many of the proliferating CD4+ subpopulations. To determine
whether either one was a more important predictor a multivariate analysis was
performed - Table 7-9 . Of interest for CD45RA+CD31+ / CD45RA+CD31+ Ki67+ /
CD45RA+CD31- Ki67+ / CD45RA-CD31- subpopulations both age and CD4
percentage were independently significant predictors in both HIV infected, ART
naïve and HIV uninfected children (p≤0.05). Within the CD45RA- CD31+ 
subpopulation age and CD4 percentage were both significant predictors in HIV
uninfected children (p=0.01), whilst in the ART naïve children only CD4 percentage
was significant (p=0.001). Age was significantly related to the proportion of
CD45RA+CD31- cells in HIV infected ART naïve and ART experienced children
(p≤0.05). CD4 percentage was a significant predictor of CD45RA-CD31+Ki67+ ad 
CD45RA-CD31-Ki67+ subpopulations in the HIV uninfected children (p≤0.04). 
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Table 7-9. Multi-variable analysis exploring the relationship between the proportion
of total and proliferating CD4+ sub-populations (based upon expression of CD45
RA and CD31) age and CD4 percentage.
co-efficient p value co-efficient p value
ART naïve -0.02 -0.03 -0.01 0.001 0.01 0.01 0.01 <0.001
ART experienced 0.00 -0.03 0.02 0.71 0.00 0.00 0.01 0.23
HIV uninfected -0.01 -0.01 0.00 <0.001 0.00 0.00 0.01 <0.001
ART naïve 0.02 0.00 0.04 0.03 -0.01 -0.02 -0.01 <0.001
ART experienced -0.01 -0.05 0.04 0.74 0.00 -0.01 0.01 1.00
HIV uninfected 0.03 0.01 0.05 0.002 -0.02 -0.03 -0.01 <0.001
ART naïve -0.02 -0.04 0.00 0.03 0.00 -0.01 0.00 0.14
ART experienced -0.04 -0.08 0.00 0.05 0.00 0.00 0.01 0.38
HIV uninfected 0.00 -0.01 0.01 1.00 0.00 -0.01 0.00 0.27
ART naïve 0.04 0.01 0.06 0.003 -0.02 -0.03 -0.01 <0.001
ART experienced -0.02 -0.08 0.05 0.63 0.01 -0.01 0.02 0.31
HIV uninfected 0.05 0.02 0.07 <0.001 -0.02 -0.03 -0.01 <0.001
MEMORY T-CELLS
ART naïve 0.01 0.00 0.02 0.15 -0.01 -0.01 0.00 0.001
ART experienced 0.02 -0.02 0.05 0.30 -0.01 -0.01 0.00 0.08
HIV uninfected 0.02 0.00 0.03 0.01 -0.01 -0.01 0.00 0.01
ART naïve 0.00 -0.02 0.02 0.92 0.00 -0.01 0.00 0.34
ART experienced 0.00 -0.03 0.04 0.84 0.00 -0.01 0.01 0.92
HIV uninfected -0.02 -0.03 0.00 0.08 -0.01 -0.01 0.00 0.04
ART naïve 0.02 0.01 0.04 0.002 -0.01 -0.01 0.00 0.004
ART experienced 0.00 -0.02 0.03 0.76 -0.01 -0.01 0.00 0.07
HIV uninfected 0.02 0.01 0.03 0.001 -0.01 -0.01 0.00 <0.001
ART naïve 0.01 -0.01 0.03 0.20 0.00 -0.01 0.00 0.19
ART experienced -0.01 -0.05 0.02 0.39 0.00 -0.01 0.01 0.98
HIV uninfected 0.01 -0.02 0.03 0.60 -0.01 -0.02 0.00 0.01
CD45RA+
CD31+
CD45RA+
CD31+
Ki67+
95% CI 95% CI
Age CD4 percentage
NAÏVE T-CELLS
CD45RA-
CD31- Ki67+
CD45RA+
CD31-
CD45RA+
CD31- Ki67+
CD45RA-
CD31+
CD45RA-
CD31+
Ki67+
CD45RA-
CD31-
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7.5.3 Effects of age on percentage of recent thymic emigrants
In HIV-infected, ART naïve and HIV uninfected children a significant negative
correlation between age and proportion of CD4+ cells that were recent thymic
emigrants was demonstrated (p<0.001). In the smaller number of ART experienced
children there was no evidence of an association (p=0.42) - Figure 7-9.
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Figure 7-9. Effect of age on percentage of recent thymic emigrants
A) HIV-infected, ART naïve
B) HIV-infected ART experienced
C) HIV uninfected control children.
A significant inverse relationship between age and proportion of recent thymic emigrants
was demonstrated in the HIV-infected ART naïve children and the HIV uninfected control
group. No significant effect was seen in the (older) HIV-infected, ART experienced children.
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7.5.4 The relationship between markers of activation and proliferation
The degree of association between markers of activation (HLA DR and CD38) in
CD4+ and CD8+ T-cells with the total and proliferating proportions of naïve and
memory CD31+ and CD31- subpopulations was calculated, Table 7-10.
In the HIV-infected naïve and uninfected groups there were no associations
between any naïve subpopulation, or proliferation in any naïve sub-population, and
levels of activation in CD4+ and CD8+ T-cells (p>0.05). The only significant
association in the HIV-infected ART-experienced was an inverse relationship
between CD31- naive (central naïve) T-cells and activation in CD4+ T-cells
(p=0.003).
In the memory population, interestingly the most consistent significant relationship
were between CD31+ memory T-cells and activation in both CD4+ and CD8+ T-
cells in the HIV-infected naïve group (p≤0.03). ART-experienced children with higher 
proportions of CD31+ memory T-cells also had higher CD4+ activation (p=0.02).
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Table 7-10. Correlation between markers of activation (HLA DR and CD38) in
CD4+ and CD8+ T-cells with expression of Ki67 as a marker of proliferation in 4
sub-populations of CD4+ T-cells based upon their expression of CD45RA and
CD31.
r p r p
ART naïve -0.14 0.06 0.00 0.97
ART experienced -0.11 0.42 -0.10 0.43
HIV uninfected -0.09 0.20 -0.09 0.20
ART naïve -0.07 0.34 -0.08 0.27
ART experienced 0.14 0.27 -0.01 0.93
HIV uninfected -0.04 0.56 0.03 0.69
ART naïve 0.05 0.53 0.04 0.63
ART experienced -0.37 0.003 0.01 0.97
HIV uninfected -0.02 0.81 0.00 1.00
ART naïve -0.09 0.24 -0.02 0.76
ART experienced -0.19 0.14 0.10 0.43
HIV uninfected -0.05 0.42 0.07 0.33
ART naïve 0.05 0.51 -0.10 0.20
ART experienced 0.31 0.02 0.06 0.67
HIV uninfected 0.05 0.45 0.00 0.97
ART naïve 0.23 0.002 0.16 0.03
ART experienced 0.01 0.96 0.09 0.49
HIV uninfected 0.00 0.97 0.01 0.87
ART naïve 0.12 0.11 0.07 0.38
ART experienced -0.04 0.74 0.05 0.68
HIV uninfected 0.08 0.25 0.14 0.04
ART naïve 0.11 0.16 0.15 0.05
ART experienced -0.17 0.18 0.20 0.13
HIV uninfected -0.04 0.55 0.08 0.24
NAÏVE
CD45RA+
CD31+
CD45RA+
CD31+
Ki67+
CD45RA+
CD31-
CD45RA+
CD31-
Ki67+
MEMORY
CD4+ HLA DR+
CD38+
CD8+ HLA DR+
CD38+
CD45RA-
CD31+
CD45RA-
CD31+
Ki67+
CD45RA-
CD31-
CD45RA-
CD31-
Ki67+
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7.5.5 Relationship between immunophenotyping data, vascular
function and biomarkers.
Associations between immunophenotyping data, biomarkers, viral load, IMT and
PWV were investigated in each group (ART naïve, ART experienced and HIV
uninfected) at baseline using univariable Spearman correlation coefficients.
ART naive
All correlations between the immunophenotyping data and biomarkers, viral load,
age, IMT or PWV were <0.35 in magnitude. As illustrated in Figure 7-10, significant
correlations exist at baseline between:
 The 2 markers of activation CD4+ HLADR+ CD38+ and CD8+ HLADR+
CD38+ (correlation coefficient r=0.71).
 Within the population of proliferating CD4+ cells, the proportion of CD45RA-
CD31-Ki67+ cells positively correlated with the total proportion of
proliferating memory cells (r=0.9), the total proportion of proliferating naïve
cells (r=0.54) and to a lesser extent the proportion of CD45RA+CD31+Ki67+
cells (r=0.38).
 The proportion of total CD4+ memory cells that were proliferating was
significantly correlated with the proportion of naïve cells that were
proliferating (r=0.51) and the percentage of CD4+CD45RA+CD31+Ki67+
cells (r=0.4).
 The proportion of CD4+ naïve proliferating cells was significantly correlated
with the CD4+CD45RA+CD31+Ki67+ population (r=0.8).
The ratio of CD4:CD8 had a significant negative correlation with the total proportion
of proliferating naïve cells (r=-0.59), all other correlations were <0.35. Relationships
between age, viral load and biomarkers were as described in chapter 6.
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Figure 7-10. Relationship between immunophenotyping, biomarkers, viral load,
age, IMT and PWV at baseline in ART naïve HIV-infected children.
In the correlation matrix (A) the strength of positive relationships are demonstrated using
blue scale and negative correlations on the red scale. In the nodal diagram (B)
relationships with a spearman correlation of >0.35 are demonstrated, positive correlations
shown in green and negative correlations in red.
AN2, ANG2:1, ratio of angiopoietin-2:1 CD4, CD4:CD8, CDC, CD3+CD8-HLA DR+ CD38+,
CHC, CD3+CD8+HLA DR+ CD38+, CRP, C reactive protein; DD, d-dimer; IL-10,
interleukin-10; IL-6, interleukin-6; SI, IMT, intimal medial thickness; Mmp, proportion of
memory cells that are proliferating; naïve prolif, proportion of naïve cells that are
proliferating PWV, pulse wave velocity; sICAM, soluble intracellular adhesion molecule;
VCA, soluble vascular cell adhesion molecule-1; VL, viral load;
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ART experienced
As illustrated in Figure 7-11, similar to the patterns seen in ART naïve children
significant correlations exist between:
 the 2 markers of activation CD4+ HLADR+ CD38+ and CD8+ HLADR+
CD38+ (r=0.68),
 CD4+CD45RA-CD31-Ki67+ cells and the total proportion of proliferating
CD4+ memory cells (r=0.78)
 CD4+CD45RA+CD31+Ki67+ and the total number of naïve CD4+ cells that
were proliferating (r=0.7)
Interestingly there were no significant correlation between immunophenotyping data,
IMT, PWV and age (r all≤0.35). 
Within this group stronger correlations were seen between some
immunophenotyping data and the biomarkers
 The proportion of proliferating CD4+ naïve cells had an inverse relationship
with the Angiopoietin 2:1 ratio (r=-0.38)
 The proportion of CD4+CD45RA-CD31-Ki67+ was inversely correlated with
IL-10 (r=-0.42) and positively correlated with d-dimer (r=0.37)
 The proportion of proliferating CD4+ memory cells was negatively correlated
with IL-10 (r=-0.36) and positively correlated with sICAM (r=0.37) and d-
dimer (r=0.46)
 The CD4:8 ratio was positively correlated with IL-10 (r=0.46)
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Figure 7-11. Relationship between immunophenotyping, biomarkers, viral load,
age, IMT and PWV at baseline in ART experienced HIV-infected children.
In the correlation matrix (A) the strength of positive relationships are demonstrated using
blue scale and negative correlations on the red scale. In the nodal diagram (B) relationships
with a spearman correlation of >0.35 are demonstrated, positive correlations shown in
green and negative correlations in red.
AN2, = ANG2:1, ratio of angiopoietin-2:1 CD4, CD4:CD8, CDC, CD3+CD8-HLA DR+
CD38+, CHC, CD3+CD8+HLA DR+ CD38+, CRP, C reactive protein; DD, d-dimer; IL-10,
interleukin-10; IL-6, interleukin-6; SI, IMT, intimal medial thickness; Mmp, proportion of
memory cells that are proliferating; naïve prolif, proportion of naïve cells that are
proliferating PWV, pulse wave velocity; sICAM, soluble intracellular adhesion molecule;
VCA, soluble vascular cell adhesion molecule-1; VL, viral load;
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HIV uninfected controls
As illustrated in Figure 7-12, interestingly similar to the patterns seen in ART naïve
and experienced children significant correlations exist between:
 the 2 markers of activation CD4+HLADR+CD38+ and CD8+HLADR+CD38+
(r=0.72)
 CD4+CD45RA-CD31-Ki67+ cells and the total proportion of proliferating
CD4+ memory cells (r=0.68)
 CD4+CD45RA+CD31+Ki67+ and the total number of CD4+ naïve cells that
were proliferating (r=0.89)
 No significant correlation between immunophenotyping data, IMT, PWV and
age (r all ≤0.35) 
Additionally some associations seen only in naïve children were also seen in the
HIV uninfected controls:
 CD4+CD45RA-CD31-Ki67+ cells were positively correlated with
CD4+CD45RA+CD31+Ki67+ (r=0.52) and the total proportion of CD4+ naïve
proliferating cells (r=0.57)
 CD4:8 ratio was negatively associated with the total proportion of CD4+
naïve proliferating cells (r=-0.57)
Finally significant negative associations were observed between the CD4:8 ratio and
CD4+CD45RA-CD31-Ki67+ / CD4+CD45RA+CD31+Ki67+ cells (r =-0.48/-0.54) in
the HIV uninfected group only.
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Figure 7-12. Relationship between immunophenotyping, biomarkers, viral load,
age, IMT and PWV at baseline in HIV-uninfected children.
In the correlation matrix(A) the strength of positive relationships are demonstrated using
blue scale and negative correlations on the red scale. In the nodal diagram (B)
relationships with a spearman correlation of >0.35 are demonstrated, positive correlations
shown in green and negative correlations in red.
AN2, = ANG2:1, ratio of angiopoietin-2:1 CD4, CD4:CD8, CDC, CD3+CD8-HLA DR+
CD38+, CHC, CD3+CD8+HLA DR+ CD38+, CRP, C reactive protein; DD, d-dimer; IL-10,
interleukin-10; IL-6, interleukin-6; SI, IMT, intimal medial thickness; Mmp, proportion of
memory cells that are proliferating; naïve prolif, proportion of naïve cells that are
proliferating PWV, pulse wave velocity; sICAM, soluble intracellular adhesion molecule;
VCA, soluble vascular cell adhesion molecule-1; VL, viral load;
293
7.5.6 Does duration of ART influence markers of activation and
proliferation?
Looking just at the HIV-infected, ART experienced children no relationship between
age at starting ART and markers of activation on CD4+ and CD8+ T-cells was seen
(p=0.47/0.35). A significant inverse relationship between levels of both CD4+ and
CD8 HLA DR+ CD38+ cells and duration on ART was demonstrated (p=0.03 / 0.01)
- Figure 7-13. Comparing age at starting ART and duration on ART with the levels of
proliferating CD4+ subpopulations in the HIV-infected, ART experienced children, no
significant relationship was identified with age at starting ART (all p≥0.56), whereas 
the effect of duration on ART persisted.
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Figure 7-13. The relationship between duration of ART and markers of activation
on CD4+ and CD8+ T-cells.
A significant relationship between markers of activation and duration on ART is
demonstrated in both CD4+ and CD8+ T-cells.
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7.5.7 Can T-cell activation or proliferation predict baseline markers of
cardiovascular structure and arterial stiffness?
Not all children had both baseline IMT / PWV and activation / proliferation panels
available. As summarised in Table 7-11 the following calculations were performed
on the 60 – 84% of children with both measurements available.
For IMT in HIV infected, ART naïve and controls 3 variables
(CD4+CD45RA+CD31+, CD4+CD45RA+CD31-Ki67+ and CD4+CD45RA-CD31-
added significant (p≤0.03) prognostic information to the previous model including 
total cholesterol, age, site plus case/control status (section 5.5.3) when included one
at a time. Including these three together showed that only CD4+CD45RA+CD31+
and CD4+CD45RA+CD31-Ki67+ were independent predictors. The effects of age,
total cholesterol, site and case/control were unchanged but IMT was independently
higher in children with greater CD4+CD45RA+CD31+ and CD4+CD45RA+CD31-
Ki67+ Table 7-12.
Total recruited 208 209 74 75
Baseline IMT (% total) 145 (70%) 167 (80%) 72 (97%) 67 (89%)
Baseline PWV (% total) 141 (68%) 155 (74%) 73 (99%) 75 (100%)
Baseline DR (% total) 177 (85%) 162 (78%) 60 (81%) 62 (83%)
Baseline Ki67 (% total) 187 (90%) 161 (77%) 60 (81%) 63 (84%)
Patients with both baseline IMT and
activation (DR) panel (% total) 127 (61%) 135 (65%) 59 (80%) 56 (75%)
Patients with both baseline IMT and
proliferation (Ki67) panel (% total) 129 (62%) 136 (65%) 59 (80%) 57 (76%)
Patients with both baseline PWV and
(activation (DR) panel (% total) 124 (60%) 130 (62%) 60 (81%) 62 (83%)
Patients with both baseline PWV and
proliferation (Ki67) panel (% total) 126 (61%) 129 (62%) 60 (81%) 63 (84%)
HIV+ ART naïve
(group 1)
HIV- controls
matched to group 1
HIV+ ART
experienced (group
2)
HIV- controls
matched to group 2
Table 7-11. Summary of available cardiovascular, activation and proliferation
results by group
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For IMT in HIV infected, ART experienced and controls 1 variable (CD4+CD45RA-
CD31+Ki67+ added significant (p=0.01) prognostic information to the previous
model including weight for age, age, site plus case/control status (section 5.5.3).
Adding the effect of CD4+CD45RA-CD31+Ki67+ the effects of age, weight for age,
site and case/control were unchanged but IMT was independently lower in children
with a greater proportion of CD4+CD45RA-CD31+Ki67+ cells, Table 7 12.
Estimate of
impact on IMT
(mm)
p value
Mean at reference category + 0.452 ( + 0.426 : + 0.478 ) <0.001
Total cholesterol (per 1 mmol/L
higher) - 0.005 ( -0.009 : - 0.001 ) 0.01
HIV-infected case vs uninfected
control + 0.010 ( + 0.020 : + 0.004 ) 0.04
Site (UTH vs JCRC) - 0.012 ( + 0.025 : + 0.001 ) 0.08
Age (per 1 year older) - 0.001 ( - 0.004 : + 0.001 ) 0.22
CD45RA+ CD31+ + 0.0004 ( + 0.0001 : + 0.001 ) 0.01
CD45RA+ CD31+ Ki67+ + 0.003 ( + 0.0004 : + 0.005 ) 0.02
Mean at reference category + 0.480 ( + 0.445 : + 0.514 ) <0.001
HIV-infected case vs uninfected
control + 0.026 ( + 0.004 : + 0.048 ) 0.01
Weight-for-age in cases (per 1 unit
higher) + 0.010 ( + 0.0004 : + 0.019 ) 0.04
Weight-for-age in controls (per 1
unit higher) + 0.002 ( - 0.010 : + 0.006 ) 0.64
Site (UTH vs JCRC) - 0.003 ( -0.017 : + 0.012 ) 0.72
Age (per 1 year older) + 0.001 ( - 0.003 : + 0.004 ) 0.80
CD45RA- CD31+ Ki67+ - 0.002 ( -0.004 : 0.000 ) 0.01
95% CI
Naïve & controls
Experienced & controls
Reference category = age 0 and total cholesterol 0. IMT, Intimal Medial Thickness; JCRC, Joint Clinical
Research Centre, Kampala; UTH, University Teaching Hospital, Lusaka;
Table 7-12. Final multivariable models for baseline IMT including the addition of
immunophenotyping data.
297
7.6 Longitudinal changes in markers of activation and proliferation
7.6.1 Activation
As summarised in Table 7-13 and illustrated in Figure 7-14 significant changes
occurred in total lymphocytes, CD4+ and CD8+ activated (HLA DR+ CD38+) T-cells
percentages and the ratio of CD4 to CD8 over 96 weeks in the children who were
ART naïve at baseline. Lymphocytes and the CD4:CD8 ratio increased over the 96
weeks whilst the markers of activation fell (all p<0.001). The children who were ART
experienced at baseline had a significant increase in the percentage of lymphocytes
(p<0.001) whilst no significant change in the proportion of activated CD4+ and CD8+
T-cells were seen (p≥0.25). By 96 weeks absolute levels of activated CD4+ and 
CD8+ T-cells in HIV-infected naïve children (initiating ART) were similar to those in
ART-experienced children and HIV-uninfected controls at baseline.
Table 7-13. Changes in markers of activation and CD4:CD8 ratio over 96 weeks
by group.
No Median No Median No Median
1 177 26.6 ( 17.7 :34.9 ) 161 31.6 ( 20.2 : 41.1 ) 141 37.1 ( 27.2 : 44.9 ) <0.001
2 60 31.1 ( 26.1 :37.1 ) 61 36.7 ( 29.4 : 41.3 ) 63 40.5 ( 33.9 : 50.6 ) <0.001
1 177 4.2 ( 1.9 :8.0 ) 161 1.1 ( 0.5 : 2.2 ) 141 1.3 ( 0.8 : 2.4 ) <0.001
2 60 0.8 ( 0.4 :1.6 ) 61 0.6 ( 0.3 : 1.0 ) 63 1.1 ( 0.6 : 2.0 ) 0.79
1 177 12.1 ( 6.7 :20.4 ) 161 3.3 ( 1.4 : 6.1 ) 141 3.6 ( 2.2 : 7.1 ) <0.001
2 60 2.9 ( 1.5 :4.8 ) 61 2.7 ( 1.1 : 4.1 ) 63 2.9 ( 1.8 : 5.3 ) 0.91
1 177 0.4 ( 0.2 :0.7 ) 161 1.0 ( 0.6 : 1.5 ) 141 1.1 ( 0.6 : 1.7 ) <0.001
2 60 0.8 ( 0.6 :1.4 ) 61 1.1 ( 0.7 : 1.2 ) 63 0.9 ( 0.7 : 1.3 ) 0.25
Log10 values used to calculatechanges over time. Wilcoxon paired test to look at change over 96 weeks, Kruskal Wallis used to calculate
difference between arms
Difference
between
logweek 96
and log
week 0
CD4:CD8
Lymphocytes
(% of total
white cells)
% of CD4+
expressing
HLA DR+
CD38+
IQR IQR IQR
Group
Week 0 Week 48
% CD8+
expressing
HLA DR+
CD38+
Week 96
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Figure 7-14. Changes in lymphocytes, markers of activation and CD4:CD8 ratio
over 96 weeks by ART naïve vs experienced at enrolment and by randomised
NRTI.
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7.6.2 Proliferation
Results are summarised in Table 7-14 and illustrated in Figure 7-15 and 7-16.
Table 7-14. Changes in naïve and memory CD4+ T-cells and markers of
proliferation over 96 weeks.
No Median No Median No Median
1 187 6.4 ( 3.9 9.2 ) 157 1.8 ( 1.1 3.3 ) 150 2.2 ( 1.2 3.9 ) <0.001
2 60 3.6 ( 2.7 4.7 ) 63 2.6 ( 1.7 3.9 ) 62 2.9 ( 1.8 3.9 ) <0.001
1 187 57.9 ( 46.6 67.8 ) 157 68.7 ( 60.6 74.8 ) 150 69.6 ( 61.2 74.7 ) <0.001
2 60 59.0 ( 52.0 68.0 ) 63 63.9 ( 57.4 70.0 ) 62 64.4 ( 55.2 69.1 ) 0.01
1 187 3.4 ( 1.6 6.5 ) 157 1.2 ( 0.7 2.9 ) 150 1.3 ( 0.7 2.9 ) <0.001
2 60 2.3 ( 1.5 4.4 ) 63 2.4 ( 1.0 4.1 ) 62 3.2 ( 0.8 5.7 ) 0.14
1 187 48.4 ( 38.1 59.9 ) 157 59.1 ( 51.8 65.7 ) 150 59.8 ( 51.9 65.4 ) <0.001
2 60 51.2 ( 44.1 59.6 ) 63 56.0 ( 51.2 62.0 ) 62 53.6 ( 47.6 61.2 ) 0.07
1 187 1.4 ( 1.0 :2.4 ) 157 0.8 ( 0.4 : 1.4 ) 150 0.6 ( 0.4 : 1.5 ) <0.001
2 60 1.2 ( 0.8 :1.5 ) 63 1.3 ( 0.6 : 2.5 ) 62 1.6 ( 0.5 : 2.7 ) 0.82
1 187 8.1 ( 4.6 11.8 ) 157 8.6 ( 6.0 11.7 ) 150 8.7 ( 6.7 12.2 ) <0.001
2 60 5.3 ( 3.6 8.0 ) 63 7.1 ( 5.1 9.5 ) 62 7.1 ( 4.7 12.4 ) 0.003
1 187 1.6 ( 0.5 :4.1 ) 157 0.6 ( 0.1 : 1.2 ) 150 0.6 ( 0.2 : 1.5 ) <0.001
2 60 1.1 ( 0.6 :2.6 ) 63 0.8 ( 0.3 : 2.0 ) 62 1.1 ( 0.3 : 3.1 ) 0.68
1 187 41.8 ( 32.2 50.4 ) 157 30.9 ( 25.2 38.2 ) 150 30.5 ( 25.3 38.1 ) <0.001
2 60 40.5 ( 31.6 47.4 ) 63 35.5 ( 30.0 42.6 ) 62 35.3 ( 30.7 43.8 ) 0.003
1 187 23.2 ( 15.9 31.9 ) 157 6.9 ( 3.4 12.4 ) 150 9.1 ( 4.2 15.1 ) <0.001
2 60 12.7 ( 9.7 15.6 ) 63 9.8 ( 6.6 13.8 ) 62 10.3 ( 6.4 12.7 ) 0.003
1 187 16.9 ( 11.6 22.6 ) 157 9.4 ( 6.8 13.7 ) 150 5.9 ( 3.7 11.7 ) <0.001
2 60 17.0 ( 9.9 22.6 ) 63 11.6 ( 6.7 17.4 ) 62 9.5 ( 5.3 19.6 ) <0.001
1 187 11.9 ( 7.3 :16.1 ) 157 3.7 ( 1.7 : 6.2 ) 150 4.4 ( 1.8 : 7.1 ) <0.001
2 60 5.6 ( 4.1 :7.5 ) 63 4.8 ( 3.1 : 6.9 ) 62 4.5 ( 2.8 : 6.3 ) 0.02
1 187 22.7 ( 13.3 .33.4 ) 157 20.9 ( 15.1 27.2 ) 150 23.3 ( 17.7 28.6 ) 0.01
2 60 23.2 ( 16.9 27.8 ) 63 23.9 ( 16.9 29.2 ) 62 23.2 ( 17.3 30.7 ) 0.79
1 187 11.9 ( 7.2 :16.6 ) 157 3.4 ( 1.3 : 6.7 ) 150 4.8 ( 1.9 : 8.1 ) <0.001
2 60 6.4 ( 5.0 :8.2 ) 63 5.2 ( 2.9 : 6.4 ) 62 4.9 ( 2.9 : 7.1 ) 0.01
Difference
between
logweek 96
and log
week 0
IQR IQR IQR
Markers of proliferation in CD4+ T-cells
Group
Week 0 Week 48 Week 96
Naïve cells
% CD4+
CD45RA+
CD31+ (Q2)
% CD4+
CD45 RA+
Ki67+
% CD4+
CD45 RA+
% CD4+
Ki67+
Log10 values used to calculate changes over time. Wilcoxon paired test to look at change over 96 weeks, Kruskal Wallis used to calculate
difference between arms. Group 1: ART naïve at baseline Group 2: ART experienced at baseline
Memory cells
% CD4+
CD45RA-
CD31+ (Q1)
% CD4+
CD45RA+
CD31- Ki67+
% CD4+
CD45RA+
CD31- (Q3)
% CD4+
CD45RA+
CD31+ Ki67+
% CD4+
CD45 RA-
% CD4+
CD45 RA-
Ki67+
%CD4+
CD45RA-
CD31-
%CD4+ CD45
RA- CD31+
Ki67+
% CD45RA-
CD31-(Q4)
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Total CD4+ T-cell proliferation
A significant decrease in the proportion of proliferating CD4+ T-cells was observed
over 96 weeks in both children who were ART naïve and experienced at baseline
(p<0.001) - Figure 7-15 A and B – with the decrease predominantly occurring by 48
weeks in both groups.
Total naïve cells
A significant increase in naïve CD4+ T-cells was observed over 96 weeks in both
children who were ART naïve and ART experienced at baseline (p≤0.01), with most 
of the increase by 48 weeks. In ART naïve children a significant reduction in the
proportion of proliferating CD4+ T-cells was seen 48 weeks after starting ART
(p<0.001), a decrease that was maintained until 96 weeks. In contrast, in ART
experienced children a further 96 weeks of ART did not significantly affect the
proportion of proliferating cells (p=0.14 compared to baseline) - Figure 7-15 C - F.
Naïve CD4+ CD31 subpopulations
A significant increase was seen in the CD45RA+ CD31+ subpopulation by 48 weeks
after commencing ART in the ART naïve children, together with a significant
reduction in the proportion of this population that were proliferating, changes that
were maintained to 96 weeks (p<0.001 versus baseline). In contrast, there were no
significant changes in the proportion of RTEs nor the level of proliferation within the
ART experienced group following a further 96 weeks of ART (p≥0.07) - Figure 7-16 
A - D.
Within the CD31- subpopulation (central naïve cells) significant increases were seen
in both ART naïve and ART experienced children after 96 weeks of ART (p≤0.003). 
A significant fall in the proportion of proliferating central naïve cells was seen by
week 96 in the ART naïve children (p<0.001) whilst no significant change in the
proportion of proliferating central naïve cells was seen in the ART experienced
group (p=0.68) - Figure 7-16 E - H. Data is also presented by NRTI randomisation
arm which will be discussed in further detail in section 7.7.
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Figure 7-15. Changes in total proliferating CD4+ T-cells and proportions of naïve
CD4+ cells over 96 weeks.
Effect of baseline group (ART naïve v ART experienced) demonstrated and effect of
NRTI randomisation arm (d4T v ZDV v ABC).
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Figure 7-16. Changes proportions of naïve CD4+ T-cells subpopulations over 96
weeks
Effect of baseline group (ART naïve v ART experienced) demonstrated and effect
of NRTI randomisation arm (d4T v ZDV v ABC).
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Total memory CD4+ T-cells
Significant reductions in the proportion of total memory CD4+ T-cells and
proliferating memory cells was demonstrated in both ART naïve and ART
experienced children after 96 weeks on ART (p≤0.02) - Figure 7-17. Levels at 96 
weeks were similar to the control groups.
Memory CD4+ CD31 subpopulations
A significant decrease in the total CD31+ memory cell population was seen over 96
weeks in both ART naïve and ART experienced children accompanied by a
significant decrease in the proportion of this population that was proliferating
(p≤0.003) - Figure 7-18 A - D. 
In the CD31- memory population a significant increase was demonstrated by week
96 in the ART naïve group (p=0.01) whilst no significant difference was seen over
96 weeks in the ART experienced group (p=0.79). However, both ART naïve and
ART experienced children had significant reductions in the proportion of CD31-
memory T-cells that were proliferating over 96 weeks (p≤0.01) - Figure 7-18 E - H. 
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Figure 7-17. Change in total and proliferating memory CD4+ T-cells over 96
weeks
Effect of baseline group (ART naïve v ART experienced) demonstrated and
effect of NRTI randomisation arm (d4T v ZDV v ABC).
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Figure 7-18. Changes in proportions of memory CD4+ T-cells subpopulations
over 96 weeks
Effect of baseline group (ART naïve v ART experienced) demonstrated and effect
of NRTI randomisation arm (d4T v ZDV v ABC).
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7.7 Impact of NRTI regimen on changes in immunophenotyping data
Adjusted regression analysis was used to investigate the effect of randomized NRTI
on mean change in the immunophenotyping markers over 48 and 96 weeks. The
numbers of children overall and by group who had complete data at baseline and
weeks 48 and 96 is summarised in Table 7-15.
As overall changes in each IPT subpopulation were broadly similar in naïve and
experienced children (figures 7-12 to 7-15) I pooled both groups to gain the greatest
power to detect any differences between randomized NRTI. I then checked that this
pooled analysis had not masked detrimental effects of randomized NRTI according
to whether the child was naïve or experienced by testing for significant interactions
between randomized NRTI and naïve / experienced strata. All models included the
baseline IPT variable as a factor to adjust for regression to the mean effects.
Activation
panel (DR)
Proliferation
panel (Ki67)
153 157
d4T arm 47 51
ZDV arm 54 55
ABC arm 52 51
110 114
d4T arm 35 38
ZDV arm 35 37
ABC arm 40 39
43 43
d4T arm 12 13
ZDV arm 19 18
ABC arm 12 12
ABC, abacavir; d4T, stavudine; ZDV, zidovudine;
Overall Group 1 and 2
ART naïve at baseline
(group 1)
ART experienced at
baseline (group 2)
Total
Total
Total
Table 7-15. Summary of patients who had complete immunophenotyping data
at baseline, week 48 and week 96.
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Of 26 IPT markers compared at two time-points (52 models), I found only one
interaction p-value <0.05 (Table 7-16). Therefore there is no evidence that pooling
naïve and experienced groups is masking genuine differences between randomized
NRTIs.
Considering these pooled (main effects) models, if there were no differences
between randomized NRTI groups I would expect 26 IPT markers explored at 2 time
points to have 26*2*0.05= 2.6 global tests of differences between NRTI to have a
p<0.05 and 26*2*0.1=5.2 tests to have a p<0.1 just by chance.
In fact three global tests were p<0.05 (Table 7-16); the percentage of
CD4+CD45RA+CD31+Ki67+ cells at 48 and 96 weeks (global p=0.05/0.01), and the
percentage CD4+CD45RA-CD31+Ki67+ cells at 48 weeks (global p=0.04). There
was no consistent evidence of a difference between randomized groups in change
in any of the immunophenotyping markers from baseline to week 48 or 96 adjusting
for site, age and baseline immunophenotyping marker. Given the multiple tests
performed it is likely that the results are a reflection of multiple testing rather than
genuine differences.
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Table 7-16. Results (p-values) of adjusted regression analysis to investigate effects
of randomised NRTI on change in immunophenotyping markers over 48 and 96
weeks.
Randomised NRTI comparisons from a main effects model: interaction model also fitted to
check for effect modification by ART naïve vs experienced group. In the interaction model
columns, p-values for modification by ZDV (vs d4T) and ABC (vs d4T) are shown
Global
test
d4T v
ZDV
d4T v
ABC
ZDV v
ABC
Global
test
d4T v
ZDV
d4T v
ABC
ZDV v
ABC
Lymphocytes 0.30 0.96 0.19 0.17 0.57 0.29 0.62 0.55
% CD3+ 0.72 0.44 0.84 0.57 0.43 0.26 0.98 0.26
% CD4+ 0.95 0.75 0.82 0.93 0.84 0.69 0.89 0.57
% CD3+ CD8+ 0.75 0.45 0.80 0.62 0.99 0.91 0.97 0.94
CD4:CD8 0.69 0.73 0.62 0.40 0.98 0.91 0.94 0.85
% CD4+ DR- CD38+ (Q1) 0.36 0.42 0.54 0.15 0.19 0.71 0.46 0.96
% CD4+ DR+ CD38+ (Q2) 0.63 0.35 0.52 0.77 0.92 0.75 0.98 0.72
% CD4+ DR+ CD38- (Q3) 0.07 0.18 0.36 0.02 0.26 0.43 0.10 0.38
% CD4+ DR- CD38- (Q4) 0.67 0.77 0.57 0.38 0.47 0.85 0.35 0.25
% CD8+ DR- CD38+ (Q1) 0.68 0.83 0.40 0.53 0.21 0.11 0.15 0.86
% CD8+ DR+ CD38+ (Q2) 0.08 0.05 0.91 0.06 0.99 0.90 1.00 0.90
% CD8+ DR+ CD38- (Q3) 0.89 0.97 0.66 0.69 0.24 0.23 0.10 0.65
% CD8+ DR- CD38- (Q4) 0.65 0.41 0.96 0.44 0.50 0.95 0.33 0.29
Markers of proliferation in CD4+ T-cells
% CD4+ Ki67+ 0.07 0.03 0.09 0.63 0.15 0.06 0.49 0.22
% CD45 RA+ 0.10 0.83 0.08 0.05 0.77 0.55 0.97 0.52
% CD45 RA+ Ki67+ 0.36 0.47 0.50 0.15 0.42 0.32 0.84 0.22
% CD45RA+ CD31+ (Q2) 0.12 0.92 0.09 0.06 0.89 0.63 0.80 0.81
% CD45RA+ CD31+ Ki67+ 0.05 0.09 0.50 0.02 0.01 0.16 0.14 0.004
% CD45RA+ CD31- (Q3) 0.58 0.91 0.41 0.34 0.84 0.66 0.90 0.57
% CD45RA+ CD31- Ki67+ 0.86 0.79 0.58 0.76 0.51 0.25 0.46 0.67
% CD45 RA- 0.13 0.47 0.05 0.19 0.10 0.08 0.88 0.05
% CD45 RA- Ki67+ 0.04 0.01 0.41 0.09 0.19 0.08 0.62 0.2
% CD45RA- CD31+ (Q1) 0.33 0.83 0.25 0.17 0.68 0.99 0.46 0.44
% CD45RA- CD31+ Ki67+ 0.07 0.02 0.12 0.48 0.37 0.16 0.45 0.51
% CD45RA- CD31-(Q4) 0.75 0.46 0.79 0.64 0.22 0.16 0.86 0.11
% CD45RA- CD31- Ki67+ 0.06 0.02 0.46 0.11 0.16 0.09 0.88 0.12
CD4
CD8
Naïve cells
Memory cells
Week 48 Week 96
General
Markers of activation
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7.8 Discussion
7.8.1 Activation
I have demonstrated, as others have previously found, a reduction in the proportion
of activated T-cells expressing CD4+ HLA DR+ CD38+ and CD8+ HLA DR+ CD38+
with the use of ART in HIV-infected children [463-465]. I did not find any significant
correlation between these as markers of activation and viral load, age, CD4 count,
CD4 percentage or CD4 z score, this is in contrast with the findings of a smaller
Spanish paediatric study that found levels of HLA DR CD38 correlated with viraemia
[439]. Whilst no significant relationship between age at baseline or age at starting
ART existed, duration of ART did prove to be inversely related to levels of activation.
The significance of increased levels of activation were described in a study of
Ugandan HIV-infected adults in whom higher levels of T-cell activation were
significantly associated with increased mortality [455] conversely HIV viral load
rather than degree of activation was found to be a stronger predictor of disease
progression in a different Ugandan adult cohort [466].
7.8.2 Relationship between activation and proliferation
When all HIV infected and uninfected children at baseline were looked at a
significant relationship between increasing activation (CD4+ and CD8+ HLA DR+
CD38+) and higher levels of proliferating CD4+ CD45RA- CD31+ and CD4+
CD45RA- CD31- T-cells was demonstrated. This was also seen when the ART
naïve children were looked at separately but no significant relationship was seen in
the smaller group of virologically suppressed ART experienced or in the HIV-
uninfected children. The PENTA 11 study, examined the immunological and
virological consequences of planned treatment interruption (PTI). Findings of
PENTA 11 showed that in the PTI arm there was a rapid fall in the total CD4 cell in
the first 12 weeks off ART, with decreases in both naïve and memory cells.
However, the proportion of CD45RA+ and CD45RO+ CD4 cells remained constant
in both the PTI and continuous treatment arm. The increase in CD8 cells in the first
12 weeks off ART in the PTI group was predominantly due to increases in RO+
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expressing cells. PTI was associated with a rapid and sustained increase in CD4
cells expressing Ki67 and HLA-DR [318].
7.8.3 Changes in CD4 subpopulations
Throughout this thesis naïve cells have been defined by CD45RA expression; this
will include CD45RA+ CD45RO- (truly naïve cells) and a very small proportion of
primed CD45RA+ CD45RO+ cells. Work by Sefe (thesis 2012 unpublished) showed
that >99% of CD45RA+ cells expressed both CD27 and CCR7, markers of naïve
cells, suggesting that in a paediatric population the proportion of CD45RA+RO+ is
very small. Memory cells have been defined by the lack of CD45RA expression; this
will include both CD45RA-CD45RO+ and CD45RA- CD45RO- cells – the phenotype
of the later in unknown and may be a population of apoptotic cells derived from
memory cells [467] or contamination as the process to lyse HIV-infected red blood
cells can be tricky as the cells are notoriously sticky.
CD4+ T-cells fall when destruction of CD4+ cells overcomes compensatory
mechanisms that include proliferation of memory cells, increased naïve cell
production and proliferation. At birth naïve cells predominate, levels fall throughout
childhood accompanied by an increase in memory cells. In HIV a decrease in the
naïve pool is seen with advancing immunosuppression.
With advanced HIV there is an increase in memory cells, which are a rapidly
replicating population with shorter half-lives and telomeres compared to naïve cells,
and are more susceptible to apoptosis and infection by HIV. I have shown that
significantly increased numbers of memory cells are seen in both ART naïve and
experienced children with both CD31+ and CD31- sub populations being
significantly higher in HIV-infected children compared to controls. I have confirmed
previous findings that in ART naïve children there is evidence that compensatory
mechanisms continue to operate as evidenced by increased Ki67 expression on
CD45RA- (memory) cells with declining CD4 count [318].
In adults commencing ART is associated with a redistribution of memory cells
followed later by an increase in naïve cell production [319] whilst immune
reconstitution of CD4+ T cells in HIV-infected children following the commencement
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of ART follows a different pattern characterized by an early and sustained increase
in naïve cells [47, 48, 465].
7.8.4 Recent thymic emigrants
CD45RA+ CD31+ T-cells are often referred to as recent thymic emigrants (RTE)
[468, 469]. Similar to other findings I have shown that the proportion of RTEs
decreased with age in HIV uninfected individuals and HIV-infected, ART naïve
children [470]. I have also shown a significantly lower proportion of recent thymic
emigrants in ART naïve children compared to their uninfected controls but the RTEs
have higher levels of proliferation. HIV-infected children stable on ART have similar
proportions of RTEs to their control group complementary to findings by Vrisekoop
et al who demonstrated after 4 years on ART proportions of RTEs were similar
between HIV-infected and uninfected controls [471]. I have shown that absolute
CD4 counts are positively associated with a higher proportion of RTEs suggesting it
is important to maintain naïve cell production to maintain CD4. Data from the
ARROW study has shown that the proportion of naïve CD31+ cells prior to
commencing ART is an important indicator of eventual immune recovery [472].
RTEs by virtue of their telomere length and telomerase activity are believed to have
a very limited replicative ability [473] which is supported by my findings that only a
very small proportion of RTE are actively proliferating. In healthy individuals <5%
cells express Ki67.
The thymus is crucial in immune recovery and determining the ratio of naïve to
memory cells. Thymic volume in HIV infected children is positively correlated with
naïve CD4+ T-cells and inversely correlated with viral load [474]. Age adjusted
thymic output is reduced in HIV-infected children; early ART can maintain thymic
output and a longer duration on ART is associated with increased thymic output in
children [475]. Higher thymic output is important for the reconstitution of naïve T-
cells [476] however severe T-cell depletion at ART initiation in HIV infected children
limits the ability for immune recovery [17, 477, 478].
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7.8.5 Central naïve cells
CD31- naïve cells represent a population with lower TREC content in which CD31
expression is decreased in response to homeostatic expansion [470]. A model has
been proposed of CD4 homeostasis whereby RTE in the periphery respond to
antigen, proliferate and differentiate into central naïve cells (CD45RA+CD31-) to
compensate for falling thymic output [470]. I have shown that the proportions of
these CD45RA+ CD31- cells are significantly lower in HIV-infected ART
experienced children compared to their control groups. A trend towards lower levels
in ART naïve children compared to controls was seen but was not significant. Less
work has focused upon this sub population of T-cells; differences in adult
populations are subtle, are unaffected by age and it appears the proportion remains
fairly constant. They may have a suppressor role further contributing to the immune
dysregulation in HIV [479].
7.8.6 Vascular structure and arterial stiffness
As presented in section 7.5.7 higher levels of 2 variables (CD4+ CD45RA+CD31+
and CD4+ CD45RA+ CD31-Ki67+) in HIV infected ART naïve and HIV uninfected
controls were independent predictors of an increase in IMT. In HIV infected, ART
experienced higher proportions of CD4+ CD45RA-CD31+Ki67+ were associated
with a thinner IMT. Previously published findings have shown mixed results, in one
study in both ART naïve and experienced HIV-infected women higher T-cell
activation levels significantly predicted carotid artery stiffness as measured by
ultrasound assessment of atrial distension [480]. However no significant relationship
between markers of immune activation and changes in IMT have been seen in other
studies [245, 450, 451].
7.9 Conclusions and future work
Considerable heterogeneity exists within the immunophenotyping results; some ART
naïve children are coping well before the introduction of ART with high levels of
naïve cells and low levels of activation and proliferation, the opposite is true in some
virologically suppressed ART experienced children. Understanding these complex
relationships in more depth would be fascinating although fitting multiple regression
models to each marker of activation and proliferation individually would be extremely
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time consuming. A more efficient approach would be to use dimension reduction
techniques such as principal component analysis (PCA) and clustering to identify
underlying groups of children in the data, then try to characterise each group of
children in terms of other markers.
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Chapter 8 Discussion
8.1 How this study has contributed to the understanding of
paediatric HIV?
The key aims of this thesis were:
1. To determine the influence of HIV infection on vascular phenotype by
comparing HIV infected ART naïve children with HIV uninfected African
controls
2. To determine the effects of ART on vascular phenotype by comparing
children stable on ART to ART naïve about to start treatment and monitor
changes in arterial stiffness over time.
3. To gain insight into the potential mechanisms operating to mediate vascular
dysfunction
This study was conceived at a time when a large proportion of HIV infected children
were not receiving ART, the decision to start ART after the 1st year of life was based
upon immunological and clinical criteria. Since the publication of the START study
results the World Health Organisation have released updated guidelines
recommending all HIV-infected infants, children and adults commence lifelong ART
as soon as possible following diagnosis [46, 481]. As such children will commence
lifelong ART as soon as possible following diagnosis. For the majority of HIV
infected children, where effective ART is available and taken, survival into
adolescence and adulthood should be the norm however optimising effective ART
combinations to minimise toxicities remains a priority. The main findings of
CHAPAS-3 have shown that the three NRTI regimens studied were equally
successful in terms of virological suppression, CD4 cell recovery with low levels of
toxicity. The cardiovascular sub study results have added to these findings by
showing that the three treatment arms were equally effective in improving markers
of vascular structure/ arterial stiffness, biomarkers and immunophenotyping.
In chapter 5 I have addressed aims 1 and 2 by showing that even at a mean age of
2.9 years adverse changes are demonstrated in IMT and PWV compared to age
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matched HIV-uninfected children. The benefits of ART are demonstrated with the
ART experienced children in whom no significant difference in IMT and PWV was
demonstrated compared to their HIV-uninfected controls. Duration of ART was
demonstrated to be important in ART experienced children, who having been on
ART for a mean of 3.7 years, following a further 96 weeks of ART had significant
improvements in IMT. For PWV improvements were seen in ART naïve children
commencing ART but an increase in PWV was demonstrated in ART experienced
children. Unfortunately to date no data on the normal progression of PWV in healthy
African children and adolescents are available and the significant increase in PWV
over 96 weeks may be an expected age related finding regardless of HIV status.
Aim 3 was addressed in chapters 6 and 7. Originally the biomarker panels were set
up a priori to cover 3 mechanisms of damage; inflammation, disordered
thrombogenesis and cardiovascular injury/repair. All biomarkers studied were
abnormal in ART naïve compared to controls and the majority of biomarkers in ART
experienced were not restored to the levels measured in HIV uninfected controls.
Whilst vascular function appears to be improving the biomarker results were not as
straight forward. Interestingly, the biomarkers did not cluster as originally predicted
and the interplay between viral replication, chronic HIV associated inflammation and
the cumulative adverse effects of ART was complex. The biomarker and
immunophenotyping work has provided rich data on normal ranges in HIV
uninfected healthy African children upon which future work can develop.
An aim of identifying biomarkers that could be useful in predicting future
atherosclerotic risk has not resulted in any clear biomarker changes or patterns that
are predictive of measureable changes in either IMT or PWV, in contrast to other
paediatric studies that have demonstrated a relationship between higher CRP and
adverse changes in IMT [442]. Biomarkers fluctuate within an individual so it is
difficult to use them to predict an individual’s risk.
With very early diagnosis HIV-infected babies treated within a few days of birth have
been shown to have a very small pool of integrated viruses [50], have an impressive
capacity to regenerate their immunological repertoire [482, 483] and high
proportions of relatively HIV resistant naïve T-cells [484]. This population of children
offers an opportunity to investigate the potential efficacy of immune based therapies
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and possible treatment interruption strategies. Understanding the dynamics of
biomarker changes is one way in which these could potentially be utilized in guiding
which seronegative HIV infected children could undergo treatment interruption
strategies [485].
In chapter 4 I described the methods used to set up an African study of young
children in resource limited settings. This is the largest study within a population with
a high HIV burden and limited ART options. No studies had previously been
published that included a sizeable proportion of children under the age of 5 years
due to the belief that young infants and children would either be unable to tolerate
the measurement of IMT and PWV or that anatomically their necks were too short.
This study has shown that both are possible within this age group.
8.2 Strengths and limitations of the study
This was a prospective study with a significant and carefully matched control group
that helped to ascertain the impact of HIV infection against a background risk of
confounders such as for example co-infections and malnutrition. Studying vertically
infected children allowed accurate dating of the time of infection. Within the
population studied no child was obese; obesity has independent effects on markers
of inflammation [438]. The confounding impact of different ART regimens has been
limited by studying children on a limited number of ART regimens and with no use of
PIs, which have been associated with metabolic derangement [486].
This is the first study to provide data from an African setting. Comparisons with
Northern America and Europe studies must be interpreted with caution given the
heterogeneous array of ART prescribed, differing prevalence of obesity and also the
increased risk of vitamin D deficiency that may affect levels of immune activation
within American / European cohorts [487]. Co-infections such as CMV and TB are
commoner in an African setting and clear relationships between CMV infection and
abnormalities in markers of inflammation are described [488].
Whilst this study has added to the understanding of IMT and PWV changes in HIV
infected children compared to HIV uninfected children, deficiencies in our knowledge
persist such as the natural progression of IMT / PWV changes in HIV infected ART
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naïve children who do not commence ART. Given the current WHO guidelines all
HIV infected children should be commenced immediately on ART, this question is
unlikely to ever be answered. The control group provided important information and
normative data but due to the difficulty recruiting controls, the number of staff
available for repeat visits and financial limitations, the controls were only assessed
at a single time point. The parameters measured had not been studied in this or
similar populations previously so the data was used to devise population norms. It is
of regret that is was not possible to collect longitudinal cardiovascular data to start to
understand the natural progression of IMT and PWV in healthy HIV uninfected
African controls.
8.3 Recommendations for future research
The findings presented within this thesis support the current WHO guidelines, to
treat all HIV infected children early regardless of immunological or clinical status in
that early and persistent treatment does make biological sense. As summarised in a
recently published personal view, children have a greater risk of morbidity and
mortality yet the greatest potential for recovery with early and prolonged ART [485].
Longer term follow up is needed with the growing cohort of HIV infected children
who receive very early and prolonged ART however the normal changes in IMT,
PWV and biomarkers in healthy HIV non infected children over time must be
understood in order for results to be put into context.
In chapter 5 a surprising result that an increase in total cholesterol was associated
with thinner (healthier) IMT was presented. Initially this seems counterintuitive
however increasing evidence is emerging of the complex underlying changes in
lipids in HIV infected adults and to lesser extent children. It has long been known
that HIV infection causes an early decrease in HDL cholesterol, an elevation of
triglycerides with a delayed decrease in LDL-C later in infection [489, 490]. However
there may be more subtle changes underlying. HDL dysfunction may represent a
novel mechanism linking inflammation with progression of atheroma; recent findings
that even minor alterations in systemic inflammation can impair the endothelial
protective effects of HDL [340]. Functionally defective high density lipoproteins
(HDL) are related to heightened T cell activation in vertically HIV-infected
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adolescents [491]. Published work showing the addition of statins on overall
cardiovascular risk show mixed results to data [92, 492] and future trials will
evaluate other interventions that effect lipids. Lipoprotein-associated phospholipase
A2 (Lp-PLA2), a recently described marker of inflammation, oxidizes phospholipids
on LDL in the arterial intima to produce oxidized free fatty acids and
lysophosphatidylcholine which stimulate key steps in the atherosclerotic process.
Early work has suggested that this may be of promise as a biomarker of CVD risk
[493].
During this research abnormalities in other biomarkers such as the monocyte
activation marker, sCD163 and the kynurenine-to-tryptophan (KT) ratio have been
linked with increased cardiovascular risk in adults [316, 494]; no paediatric data
exists to date. CMV and other co-infections are implicated in immune activation,
increased cardiovascular disease and progression of HIV infection [495, 496].
Microbial translocation may be a key factor and has been implicated as part of the
immunopathology underlying HIV disease progression and cardiovascular risk [497,
498]. Further work using CHAPAS-3 samples will focus on microbial translocation in
more detail. What is not known is whether identifying and treating inflammation and
immune dysfunction will decrease morbidity and mortality. The use of anti-
inflammatory agents such as histone deacetylase inhibitors in HIV infected patients
has shown that inflammatory markers can be reduced; this opens the potential for
trials of therapeutic interventions for high risk patients with persistently high levels of
inflammation [499].
8.4 Conclusions, key findings and implications for practice
Without ART, detrimental changes in vascular structure and arterial stiffness can be
seen from a very young age but are in part reversible with ART. Biomarker data
hints at aetiology and provides additional evidence that early ART is beneficial.
Results are in accordance with current WHO guidelines that ART is life saving and
children need to be started early on first line ART. Optimising first line ART is a
careful consideration between cost, available formulations and adverse effects.
CHAPAS 3 and the cardiovascular sub study have shown that there are no
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significant differences in terms of toxicity or virological suppression between three
first line NRTI options.
Ongoing work needs to focus on cardiovascular disease in vertically infected
adolescents as they enter adulthood. In the meantime the medical care of HIV-
infected children must recognise that they remain at increased cardiovascular risk;
counselling over the need to remain active, avoid obesity, not to smoke and be
screened for renal complications, hypertension and subclinical cardiovascular
damage should be considered standard of care.
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Appendices
Appendix I:CHAPAS 3 cardiovascular clinical report forms
Consent form
Form B: Contact details
Form 1: Screening
Form 3: Enrolment
Form 4: Lipodystrophy
Form 17: Socioeconomic questionnaire
Form 19: Cardiovascular sub-study
Form 7: Lab request
Form 11: Haematology
Form 12: Biochemistry
Form 13: Lymphocyte subsets
Form 14: Sample Storage
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Oral abstract presentation at the 4th International Pediatric HIV Workshop, Washington, July
2012
Kenny J, Mirembe G, Musiime V, Masaku D, Kavindele D, Odongo F, Wavamunno P,
Rapala A, Cook A, Deanfield J, Gibb D, Klein N. Cardiovascular structure and function
in HIV-infected children in Zambia and Uganda Reviews in Antiviral Therapy &
Infectious Diseases 2012 8 Oral abstract 17, page 19.
1Institute of Child Health, University College London, 2Clinical Trials Unit, Medical Research
Council, 3Joint Clinical Research Centre, Lubowa, Kampala, 4University Teaching Hospital,
Lusaka, 5Vascular Physiology Laboratory, Institute of Child Health, University College
London.
Background / introduction
Carotid intimal medial thickness (cIMT) and pulse wave velocity (PWV), as measures of
cardiovascular structure/function, are impaired in HIV-infected UK children, although the
impact of ART and obesity/lifestyle factors has been difficult to determine. No studies have
been undertaken in Africa where 90% HIV-infected children live. We are undertaking a
longitudinal study of arterial structure/function, nested within a large randomised trial
(CHAPAS 3) of different ART regimens in Uganda/Zambia. We present baseline data on
ART-naïve and ART-experienced children.
Methods
All cooperative ART-naive and experienced (stable on d4T+3TC+NNRTI for >2years) HIV-
infected children recruited from 2 sites in Uganda/Zambia had baseline cIMT and PWV
measurements undertaken by the same operators in each country. Differences between
ART-naïve and experienced children, accounting for age and ART duration, were analysed
using linear regression.
Results
180(121:59 ART-naive:experienced) children had cIMT and 212(139:73) had PWV
measured; median(range) age was 4.7(0.7-13.6 years); 53% male; median CD4% in
naïve:experienced 18:33%.
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In ART-naïve vs experienced children, mean(sd) cIMT was 0.46(0.44)mm vs 0.47(0.35)mm
(p=0.4) and PWV was 5.79(0.8)metre/second vs 5.63(0.61)metre/second (p=0.14), with a
non-significant trend towards IMT and PWV increasing with age. (IMT p=0.08, PWV p=0.09)
In ART-experienced children, duration of ART (median(range) 3.9(2-6.2 years)) did not
influence cIMT(p=0.2) or PWV(p=0.5). Values were comparable to those of UK HIV-
uninfected and lower than HIV-infected children.
Discussion
In this first large study of arterial structural and function in HIV-infected children in Africa,
results were similar to HIV-uninfected UK children and were unrelated to ART status. Follow-
up data, comparison with African controls, and further analyses exploring the impact of lipid
levels and markers of inflammation on these vascular markers may all provide insight into
the pathogenesis of HIV and ART-mediated mechanisms of vascular injury and repair as
well as providing guidance on optimal first-line ART for HIV-infected children in Africa.
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CROI 2015, Seattle, USA. Oral presentation.
Kenny J, Mirembe G, Musiime V, Masaku D, Odongo F, Wavamunno P, Thomason M,
Rapala A, Cook A, Deanfield J, Walker S, Gibb D, Klein N.
Structural cardiovascular changes are reversible in HIV-infected children in Zambia
and Uganda
Background
Carotid intimal medial thickness (IMT) and pulse wave velocity (PWV), as measures of
cardiovascular structure/function, are impaired in HIV-infected children in high-income
countries. Few longitudinal data are available: none come from Africa where 90% HIV-
infected children live.
Methods
ART-naïve and ART-experienced (on d4T+3TC+NNRTI for >2years, virologically
suppressed at enrolment) HIV-infected children had IMT and PWV measured at baseline, 48
and 96 weeks within the CHAPAS-3 trial which evaluated d4T vs ZDV vs ABC-based first-
line ART in Uganda/Zambia. Age-matched HIV-uninfected controls had a single
assessment. Baseline differences between ART-naïve/experienced children vs controls,
and longitudinal changes in HIV-infected children were compared using two-sample and
paired t-tests respectively.
Results
In 208 ART-naïve children with median age 2.9y (IQR 1.7–4.4), median CD4% 18% (11-23)
and 209 HIV-uninfected controls median age 3.0y (2.1–4.1), mean(sd) cIMT was 0.46(0.04)
v 0.44(0.04)mm respectively (p=0.0001); PWV was 5.85(0.8) vs 5.67(0.74)m/sec
respectively (p=0.04). Among 74 ART-experienced children on ART for mean 3.7y with
median age 6.9y (5.9–8.50, median CD4% 33% (27-39) and 75 uninfected controls with
median age 6.7y (5.6-8.6), mean(sd) cIMT was 0.46(0.05) vs 0.45(0.04)mm respectively
(p=0.09); PWV was 5.63(0.61) vs 5.69(0.69)m/s respectively (p=0.57). In ART naïve
children IMT and PWV significantly decreased from baseline (ART initiation) to week 96
mean(sd) cIMT -0.02(0.04)mm (p=0.0001), PWV -0.38(0.83)m/s (p<0.0001). In contrast
whereas cIMT had significantly reduced by mean -0.2(0.06)mm (p=0.01) at week 96 in the
ART experienced group PWV increased by 0.35(0.63)m/s (p<0.0001). There was no
evidence that the changes differed by randomisation ART in either group (p=0.6).
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Conclusion
In this large study of arterial structural and function in HIV-infected children in Africa, ART-
naïve HIV-infected children had significantly poorer IMT and PWV compared to age-matched
controls but significant improvement seen after 96 weeks of ART. After a mean 3.7 years on
ART, HIV-infected children had cIMT and PWV comparable to uninfected age-matched
controls. IMT continued to improve after a further 96 weeks on ART. ART can reverse
some of the structural/functional changes caused by HIV, strengthening the argument for
early diagnosis and treatment of HIV-infected infants and children.
